Nothing Special   »   [go: up one dir, main page]

US20080249018A1 - Exendin Analog Formulations - Google Patents

Exendin Analog Formulations Download PDF

Info

Publication number
US20080249018A1
US20080249018A1 US12/100,880 US10088008A US2008249018A1 US 20080249018 A1 US20080249018 A1 US 20080249018A1 US 10088008 A US10088008 A US 10088008A US 2008249018 A1 US2008249018 A1 US 2008249018A1
Authority
US
United States
Prior art keywords
xaa
exendin
ala
formulation
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/100,880
Inventor
Orville G. Kolterman
Andrew A. Young
James J. L'Italien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46323143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20080249018(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/889,331 external-priority patent/US6872700B1/en
Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC
Priority to US12/100,880 priority Critical patent/US20080249018A1/en
Assigned to AMYLIN PHARMACEUTICALS, INC. reassignment AMYLIN PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: L'ITALIEN, JAMES L., YOUNG, ANDREW A., KOLTERMAN, ORVILLE G.
Publication of US20080249018A1 publication Critical patent/US20080249018A1/en
Priority to US12/389,509 priority patent/US7906146B2/en
Priority to US13/045,334 priority patent/US20110281798A1/en
Priority to US13/672,562 priority patent/US20130165379A1/en
Priority to US14/553,237 priority patent/US20150080308A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present application relates to novel formulations containing exendins, exendiln agonists and exendin analogs.
  • exendins are peptides that are found in the salivary secretions of the Gila monster and the Mexican Beaded Lizard, reptiles that are endogenous to Arizona and Northern Mexico.
  • Exendin-3 [SEQ ID NO: 1, i.e., His Ser Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Pro Ser-NH 2 ] is present in the salivary secretions of Heloderma horridum (Mexican Beaded Lizard), and exendin-4 [SEQ ID NO: 2, i.e., His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser-NH 2 ] is
  • exendin-3 The amino acid sequence of exendin-3 is shown in FIG. 1 .
  • the amino acid sequence of exendin-4 is shown in FIG. 2 .
  • Exendin-4 was first thought to be a (potentially toxic) component of the venom. It now appears that exendin-4 is devoid of toxicity, and that it instead is made in salivary glands in the Gila monster.
  • exendins have some sequence similarity to several members of the glucagon-like peptide family, with the highest homology, 53%, being to GLP-1[7-36]NH 2 [SEQ ID NO: 3] (Goke, et al., J. Biol. Chem., 268:19650-55, 1993).
  • GLP-1[7-36]NH 2 also sometimes referred to as proglucagon[78-107] or simply “GLP-1” as used most often herein, has an insulinotropic effect, stimulating insulin secretion from pancreatic beta-cells; GLP-1 has also been reported to inhibit glucagon secretion from pancreatic alpha-cells ( ⁇ rsov, et al., Diabetes, 42:658-61, 1993; D'Alessio, et al., J. Clin. Invest., 97:133-38, 1996).
  • GLP-1 has been reported to inhibit gastric emptying (Willms B, et al., J Clin Endocrinol Metab 81 (1): 327-32, 1996; Wettergren A, et al., Dig Dis Sci 38 (4): 665-73, 1993), and gastric acid secretion (Schjoldager B T, et al., Dig Dis Sci 34 (5): 703-8, 1989; O'Halloran D J, et al., J Endocrinol 126 (1): 169-73, 1990; Wettergren A, et al., Dig Dis Sci 38 (4): 665-73, 1993)).
  • a transmembrane G-protein adenylate-cyclase-coupled receptor said to be responsible at least in part for the insulinotropic effect of GLP-1 has reportedly been cloned from a beta-cell line (Thorens, Proc. Natl. Acad. Sci. USA 89:8641-45, 1992).
  • GLP-1 has been the focus of significant investigation in recent years due to its reported action on the amplification of stimulated insulin production (Byrne M M, Goke B.
  • GLP-1 has also been reported to restore islet glucose sensitivity in aging rats, restoring their glucose tolerance to that of younger rats (Egan J M, et al., Glucagon-like peptide-1 restores acute-phase insulin release to aged rats, Diabetologia 1997 June;40(Suppl 1):A130).
  • the short duration of biological action of GLP-1 in vivo is one feature of the peptide that has hampered its development as a therapeutic agent.
  • exendin-4 can act at GLP-1 receptors on certain insulin-secreting cells, at dispersed acinar cells from guinea pig pancreas, and at parietal cells from stomach; the peptide is also reported to stimulate somatostatin release and inhibit gastrin release in isolated stomachs (Goke, et al., J. Biol. Chem. 268:19650-55, 1993; Schepp, et al., Eur. J. Pharmacol., 69:183-91, 1994; Eissele, et al., Life Sci., 55:629-34, 1994).
  • Exendin-3 and exendin-4 were reportedly found to stimulate cAMP production in, and amylase release from, pancreatic acinar cells (Malhotra, R., et al., Regulatorv Peptides, 41:149-56, 1992; Raufman, et al., J. Biol. Chem. 267:21432-37, 1992; Singh, et al., Regul. Pept. 53:47-59, 1994).
  • exendin-4 has a significantly longer duration of action than GLP-1. For example, in one experiment, glucose lowering by exendin-4 in diabetic mice was reported to persist for several hours, and, depending on dose, for up to 24 hours (Eng J.
  • glucagon is a polypeptide hormone that is produced by the alpha cells of the pancreatic islets of Langerhans. It is a hyperglycemic agent that mobilizes glucose by activating hepatic glycogenolysis. It can to a lesser extent stimulate the secretion of pancreatic insulin.
  • Glucagon is used in the treatment of insulin-induced hypoglycemia, for example, when administration of glucose intravenously is not possible.
  • glucagon reduces the motility of the gastro-intestinal tract it is also used as a diagnostic aid in gastrointestinal radiological examinations.
  • Glucagon has also been used in several studies to treat various painful gastrointestinal disorders associated with spasm. Daniel, et al. (Br. Med. J., 3:720, 1974) reported quicker symptomatic relief of acute diverticulitis in patients treated with glucagon compared with those who had been treated with analgesics or antispasmodics. A review by Glauser, et al. ( J. Am. Coll. Emergency Physns, 8:228, 1979) described relief of acute esophageal food obstruction following glucagon therapy. In another study, glucagon significantly relieved pain and tenderness in 21 patients with biliary tract disease compared with 22 patients treated with placebo (M. J. Stower, et al., Br. J. Surg., 69:591-2, 1982).
  • Novel exendin agonist compounds are described in commonly owned PCT Application Serial No. PCT/US98/16387 filed Aug. 6, 1998, entitled “Novel Exendin Agonist Compounds,” published as WO 99/07404, which claims the benefit of U.S. Patent Application Ser. No. 60/055,404, filed Aug. 8, 1997.
  • PEG modification of therapeutic peptides and proteins may yield both advantages and disadvantages. While PEG modification may lead to improved circulation time, reduced antigenicity and immunogenicity, improved solubility, resistance to proteolysis, improved bioavailability, reduced toxicity, improved stability, and easier formulation of peptides (See, Francis et al., International Journal of Hematology, 68:1-18, 1998) problems with PEGylation in most cases is substantial reduction in bioactivity. Id. In addition, most methods involve use of linkers that have several types of adverse effects including immunogenicity, instability, toxicity, and reactivity. Id.
  • Glucagonoma (tumor of glucagon-secreting cells) produces, in addition to glucose intolerance, a skin condition, necrolytic migratory erythema. This is a raised scaly red rash, sometimes blistering and eventually crusting, localized to the face, abdomen, extremities and perineum. It can also be associated with inflamation of the tongue and mouth, and diseased nails and thining of the hair. The condition is reported to respond to octreotide, a glucagonostatic hormone analog.
  • the compounds described herein are also useful as glucagonastatic agents and thus in the treatment of this disease, which was was first described in 1966 (Kaplan, L. M.
  • the compounds described herein that are useful for lowering glucagon levels and/or suppressing glucagon secretion include exendin, exendin agonists, and modified exendins and exendin agonists and related formulations, and dosage formulations.
  • the present invention provides novel exendin agonist compound formulations and dosages thereof exhibiting advantageous properties that include effects in slowing gastric emptying and lowering plasma glucose levels.
  • this aspect of the invention includes formulations of exendins and exendin agonists that comprise an exendin or exendin agonist mixed together with a buffer (preferably an acetate buffer), an iso-osmolality modifier (preferably mannitol), and optionally containing a preservative (preferably m-cresol), said formulation having a pH of between about 3.0 and about 7.0 (preferably between about 4.0 and about 5.0).
  • Additional formulations within the scope of the invention include a parenteral liquid dosage form, a lyophilized unit-dosage form, a lyophilized multi-use dosage form, and modifications of these dosage forms that are useful in the oral, nasal, buccal, sublingual, intra-tracheal, and pulmonary delivery of exendins and exendin agonists.
  • the invention includes parenteral liquid dosage forms that comprise approximately 0.005 to about 0.4%, more specifically from about 0.005 to about 0.02%, or from about 0.005 to about 0.05% (w/v), respectively of the active ingredient in an aqueous system along with approximately 0.02 to 0.5% (w/v) of an acetate, phosphate, citrate or glutamate or similar buffer either alone or in combination to obtain a pH of the final composition of approximately 3.0 to 7.0, more specifically from about pH 4.0 to about 6.0, or from about 4.0 to 5.0, as well as either approximately 1.0 to 10% (w/v) of a carbohydrate or polyhydric alcohol iso-osmolality modifier (preferably mannitol) or up to about 0.9% saline or a combination of both leading to an isotonic or an iso-osmolar solution in an aqueous continuous phase.
  • parenteral liquid dosage forms that comprise approximately 0.005 to about 0.4%, more specifically from about 0.005 to about 0.02%, or from about
  • an anti-microbial preservative selected from the group consisting of m-cresol, benzyl alcohol, methyl, ethyl, propyl and butyl parabens and phenol is also present if the formulation is packaged in a multi-use container. A sufficient amount of water for injection is added to obtain the desired concentration of solution. Sodium chloride, as well as other excipients, may also be present, if desired. Such excipients, however, must maintain the overall stability of the active ingredient.
  • Useful polyhydric alcohols include such compounds as sorbitol, mannitol, glycerol, and polyethylene glycols (PEGs).
  • the polyhydric alcohols and the carbohydrates will also be effective in stabilizing protein against denaturation caused by elevated temperature and by freeze-thaw or freeze-drying processes.
  • Suitable carbohydrates include galactose, arabinose, lactose or any other carbohydrate which does not have an adverse affect on a diabetic patient, if intended for that use, i.e., the carbohydrate is not metabolized to form large concentrations of glucose in the blood.
  • the peptides of the present invention are admixed with a polyhydric alcohol such as sorbitol, mannitol, inositol, glycerol, xylitol, and polypropylene/ethylene glycol copolymer, as well as various polyethylene glycols (PEG) of molecular weight 200, 400, 1450, 3350, 4000, 6000, and 8000).
  • a polyhydric alcohol such as sorbitol, mannitol, inositol, glycerol, xylitol, and polypropylene/ethylene glycol copolymer, as well as various polyethylene glycols (PEG) of molecular weight 200, 400, 1450, 3350, 4000, 6000, and 8000).
  • PEG polyethylene glycols
  • the lyophilized unit-dose formulations of the present invention are also stable, but need not be isotonic and/or iso-osmolar. They include active ingredient(s), a bulking agent to facilitate cake formation (which may also act as a tonicifer and/or iso-osmolality modifier upon reconstitution to either facilitate stability of the active ingredient and/or lessen the pain on injection), and may also include a surfactant that benefits the properties of the cake and/or facilitates reconstitution.
  • the lyophilized unit-dose formulations of the present invention include approximately 0.005 to about 0.4%, more specifically from about 0.005 to about 0.02%, or 0.005 to 0.05% (w/v) of the active ingredient.
  • the formulation and/or the reconstitution solvent may contain individually or collectively approximately 0.02 to 0.5% (w/v) of an acetate, phosphate, citrate or glutamate buffer either alone or in combination to obtain a pH of the final composition of approximately 3.0 to 7.0, more specifically from about pH 4.0 to about 6.0, or from about 4.0 to 5.0.
  • the bulking agent may consist of either approximately 1.0 to 10% (w/v) of a carbohydrate or polyhydric alcohol iso-osmolality modifier (as described above) or up to 0.9% saline or a combination of both leading to a isotonic or iso-osmolar solution in the reconstituted aqueous phase.
  • a surfactant preferably about 0.1 to about 1.0% (w/v) of polysorbate 80 or other non-ionic detergent, may be included.
  • sodium chloride as well as other excipients, may also be present in the lyophilized unit-dosage formulation, if desired.
  • the liquid formulation of the invention prior to lyophilization will be substantially isotonic and/or iso-osmolar either before lyophilization or to enable formation of isotonic and/or iso-osmolar solutions after reconstitution.
  • the invention also includes lyophilized and liquid multi-dose formulations.
  • the lyophilized multi-unit-dosage form should contain a bulking agent to facilitate cake formation.
  • a preservative is included to facilitate multiple use by the patient.
  • These dosage forms include approximately 0.005 to about 0.4%, more specifically from about 0.005 to about 0.02%, or from about 0.005 to 0.05% (w/v), respectively of the active ingredient.
  • a buffer it may be included in the lyophile or in the reconstitution solvent, and the formulation and/or the reconstitution solvent may contain individually or collectively approximately 0.02 to 0.5% (w/v) of an acetate, phosphate, citrate or glutamate buffer either alone or in combination to obtain a pH of the final composition of approximately 3.0 to 7.0, more specifically from about pH 4.0 to about 6.0, or from about 4.0 to 5.0.
  • the bulking agent may consist of either approximately 1.0 to 10% (w/v) of a carbohydrate or a polyhydric alcohol iso-osmolality modifier (preferably mannitol) or up to 0.9% saline, or a combination of both, leading to an isotonic or iso-osmolar solution in the reconstituted aqueous phase.
  • a surfactant preferably about 0.1 to about 1.0% (w/v) of polysorbate 80 or other non-ionic detergent, may be included.
  • an anti-microbial preservative selected from the group consisting of m-cresol, benzyl alcohol, methyl, ethyl, propyl and butyl parabens and phenol (preferably m-cresol) is also present if the formulation is packaged in a multi-use container.
  • Sodium chloride, as well as other excipients, may also be present, if desired.
  • the liquid formulation of the invention should be substantially isotonic and/or iso-osmolar either before lyophilization or to enable formation of isotonic and/or iso-osmolar solutions after reconstitution.
  • the invention further includes solid dosage forms useful for oral, buccal, sublingual, intra-tracheal, nasal, and pulmonary delivery.
  • the formulations that best support pulmonary and/or intra-tracheal dosage forms may be either preserved or unpreserved liquid formulations and/or dry powder formulations.
  • the preserved or unpreserved liquid formulations will be essentially identical to the formulations described above under preserved or unpreserved liquid parenteral formulations.
  • the pH of the solution should be about 3.0 to 7.0, more specifically from about 4.0 to 6.0, or from about 4.0 to 5.0, with a pH greater than or equal to about 5.0 being most preferred to reduce the potential for bronchoconstriction.
  • the dry powder formulations may contain a bulking agent and/or salts to facilitate particle size formation and appropriate particle size distribution.
  • a surfactant and/or salts may also benefit the properties of the particle morphology and/or facilitate tissue uptake of the active ingredient.
  • Dry powder dosage forms can range from 1% to 100% (w/w), respectively of the active ingredient. It may not be necessary to include a bulking agent and/or salts to facilitate particle size formation and/or distribution.
  • the bulking agent and/or salts may consist of either approximately 0 to 99% (w/w) of a carbohydrate or polyhydric alcohol or approximately 0 to 99% salt or a combination of both leading to the preferred particle size and distribution.
  • a surfactant preferably about 0.1 to about 1.0% (w/w) of polysorbate 80 or other non-ionic detergent, may be included.
  • formulation comprising up to 50 mg/ml of an exendin or an exendin agonist in 30 mM acetate buffer (pH about 4.5) and mannitol, with or without a preservative.
  • formulations for exendin and exendin agonists having comparable potency are provided for the administration by injection of from about 0.1 to about 0.5 ⁇ g per kilogram, given one to three times per day.
  • this will result in the total administration of about 10 to about 120 ⁇ g per day in single or divided doses.
  • the doses are preferably administered two or three times per day, and more preferably, two times per day.
  • Oral dosages according to the present invention will include from about 50 to about 100 times the active ingredient, i.e., from about 500 to about 12,000 ⁇ g per day in single or divided doses, preferably from about 500 to about 5,000 ⁇ g per day.
  • Pulmonary dosages according to the present invention will include from about 10 to about 100 times the active ingredient, i.e., from about 100 to about 12,000 ⁇ g per day in single or divided doses, preferably about 500 to 1000 ⁇ g per day.
  • Nasal, buccal and sublingual dosages according to the present invention will also include from about 10 to about 100 times the active ingredient, i.e., from about 100 to about 12,000 ⁇ g per day in single or divided doses.
  • Preferred dosages for nasal administration are from about 10-1000 to about 1200-12,000 ⁇ g per day, for buccal administration from about 10-1000 to about 1200-12,000 ⁇ g per day, and for sublingual administration from about 10-1000 to about 1200-8,000 ⁇ g per day.
  • Sublingual dosages are preferably smaller than buccal dosages.
  • Administration dosages for exendin agonists having less than or greater than the potency of exendin-4 are increased or decreased as appropriate from those described above and elsewhere herein.
  • kits for administration of said novel exendin agonist compound formulations and dosages by delivery means alternative to subcutaneous injection or intravenous infusion including, for example, by nasal delivery, pulmonary delivery, oral delivery, intra-tracheal delivery, sublingual delivery, and buccal delivery.
  • the present invention provides novel exendin agonist compound formulations and dosages, and methods for the administration thereof, that are useful in treating diabetes (including type 1 and type 2 diabetes), obesity, and other conditions that will benefit from the administration of a therapy that can slow gastric emptying, lowering plasma glucose levels, and reduce food intake.
  • Preferred exendins or exendin agonists for use include:
  • exendin-4 (1-30) [SEQ ID NO: 4, i.e., His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly]; exendin-4 (1-30) amide [SEQ ID NO: 5, i.e., His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly-NH 2 ]; exendin-4 (1-28) amide [SEQ ID NO: 6, i.e., His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH 2 ]; 14 Leu, 25 Phe exendin-4
  • amino acid refers to natural amino acids, unnatural amino acids, and amino acid analogs, all in their D and L stereoisomers if their structure allow such stereoisomeric forms.
  • Natural amino acids include alanine (Ala), arginine (Arg), asparagine (Asn), aspartic acid (Asp), cysteine (Cys), glutamine (Gln), glutamic acid (Glu), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), Lysine (Lys), methionine (Met), phenylalanine (Phe), proline (Pro), serine (Ser), threonine (Thr), typtophan (Trp), tyrosine (Tyr) and valine (Val).
  • Unnatural amino acids include, but are not limited to azetidinecarboxylic acid, 2-aminoadipic acid, 3-aminoadipic acid, beta-alanine, aminopropionic acid, 2-aminobutyric acid, 4-aminobutyric acid, 6-aminocaproic acid, 2-aminoheptanoic acid, 2-aminoisobutyric acid, 3-aminoisbutyric acid, 2-aminopimelic acid, tertiary-butylglycine, 2,4-diaminoisobutyric acid, desmosine, 2,2′-diaminopimelic acid, 2,3-diaminopropionic acid, N-ethylglycine, N-ethylasparagine, homoproline, hydroxylysine, allo-hydroxylysine, 3-hydroxyproline, 4-hydroxyproline, isodesmosine, allo-isoleucine, N-methylalanine, N-methylglycine, N-methyli
  • Amino acid analogs include the natural and unnatural amino acids which are chemically blocked, reversibly or irreversibly, or modified on their N-terminal amino group or their side-chain groups, as for example, methionine sulfoxide, methionine sulfone, S-(carboxymethyl)-cysteine, S-(carboxymethyl)-cysteine sulfoxide and S-(carboxymethyl)-cysteine sulfone.
  • amino acid analog refers to an amino acid wherein either the C-terminal carboxy group, the N-terminal amino group or side-chain functional group has been chemically codified to another functional group.
  • aspartic acid-(beta-methyl ester) is an amino acid analog of aspartic acid
  • N-ethylglycine is an amino acid analog of glycine
  • alanine carboxamide is an amino acid analog of alanine.
  • amino acid residue refers to radicals having the structure: (1) —C(O)—R—NH—, wherein R typically is —CH(R′)—, wherein R′ is an amino acid side chain, typically H or a carbon containing substitutent;
  • p is 1, 2 or 3 representing the azetidinecarboxylic acid, proline or pipecolic acid residues, respectively.
  • lower referred to herein in connection with organic radicals such as alkyl groups defines such groups with up to and including about 6, preferably up to and including 4 and advantageously one or two carbon atoms.
  • Such groups may be straight chain or branched chain.
  • “Pharmaceutically acceptable salt” includes salts of the compounds of the present invention derived from the combination of such compounds and an organic or inorganic acid. In practice the use of the salt form amounts to use of the base form. The compounds of the present invention are useful in both free base and salt form, with both forms being considered as being within the scope of the present invention.
  • ACN or “CH 3 CN” refers to acetonitrile.
  • Boc tBoc or “Thoc” refers to t-butoxy carbonyl.
  • DCC refers to N,N′-dicyclohexylcarbodiimide.
  • Fmoc refers to fluorenylmethoxycarbonyl.
  • HBTU refers to 2-(1H-benzotriazol-1-yl)-1,1,3,3,-tetramethyluronium hexaflurophosphate.
  • HBt refers to 1-hydroxybenzotriazole monohydrate.
  • homoP or hPro” refers to homoproline.
  • MeAla or “Nme” refers to N-methylalanine.
  • naph refers to naphthylalanine.
  • pG or pGly refers to pentylglycine.
  • tBuG refers to tertiary-butylglycine.
  • ThioP or tPro refers to thioproline.
  • 3Hyp refers to 3-hydroxyproline.
  • 4Hyp refers to 4-hydroxyproline.
  • NAG refers to N-alkylglycine.
  • NAPG refers to N-alkylpentylglycine.
  • Neval refers to norvaline.
  • Neorleu refers to norleucine.
  • FIG. 1 depicts the amino acid sequence for exendin-3 [SEQ ID NO: 1].
  • FIG. 2 depicts the amino acid sequence for exendin-4 [SEQ ID NO: 2].
  • FIG. 3 depicts the amino acid sequences for certain exendin agonist compounds useful in the present invention [SEQ ID NOs: 10 to 40].
  • FIG. 4 depicts the amino acid sequences for certain compounds of the present invention, Compounds 1-174.
  • FIG. 5 is a graph showing the effect of functional nephrectomy on exendin-4 clearance.
  • FIG. 6 is a graph showing the terminal decay of exendin-4 plasma levels in nephrectomized and sham subjects.
  • FIG. 7 depicts the plasma levels of exendin-4 in rats after intra-tracheal administration.
  • FIG. 8A depicts the plasma exendin-4 concentration after intra-tracheal instillation in db/db mice.
  • FIG. 8B depicts the effect of intra-tracheal administration of exendin-4 on plasma glucose in db/db mice.
  • FIGS. 9A and 9B depict the effect of intra-tracheal administration of exendin-4 on plasma glucose in ob/ob mice.
  • FIG. 10A depicts the plasma exendin-4 concentration after intra-tracheal instillation into rats.
  • FIG. 10B depicts the bioavailability of exendin-4 following intra-tracheal instillation into rats.
  • FIG. 11 depicts plasma exendin-4 concentrations in rats exposed to aerosolized exendin-4 (8 ng/ml) for 10 minutes.
  • FIG. 12A depicts the effect of ten minutes of exposure to aerosolized exendin-4 on plasma glucose in db/db mice.
  • FIG. 12B depicts the plasma exendin-4 concentration after ten minutes of exposure of db/db mice to aerosolized exendin-4.
  • FIG. 13 depicts plasma exendin-4 concentrations in rats after intra-nasal administration of exendin-4.
  • FIG. 14 depicts the effect of intra-gastric administration of exendin-4 on plasma glucose in db/db mice.
  • FIG. 15A depicts the plasma exendin-4 concentration after sublingual administration to db/db mice.
  • FIG. 15B depicts the effect of sublingual administration of exendin-4 on plasma glucose in db/db mice.
  • FIG. 15C depicts the plasma exendin-4 concentration after sublingual administration to rats.
  • FIG. 15D depicts the bioavailability of exendin-4 after sublingual administration.
  • FIG. 15E depicts the Cmax of sublingual exendin-4.
  • the present invention relates to relates to methods of suppressing and/or lowering glucagon in a subject, comprising the administration of an exendin, an exendin agonist, or a modified exendin or exendin agonist having an exendin or exendin agonist peptide linked to one or more polyethylene glycol polymers or other compound useful to increase molecular weight.
  • Such methods are useful, for example, in the treatment of hyperglucagonemia and other conditions in which lower levels of glucagon or suppresion of glucagon secretion are of benefit.
  • Such conditions include, but are not limited to, glucagonoma and necrolytic migratory erythema.
  • modified exendins and exendin agonists of the present invention include, for example, one or more PEG polymers linked to an exendin or exendin agonist, such as a naturally occurring exendin, a synthetic exendin or an exendin agonist.
  • Exendin-4 is a naturally occurring peptide isolated from the salivary secretions of the Gila monster. Animal testing of exendin-4 has shown that its ability to lower blood glucose persists for several hours. Exendin-4, a 39-amino acid polypeptide, is synthesized using solid phase synthesis as described herein, and this synthetic material has been shown to be identical to that of native exendin-4.
  • exendin-4 As described herein, the nonclinical pharmacology of exendin-4 has been studied. In the brain, exendin-4 binds principally to the area postrema and nucleus tractus solitarius region in the hindbrain and to the subfornical organ in the forebrain. Exendin-4 binding has been observed in the rat and mouse brain and kidney. The structures to which exendin-4 binds in the kidney are unknown.
  • exendin-4 An insulinotropic action of exendin-4 has also been observed in rodents, improving insulin response to glucose by over 100% in non-fasted Harlan Sprague Dawley (HSD) rats, and by up to ⁇ 10-fold in non-fasted db/db mice. Higher pretreatment plasma glucose concentrations were associated with greater glucose-lowering effects. Thus the observed glucose lowering effect of exendin-4 appears to be glucose-dependent, and minimal if animals are already euglycemic.
  • Exendin-4 dose dependently slowed gastric emptying in HSD rats and was -90-fold more potent than GLP-1 for this action. Exendin-4 has also been shown to reduce food intake in NII/Sw (Swiss) mice following peripheral administration, and was at least 1000 times more potent than GLP-1 for this action. Exendin-4 reduced plasma glucagon concentrations by approximately 40% in anesthetized ZDF rats during hyperinsulinemic, hyperglycemic clamp conditions, but did not affect plasma glucagon concentrations during euglycemic conditions in normal rats. Exendin-4 has been shown to dose-dependently reduce body weight in obese ZDF rats, while in lean ZDF rats, the observed decrease in body weight appears to be transient.
  • exendins Through effects on lowering glucagon and supressing glucagon secretion, exendins, exendin agonists, and modified exendins or exendin agonists containing exendin-4, for example, will be useful in people who would benefit from lowered glucagon, for example, people with glucagonoma and necrolytic migratory erythema, and people with diabetes whether or not they retain the ability to secrete insulin. See Example 5.
  • exendin-4 has been investigated in single-dose studies in mice, rats and monkeys, repeated-dose (up to 28 consecutive daily doses) studies in rats and monkeys and in vitro tests for mutagenicity and chromosomal alterations. To date, no deaths have occurred, and there have been no observed treatment-related changes in hematology, clinical chemistry, or gross or microscopic tissue changes. Exendin-4 was demonstrated to be non-mutagenic, and did not cause chromosomal aberrations at the concentrations tested (up to 5000 ⁇ g/mL).
  • exendin-4 The apparent terminal half-life for exendin-4 given subcutaneously was approximately 90-110 minutes. This was significantly longer than the 14-41 minutes seen following intravenous dosing. Similar results were obtained using the IRMA assay. Degradation studies with exendin-4 compared to GLP-1 indicate that exendin-4 is relatively resistant to degradation.
  • exendin agonists include exendin peptide analogs in which one or more naturally occurring amino acids are eliminated or replaced with another amino acid(s).
  • Preferred exendin agonists are agonist analogs of exendin-4.
  • Particularly preferred exendin agonists include those described in commonly owned WO 99/07404 (i.e., PCT Application Serial No. PCT/US98/16387 filed Aug.
  • exendin agonists can be indicated, for example, by activity in the assays described below. Effects of exendins or exendin agonists on gastric motility and gastric emptying can be identified, evaluated, or screened for, using the methods described herein, or other art-known or equivalent methods for determining gastric motility. Negative receptor assays or screens for exendin agonist compounds or candidate exendin agonist compounds, such as an amylin receptor assay/screen using an amylin receptor preparation as described in U.S. Pat. No. 5,264,372, issued Nov.
  • one or more calcitonin receptor assays/screens using, for example, T47D and MCF7 breast carcinoma cells, which contain calcium receptors coupled to the stimulation of adenyl cyclase activity, and/or a CGRP receptor assay/screen using, for example, SK-N-MC cells.
  • One such method for use in identifying or evaluating the ability of a compound to slow gastric motility involves: (a) bringing together a test sample and a test system, the test sample containing one or more test compounds, the test system containing a system for evaluating gastric motility, the system being characterized in that it exhibits, for example, elevated plasma glucose in response to the introduction to the system of glucose or a meal; and, (b) determining the presence or amount of a rise in plasma glucose in the system. Positive and/or negative controls may be used as well.
  • compositions including said compounds and salts thereof.
  • Exendin agonist compounds also include those described in U.S. Provisional Application No. 60/065,442 (i.e., priority application to WO 99/25727) including compounds of the formula (I) [SEQ ID NO: 41]:
  • Xaa 31 , Xaa 36 , Xaa 37 and Xaa 38 are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine or N-alkylalanine; and
  • Z 2 is OH or NH 2 ; provided that no more than three of Xaa 3 , Xaa 5 , Xaa 6 , Xaa 8 , Xaa 10 , Xaa 11 , Xaa 12 , Xaa 13 , Xaa 14 , Xaa 15 , Xaa 16 , Xaa 17 , Xaa 19 , Xaa 20 , Xaa 21 , Xaa 24 , Xaa 25 , Xaa 26 , Xaa 27 and Xaa 28 are Ala.
  • N-alkyl groups for N-alkylglycine, N-alkylpentylglycine and N-alkylalanine include lower alkyl groups preferably of 1 to about 6 carbon atoms, more preferably of 1 to 4 carbon atoms.
  • Preferred exendin agonist compounds include those wherein Xaa, is His or Tyr. More preferably Xaa 1 is His.
  • Preferred compounds are those wherein Xaa 25 is Trp or Phe.
  • Preferred compounds are those where Xaa 6 is Phe or naphthylalanine; Xaa 22 is Phe or naphthylalamnne and Xaa 23 is Ile or Val.
  • Xaa 31 , Xaa 36 , Xaa 37 and Xaa 38 are independently selected from Pro, homoproline, thioproline and N-alkylalanine.
  • Z 1 is NH 2 .
  • Z 2 is NH 2 .
  • Xaa 1 is His or Tyr, more preferably His;
  • Xaa 2 is Gly;
  • Xaa 6 is Phe or naphthylalanine;
  • Xaa 14 is Leu, pentylglycine or Met;
  • Xaa 22 is Phe or naphthylalanine;
  • Xaa 23 is Ile or Val;
  • Xaa 31 , Xaa 36 , Xaa 37 and Xaa 38 are independently selected from Pro, homoproline, thioproline or N-alkylalanine. More preferably Z 1 is —NH 2 .
  • especially preferred compounds include those of formula (I) wherein: Xaa 1 is His or Arg; Xaa 2 is Gly or Ala; Xaa 3 is Asp or Glu; Xaa 5 is Ala or Thr; Xaa 6 is Ala, Phe or nephthylalaine; Xaa 7 is Thr or Ser; Xaa 8 is Ala, Ser or Thr; Xaa 9 is Asp or Glu; Xaa 10 is Ala, Leu or pentylglycine; Xaa 11 is Ala or Ser; Xaa 12 is Ala or Lys; Xaa 13 is Ala or Gln; Xaa 14 is Ala, Leu or pentylglycine; Xaa 15 is Ala or Glu; Xaa 16 is Ala or Glu; Xaa 17 is Ala or Glu; Xaa 19 is Ala or Val; Xaa 20
  • Xaa 14 is Leu, Ile, Val or pentylglycine, more preferably Leu or pentylglycine
  • Xaa 25 is Phe, Tyr or naphthylalanine, more preferably Phe or naphthylalanine.
  • Exendin agonist compounds also include those described in U.S. Provisional Application No. 60/066,029 (i.e., priority application to WO 99/25728) including compounds of the formula (II) [SEQ ID NO: 42]:
  • Xaa 31 , Xaa 36 , Xaa 37 and Xaa 38 are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine or N-alkylalanine;
  • Xaa 39 is Ser or Tyr
  • Z 2 is OH or NH 2 ;
  • N-alkyl groups for N-alkylglycine, N-alkylpentylglycine and N-alkylalanine include lower alkyl groups preferably of 1 to about 6 carbon atoms, more preferably of 1 to 4 carbon atoms.
  • Suitable compounds of formula (II) include those described in WO 99/25728 (i.e., application Serial No. PCT/US98/24273, filed Nov. 13, 1998, entitled “Novel Exendin Agonist Compounds”), identified therein in Examples 1-89 (“Compounds 1-89,” respectively), as well as those corresponding compounds identified therein in Examples 104 and 105.
  • Preferred such exendin agonist compounds include those wherein Xaa 1 is His, Ala or Norval. More preferably Xaa 1 is His or Ala. Most preferably Xaa 1 is His.
  • Preferred compounds of formula (II) are those wherein Xaa 25 is Trp or Phe.
  • Preferred compounds of formula (II) are those where Xaa 6 is Ala, Phe or naphthylalanine; Xaa 22 is Phe or naphthylalanihe; and Xaa 23 is Ile or Val.
  • Xaa 31 , Xaa 36 , Xaa 37 and Xaa 38 are independently selected from Pro, homoproline, thioproline and N-alkylalanine.
  • Z 1 is —NH 2 .
  • Z 2 is —NH 2 .
  • Xaa 1 is Ala, His or Tyr, more preferably Ala or His
  • Xaa 2 is Ala or Gly
  • Xaa 6 is Phe or naphthylalanine
  • Xaa 14 is Ala, Leu, pentylglycine or Met
  • Xaa 22 is Phe or naphthylalamne
  • Xaa 23 is Ile or Val
  • Xaa 31 , Xaa 36 , Xaa 37 and Xaa 38 are independently selected from Pro, homoproline, thioproline or N-alkylalanine
  • Xaa 39 is Ser or Tyr, more preferably Ser. More preferably Z 1 is —NH 2 .
  • especially preferred compounds include those of formula (II) wherein: Xaa 1 is His or Ala; Xaa 2 is Gly or Ala; Xaa 3 is Ala, Asp or Glu; Xaa 4 is Ala or Gly; Xaa 5 is Ala or Thr; Xaa 6 is Phe or naphthylalanine; Xaa 7 is Thr or Ser; Xaa 8 is Ala, Ser or Thr; Xaa 9 is Ala, Asp or Glu; Xaa 10 is Ala, Leu or pentylglycine; Xaa 11 is Ala or Ser; Xaa 12 is Ala or Lys; Xaa 13 is Ala or Gln; Xaa 14 is Ala, Leu, Met or pentylglycine; Xaa 15 is Ala or Glu; Xaa 16 is Ala or Glu; Xaa 17 is Ala or Glu;
  • Especially preferred compounds of formula (II) include those described in WO 99/25728 (i.e., application Serial No. PCT/US98/24273, filed Nov. 13, 1998, entitled “Novel Exendin Agonist Compounds”) as having the amino acid sequence of SEQ ID NOs: 5-93 therein.
  • Xaa 14 is Ala, Leu, Ile, Val or pentylglycine, more preferably Leu or pentylglycine
  • Xaa 25 is Ala, Phe, Tyr or naphthylalanine, more preferably Phe or naphthylalanine.
  • narrower genera of compounds having peptides of various lengths for example genera of compounds which do not include peptides having a length of 28, 29 or 30 amino acid residues, respectively.
  • present invention includes narrower genera of compounds described in PCT application Serial No. PCT/US98/24210, filed Nov. 13, 1998, entitled “Novel Exendin Agonist Compounds,” published as WO 99/25727, and having particular amino acid sequences, for example, compounds of the formula (III) [SEQ ID NO: 43]:
  • Xaa 31 , Xaa 36 , Xaa 37 and Xaa 38 are independently selected from the group consisting of Pro, homoproline, thioproline and N-methylylalanine;
  • Z 2 is OH or NH 2 ;
  • Xaa 3 , Xaa 5 , Xaa 6 , Xaag, Xaa 10 , Xaa 11 , Xaa 12 , Xaa 13 , Xaa 14 , Xaa 15 , Xaa 16 , Xaa 17 , Xaa 19 , Xaa 20 , Xaa 21 , Xaa 24 , Xaa 25 , Xaa 26 , Xaa 27 and Xaa 28 are Ala; and pharmaceutically acceptable salts thereof.
  • the present invention includes narrower genera of peptide compounds described in PCT Application Serial No. PCT/US98/24273, filed Nov. 13, 1998, entitled “Novel Exendin Agonist Compounds,” published as WO 99/25728, as having particular amino acid sequences, for example, compounds of the formula [IV] [SEQ ID NO: 44]:
  • Xaa 31 , Xaa 36 , Xaa 37 and Xaa 38 are independently Pro, homoproline, thioproline, or N-methylalanine;
  • Z 2 is -OH or —NH 2 ;
  • Preferred compounds of formula (IV) include those wherein Xaa 1 is His or Ala.
  • Xaa 1 is His.
  • Preferred compounds of formula (IV) include those wherein Xaa 2 is Gly.
  • Preferred compounds of formula (IV) include those wherein Xaa 4 is Ala.
  • Preferred compounds of formula (IV) include those wherein Xaa 9 is Ala.
  • Preferred compounds of formula (IV) include those wherein Xaa 14 is Leu, pentylglycine or Met.
  • Preferred compounds of formula (IV) include those wherein Xaa 25 is Trp or Phe.
  • Xaa 31 , Xaa 36 , Xaa 37 and Xaa 38 are independently selected from the group consisting of Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine and N-alkylalanine; and
  • Z 2 is —OH or —NH 2 ;
  • Preferred exendin agonist compounds of formula (V) include those wherein Xaa 1 is His, Tyr or 4-imidazopropionyl. More preferably Xaa 1 is His.
  • Preferred compounds of formula (V) are those wherein Xaa 14 is Leu, pentylglycine or Met.
  • Preferred compounds of formula (V) are those wherein Xaa 25 is Trp or Phe.
  • Xaa 6 is Phe or naphthylalanine
  • Xaa 22 is Phe or naphthylalanine
  • Xaa 23 is Ile or Val.
  • Z 1 is —NH 2 .
  • especially preferred are such compounds of formula (V) wherein Xaa 31 , Xaa 36 , Xaa 37 and Xaa 38 are independently selected from the group consisting of Pro, homoproline, thioproline and N-alkylalanine. More preferred, Z 2 is —NH 2 .
  • Preferred compounds of formula (V) include those wherein X 1 is Lys Asn, Lys-NH ⁇ —R Asn, or Lys-NH ⁇ —R Ala where R is Lys, Arg, C 1 -C 10 straight chain or branched alkanoyl.
  • Preferred compounds of formula (V) include compounds described in PCT application Serial No. PCT/US98/24210, filed Nov. 13, 1998, entitled “Novel Exendin Agonist Compounds,” published as WO 99/25727, and identified therein as Compound Nos. 62-69.
  • Preferred compounds of formula (V) are those wherein Xaa 25 is Trp or Phe.
  • Preferred compounds of formula (V) are those where Xaa 6 is Ala, Phe or naphthylalanine; Xaa 22 is Phe or naphthylalanine; and Xaa 23 is Ile or Val.
  • Z 1 is —NH 2 .
  • Z 2 is —NH 2 .
  • Xaa 1 is Ala, His or Tyr, more preferably Ala or His
  • Xaa 2 is Ala or Gly
  • Xaa 6 is Phe or naphthylalanine
  • Xaa 14 is Ala, Leu, pentylglycine or Met
  • Xaa 22 is Phe or naphthylalanine
  • Xaa 23 is Ile or Val
  • Xaa 31 , Xaa 36 , Xaa 37 and Xaa 38 are independently selected from Pro, homoproline, thioproline or N-alkylalanine. More preferably Z 1 is —NH 2 .
  • Especially preferred compounds of formula (V) include those described in PCT application Serial No. PCT/US98/24210, filed Nov. 13, 1998, entitled “Novel Exendin Agonist Compounds,” published as WO 99/25727, and having the amino acid sequences identified therein as SEQ ID NOs: 5-93.
  • Xaa 14 is Ala, Leu, Ile, Val or pentylglycine, more preferably Leu or pentylglycine
  • Xaa 25 is Ala, Phe, Tyr or naphthylalamnne, more preferably Phe or naphthylalanine.
  • Xaa 31 , Xaa 36 , Xaa 37 and Xaa 38 are independently selected from the group consisting of Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine and N-alkylalanine;
  • Xaa 31 is Ser or Tyr
  • Z 2 is —OH or —NH 2 ;
  • Preferred compounds of formula (VI) include those wherein Xaa 1 is His, Ala, Norval or 4-imidazopropionyl.
  • Xaa 1 is His, or 4-imidazopropionyl or Ala, more preferably His or 4-imidazopropionyl.
  • Preferred compounds of formula (VI) include those wherein Xaa 2 is Gly.
  • Preferred compounds of formula (VI) include those wherein Xaa 4 is Ala.
  • Preferred compounds of formula (VI) include those wherein Xaa 9 is Ala.
  • Preferred compounds of formula (VI) include those wherein Xaa 14 is Leu, pentylglycine or Met.
  • Preferred compounds of formula (VI) include those wherein Xaa 25 is Trp or Phe.
  • Preferred compounds of formula (VI) include those wherein Xaa 6 is Ala, Phe or naphthylalanine; Xaa 22 is Phe or naphthylalanine; and Xaa 23 is Ile or Val.
  • Preferred compounds of formula (VI) include those wherein Z 1 is —NH 2 .
  • Preferred compounds of formula (VI) include those wherein Xaa 31 , Xaa 36 , Xaa 37 and Xaa 38 are independently selected from the group consisting of Pro, homoproline, thioproline and N-alkylalanine.
  • Preferred compounds of formula (VI) include those wherein Xaa 39 is Ser or Tyr, preferably Ser.
  • Preferred compounds of formula (VI) include those wherein Z 2 is —NH 2 .
  • Preferred compounds of formula (VI) include those 42 wherein Z 1 is —NH 2 .
  • Preferred compounds of formula (VI) include those wherein Xaa 21 is Lys-NH ⁇ —R where R is Lys, Arg, C 1 -C 10 straight chain or branched alkanoyl.
  • Preferred compounds of formula (VI) include those wherein X 1 is Lys Asn, Lys-NH ⁇ —R Asn, or Lys-NH ⁇ —R Ala where R is Lys, Arg, C 1 -C 10 straight chain or branched alkanoyl.
  • Preferred compounds of formula (VI) include those described in PCT Application Serial No. PCT/US98/24273, filed Nov. 13, 1998, entitled “Novel Exendin Agonist Compounds,” published as WO 99/25728, as having an amino acid sequence selected from those identified therein as SEQ ID NOs: 95-110.
  • exendin agonist compounds described in U.S. patent application Ser. No. 09/003,869, filed Jan. 7, 1998, entitled “Use of Exendins And Agonists Thereof For The Reduction of Food Intake,” issued as U.S. Pat. No. 5,956,026, including compounds of the formula (VII) [SEQ ID NO: 47]:
  • N-alkyl groups for N-alkylglycine, N-alkylpentylglycine and N-alkylalanine include lower alkyl groups preferably of 1 to about 6 carbon atoms, more preferably of 1 to 4 carbon atoms.
  • Suitable compounds include those having amino acid sequences of SEQ ID NOs: 10 to 40.
  • Also useful in the present invention are pharmaceutically acceptable salts of the compounds of formula (VII).
  • Preferred exendin agonist compounds include those wherein Xaa 1 is His or Tyr. More preferably Xaa 1 is His.
  • Preferred compounds include those wherein Xaa 25 is Trp or Phe.
  • Xaa 6 is Phe or naphthalanine
  • Xaa 23 is Ile or Val
  • Xaa 31 , Xaa 36 , Xaa 37 and Xaa 38 are independently selected from Pro, homoproline, thioproline or N-alkylalanine.
  • N-alkylalanine has a N-alkyl group of 1 to about 6 carbon atoms.
  • Xaa 36 , Xaa 37 and Xaa 38 are the same anmno acid reside.
  • Xaa 39 is Ser or Tyr, more preferably Ser.
  • Z is —NH 2 .
  • Xaa 1 is His or Tyr, more preferably His
  • Xaa 2 is Gly
  • Xaa 6 is Phe or naphthalanine
  • Xaa 14 is Leu, pentylglycine or Met
  • Xaa 22 is Phe or naphthalanine
  • Xaa 23 is Ile or Val
  • Xaa 31 , Xaa 36 , Xaa 37 and Xaa 38 are independently selected from Pro, homoproline, thioproline or N-alkylalanine
  • Xaa 39 is Ser or Tyr, more preferably Ser. More preferably Z is —NH 2 .
  • Xaa 14 is Leu, Ile, Val or pentylglycine, more preferably Leu or pentylglycine
  • Xaa 25 is Phe, Tyr or naphthylalanine, more preferably Phe or naphthylalanine.
  • Suitable compounds of formula (VIII) include compounds described in PCT Application Serial No. PCT/US98/16387, filed Aug. 6, 1998, entitled “Novel Exendin Agonist Compounds,” published as WO 99/07404, having the amino acid sequences of SEQ ID NOs: 37-40 therein.
  • Preferred exendin agonist compounds of formula (VIII) include those wherein Xaa 1 is His, Tyr or 4-imidazopropionyl. More preferably, Xaa 1 is His or 4-imidazopropionyl.
  • Xaa 6 is Phe or naphthylalanine
  • Xaa 22 is Phe or naphthylalanme
  • Xaa 23 is Ile or Val
  • Xaa 3 l, Xaa 36 , Xaa 37 and Xaa 38 are independently selected from Pro, homoproline, thioproline or N-alkylalanine.
  • Xaa 39 is Ser or Tyr.
  • Z is —NH 2 .
  • the modified exendins and exendin agonists of the present invention may be made by linking one or more polyethylene glycol polymers to an exendin or exendin agonist.
  • the synthesis of exendins and exendin agonists is thus described first, followed by methodology for linking the polyethylene glycol polymer(s) to the exendin or exendin agonist.
  • Exendins and exendin agonist compounds such as exendin analogs and exendin derivatives, described herein may be prepared through peptide purification as described in, for example, Eng, et al., J. Biol. Chem. 265:20259-62, 1990; and Eng, et al., J. Biol. Chem. 267:7402-05, 1992, hereby incorporated by reference herein.
  • exendins and exendin agonist peptides may be prepared by methods known to those skilled in the art, for example, as described in Raufman, et al. ( J. Biol. Chem.
  • an ⁇ -N-carbamoyl protected amino acid and an amino acid attached to the growing peptide chain on a resin are coupled at room temperature in an inert solvent such as dimethylformamide, N-methylpyrrolidinone or methylene chloride in the presence of coupling agents such as dicyclohexylcarbodiimide and 1-hydroxybenzotriazole in the presence of a base such as diisopropylethylamine.
  • an inert solvent such as dimethylformamide, N-methylpyrrolidinone or methylene chloride
  • coupling agents such as dicyclohexylcarbodiimide and 1-hydroxybenzotriazole in the presence of a base such as diisopropylethylamine.
  • the ⁇ -N-carbamoyl protecting group is removed from the resulting peptide-resin using a reagent such as trifluoroacetic acid or piperidine, and the coupling reaction repeated with the next desired N-protected amino acid to be added to the peptide chain.
  • a reagent such as trifluoroacetic acid or piperidine
  • Suitable N-protecting groups are well known in the art, with t-butyloxycarbonyl (tBoc) and fluorenyhnethoxycarbonyl (Fmoc) being preferred herein.
  • the solvents, amino acid derivatives and 4-methylbenzhydryl-amine resin used in the peptide synthesizer may be purchased from Applied Biosystems Inc. (Foster City, Calif.).
  • the following side-chain protected amino acids may be purchased from Applied Biosystems, Inc.: BSD-112344.1-Arg(Pmc), Boc-Thr(Bzl), Fmoc-Thr(t-Bu), Boc-Ser(Bzl), Fmoc-Ser(t-Bu), Boc-Tyr(BrZ), Fmoc-Tyr(t-Bu), Boc-Lys(Cl-Z), Fmoc-Lys(Boc), Boc-Glu(Bzl), Fmoc-Glu(t-Bu), Fmoc-His(Trt), Fmoc-Asn(Trt), and Fmoc-Gln(Trt).
  • Boc-His(BOM) may be purchased from Applied Biosystems, Inc. or Bachem Inc. (Torrance, Calif.).
  • Anisole, dimethylsulfide, phenol, ethanedithiol, and thioanisole may be obtained from Aldrich Chemical Company (Milwaukee, Wis.). Air Products and Chemicals (Allentown, Pa.) supplies HF.
  • Ethyl ether, acetic acid and methanol may be purchased from Fisher Scientific (Pittsburgh, Pa.).
  • Solid phase peptide synthesis may be carried out with an automatic peptide synthesizer (Model 430 A, Applied Biosystems Inc., Foster City, Calif.) using the NMP/HOBt (Option 1 ) system and tBoc or Fmoc chemistry (see, Applied Biosystems User's Manual for the ABI 430A Peptide Synthesizer, Version 1.3B Jul. 1, 1988, section 6, pp. 49-70, Applied Biosystems, Inc., Foster City, Calif.) with capping. Boc-peptide-resins may be cleaved with HF ( ⁇ 50° C. to 0° C., 1 hour).
  • the peptide may be extracted from the resin with alternating water and acetic acid, and the filtrates lyophilized.
  • the Fmoc-peptide resins may be cleaved according to standard methods (Introduction to Cleavage Techniques, Applied Biosystems, Inc., 1990, pp. 6-12).
  • Peptides may also be assembled using an Advanced Chem Tech Synthesizer (Model MPS 350, Louisville, Ky.).
  • Peptides may be purified by RP-HPLC (preparative and analytical) using a Waters Delta Prep 3000 system.
  • a C4, C8 or C18 preparative column (10 ⁇ , 2.2 ⁇ 25 cm; Vydac, Hesperia, Calif.) may be used to isolate peptides, and purity may be determined using a C4, C8 or C18 analytical column (5 ⁇ , 0.46 ⁇ 25 cm; Vydac).
  • Amino acid analyses may be performed on the Waters Pico Tag system and processed using the Maxima program.
  • Peptides may be hydrolyzed by vapor-phase acid hydrolysis (115° C., 20-24 h). Hydrolysates may be derivatized and analyzed by standard methods (Cohen, et al., The Pico Tag Method: A Manual of Advanced Techniques for Amino Acid Analysis , pp. 11-52, Millipore Corporation, Milford, Mass. (1989)).
  • Fast atom bombardment analysis may be carried out by M-Scan, Incorporated (West Chester, Pa.).
  • Mass calibration may be performed using cesium iodide or cesium iodide/glycerol.
  • Plasma desorption ionization analysis using time of flight detection may be carried out on an Applied Biosystems Bio-Ion 20 mass spectrometer. Electrospray mass spectroscopy may be carried and on a VG-Trio machine.
  • Peptide active ingredient compounds useful in the formulations and dosages of the invention may also be prepared using recombinant DNA techniques, using methods now known in the art. See, eg., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2d Ed., Cold Spring Harbor (1989). Alternatively, such compounds may be prepared by homogeneous phase peptide synthesis methods. Non-peptide compounds useful in the present invention may be prepared by art-known methods. For example, phosphate- containing amino acids and peptides containing such amino acids, may be prepared using methods known in the art. See, e.g., Bartlett and Landen, Biorg. Chem. 14:356-377 (1986).
  • the attachment of a PEG on an intact peptide or protein can be accomplished by coupling to amino, carboxyl or thiol groups. These groups will typically be the N and C termini and on the side chains of such naturally occurring amino acids as lysine, aspartic acid, glutamic acid and cysteine. Since exendin 4 and other exendins and exendin agonists can be prepared by solid phase peptide chemistry techniques, a variety of moieties containing diamino and dicarboxylic groups with orthogonal protecting groups can be introduced for conjugation to PEG.
  • the present invention also provides for conjugation of an exendin or exendin agonist to one or more polymers other than polyethylene glycol which can regulate kidney clearance in a manner similar to polyethylene glycol.
  • polymers include albumin and gelatin. See, Gombotz and Pettit, Bioconjugate Chem., 6:332-351, 1995, which is incorporated herein by reference in its entirety.
  • the formulations and dosages described herein are useful in view of their pharmacological properties.
  • the compounds described herein possess activity as agents to reduce glucagon levels and suppress glucagon secretion, as evidenced by the ability to lower glucagon levels in animals and humans. They can be used to treat conditions or diseases that can be alleviated by reducing glucagon levels and suppressing glucagon secretion.
  • the compounds referenced above may form salts with various inorganic and organic acids and bases.
  • Such salts include salts prepared with organic and inorganic acids, for example, HCl, HBr, H 2 SO 4 , H 3 PO 4 , trifluoroacetic acid, acetic acid, formic acid, methanesulfonic acid, toluenesulfonic acid, maleic acid, fuimaric acid and camphorsulfonic acid.
  • Salts prepared with bases include ammonium salts, alkali metal salts, e.g., sodium and potassium salts, and alkali earth salts, e.g., calcium and magnesium salts.
  • Acetate, hydrochloride, and trifluoroacetate salts are preferred.
  • the salts may be formed by conventional means, as by reacting the free acid or base forms of the product with one or more equivalents of the appropriate base or acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is then removed in vacuo or by freeze-drying or by exchanging the ions of an existing salt for another ion on a suitable ion exchange resin.
  • Exendin and exendin agonist formulations and dosages of the invention are useful in view of their exendin-like effects, and may conveniently be provided in the form of formulations suitable for parenteral (including intravenous, intramuscular and subcutaneous) administration. Also described herein are formulations and dosages useful in alternative delivery routes, including oral, nasal, buccal, sublingual and pulmonary.
  • exendin-4 has been explored by measuring exendin-4 in the circulation in conjunction with observation of a biologic response, such as plasma glucose lowering in diabetic animals, after administration. Passage of exendin-4 has been investigated across several surfaces, the respiratory tract (nasal, tracheal and pulmonary routes) and the gut (sublingual, gavage and intraduodenal routes). Biologic effect and appearance of exendin-4 in blood have been observed with each route of administration via the respiratory tract, and with sublingual and gavaged peptide via the gastrointestinal tract. Intra-tracheal administration, nasal administration, administration via the gut, and sublingual administration have all been described.
  • modified exendin or exendin agonist and another anti-glucagon agent such as an amylin or an amylin agonist
  • another anti-glucagon agent such as an amylin or an amylin agonist
  • a suitable administration format may best be determined by a medical practitioner for each patient individually.
  • Suitable pharmaceutically acceptable carriers and their formulation are described in standard formulation treatises, e.g., Remington's Pharmaceutical Sciences by E. W. Martin. See also Wang, Y. J. and Hanson, M. A. “Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers,” Journal of Parenteral Science and Technology, Technical Report No. 10, Supp. 42:2S (1988).
  • compositions useful in the invention can be provided as parenteral compositions for injection or infusion. They can, for example, be suspended in an inert oil, suitably a vegetable oil such as sesame, peanut, olive oil, or other acceptable carrier. Preferably, they are suspended in an aqueous carrier, for example, in an isotonic buffer solution at a pH of about 3.0 to about 7.0, more specifically from about 4.0 to 6.0, and preferably from about 4.0 to about 5.0. These compositions may be sterilized by conventional sterilization techniques, or may be sterile filtered. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH buffering agents. Useful buffers include for example, sodium acetate/acetic acid buffers. A form of repository or “depot” slow release preparation may be used so that therapeutically effective amounts of the preparation are delivered into the bloodstream over many hours or days following transdermal injection or delivery.
  • the desired isotonicity may be accomplished using sodium chloride or other pharmaceutically acceptable agents such as dextrose, boric acid, sodium tartrate, propylene glycol, polyols (such as mannitol and sorbitol), or other inorganic or organic solutes.
  • sodium chloride is preferred particularly for buffers containing sodium ions.
  • the claimed compounds can also be formulated as pharmaceutically acceptable salts (e.g., acid addition salts) and/or complexes thereof.
  • Pharmaceutically acceptable salts are non-toxic salts at the concentration at which they are administered. The preparation of such salts can facilitate the pharmacological use by altering the physical-chemical characteristics of the composition without preventing the composition from exerting its physiological effect. Examples of useful alterations in physical properties include lowering the melting point to facilitate transmucosal administration and increasing the solubility to facilitate the administration of higher concentrations of the drug.
  • Pharmaceutically acceptable salts include acid addition salts such as those containing sulfate, hydrochloride, phosphate, sulfamate, acetate, citrate, lactate, tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, cyclohexylsulfamate and quinate.
  • Pharmaceutically acceptable salts can be obtained from acids such as hydrochloric acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, and quinic acid.
  • acids such as hydrochloric acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, and quinic acid.
  • Such salts may be prepared by, for example, reacting the free acid or base forms of the product with one or more equivalents of the appropriate base or acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is then removed in vacuo or by freeze-drying or by exchanging the ions of an existing salt for another ion on a suitable ion exchange resin.
  • Carriers or excipients can also be used to facilitate administration of the compound.
  • carriers and excipients include calcium carbonate, calcium phosphate, various sugars such as lactose, glucose, or sucrose, or types of starch, cellulose derivatives, gelatin, vegetable oils, polyethylene glycols and physiologically compatible solvents.
  • the compositions or pharmaceutical composition can be administered by different routes including intravenously, intraperitoneal, subcutaneous, and intramuscular, orally, topically, or transmucosally.
  • solutions of the above compositions may be thickened with a thickening agent such as methylcellulose. They may be prepared in emulsified form, either water in oil or oil in water. Any of a wide variety of pharmaceutically acceptable emulsifying agents may be employed including, for example, acacia powder, a non-ionic surfactant (such as a Tween), or an ionic surfactant (such as alkali polyether alcohol sulfates or sulfonates, e.g., a Triton).
  • acacia powder a non-ionic surfactant (such as a Tween)
  • an ionic surfactant such as alkali polyether alcohol sulfates or sulfonates, e.g., a Triton.
  • compositions useful in the invention are prepared by mixing the ingredients following generally accepted procedures.
  • the selected components may be simply mixed in a blender or other standard device to produce a concentrated mixture which may then be adjusted to the final concentration and viscosity by the addition of water or thickening agent and possibly a buffer to control pH or an additional solute to control tonicity.
  • the compounds will be provided in dosage unit form containing an amount of an exendin, exendin agonist, or modified exendin or exendin agonist, with or without another anti-glucagon agent.
  • Therapeutically effective amounts of an exendin, exendin agonist, or modified exendin or exendin agonist for use in the control of glucagon and in conditions in which glucagon levels are beneficially lowered or regulated are those that decrease post-prandial blood glucagon levels as desired. In diabetic or glucose intolerant individuals, plasma glucagon levels may be higher than in normal individuals. In such individuals, beneficial reduction or “smoothing” of post-prandial blood glucagon levels, may be obtained. As will be recognized by those in the field, an effective amount of therapeutic agent will vary with many factors including the age and weight of the patient, the patient's physical condition, the glucagon level or level of inhibition of glucagon suppression to be obtained, and other factors.
  • Such pharmaceutical compositions are useful in causing glucagon to be lowered in a subject and may be used as well in other disorders where lowered or suppressed glucagon is beneficially reduced.
  • the effective daily anti-glucagon dose of the compounds will typically be in the range of 0.01 or 0.03 to about 5 mg/day, preferably about 0.01 or 0.5 to 2 mg/day and more preferably about 0.01 or 0.1 to 1 mg/day, for a 70 kg patient, administered in a single or divided doses.
  • the exact dose to be administered is determined by the attending clinician and is dependent upon where the particular compound lies within the above quoted range, as well as upon the age, weight and condition of the individual.
  • Administration should begin at the first sign of symptoms or shortly after diagnosis of, for example, diabetes mellitus as manifested by elevated glucagon. Administration may be by injection, preferably subcutaneous or intramuscular. Orally active compounds may be taken orally, however dosages should be increased 5-10 fold.
  • the compounds of this invention may be administered to patients in need of such treatment in a dosage ranges similar to those given above, however, the compounds are administered more frequently, for example, one, two, or three times a day.
  • the exendin and exendin agonist formulations and dosages and routes of administration thereof described commonly owned WO 00/41546 and WO 00/41548 (i.e., claiming priority to U.S. Provisional Application 60/116,380, entitled “Novel Exendin Agonist Formulations And Methods Of Administration Thereof,” filed Jan. 14, 1999 (and the corresponding PCT application claiming priority from it that was filed on Jan.
  • a form of repository or “depot” slow release preparation may be used so that therapeutically effective amounts of the preparation are delivered into the bloodstream over many hours or days following transdermal injection or other form of delivery.
  • the effective daily doses of the compounds are described.
  • the exact dose to be administered may be determined by the attending clinician and may be further dependent upon the efficacy of the particular exendin or exendin agonist compound used, as well as upon the age, weight and condition of the individual.
  • the optimal mode of administration of compounds of the present application to a patient depend on factors known in the art such as the particular disease or disorder, the desired effect, and the type of patient. While the compounds will typically be used to treat human patients, they may also be used to treat similar or identical diseases in other vertebrates such as other primates, farm animals such as swine, cattle and poultry, and sports animals and pets such as horses, dogs and cats.
  • the formulation which best supports a parenteral liquid dosage form is one in which the active ingredient(s) is stable with adequate buffering capacity to maintain the pH of the solution over the intended shelf life of the product.
  • the dosage form should be either an isotonic and/or an iso-osmolar solution to either facilitate stability of the active ingredient or lessen the pain on injection or both. Devices that deliver very small injection volumes, however, may not require that the formulation be either isotonic and/or iso-osmolar. If the dosage form is packaged as a unit-dose, then a preservative may be included but is not required. If, however, the dosage form is packaged in a multi-use container, then a preservative is necessary.
  • These dosage forms include approximately 0.005 to about 0.4%, more specifically from about 0.005 to about 0.02%, or from about 0.005 to about 0.05% (w/v), respectively of the active ingredient in an aqueous system along with approximately 0.02 to 0.5% (w/v) of an acetate, phosphate, citrate or glutamate or similar buffer either alone or in combination to obtain a pH of the final composition of approximately 3.0 to 7.0, more 30 specifically from about pH 4.0 to about 6.0, or from about 4.0 to 5.0, as well as either approximately 1.0 to 10% (w/v) of a carbohydrate or polyhydric alcohol iso-osmolality modifier (preferably maunitol) or up to about 0.9% saline or a combination of both leading to an isotonic or an iso-osmolar solution in an aqueous continuous phase.
  • a carbohydrate or polyhydric alcohol iso-osmolality modifier preferably maunitol
  • an anti-microbial preservative selected from the group consisting of m-cresol, benzyl alcohol, methyl ethyl, propyl and butyl parabens and phenol is also present if the formulation is packaged in a multi-use container. A sufficient amount of water for injection is added to obtain the desired concentration of solution. Sodium chloride, as well as other excipients, may also be present, if desired. Such excipients, however, must maintain the overall stability of the active ingredient.
  • Polyhydric alcohols and carbohydrates share the same feature in their backbones, i.e., —CHOH—CHOH—.
  • the polyhydric alcohols include such compounds as sorbitol, mannitol, glycerol, and polyethylene glycols (PEGs). These compounds are straight-chain molecules.
  • the carbohydrates such as mannose, ribose, trehalose, maltose, glycerol, inositol, glucose and lactose, on the other hand, are cyclic molecules that may contain a keto or aldehyde group. These two classes of compounds will also be effective in stabilizing protein against denaturation caused by elevated temperature and by freeze-thaw or freeze-drying processes.
  • Suitable carbohydrates include galactose, arabinose, lactose or any other carbohydrate which does not have an adverse affect on a diabetic patient, i.e., the carbohydrate is not metabolized to form large concentrations of glucose in the blood. Such carbohydrates are well known in the art as suitable for diabetics.
  • the peptides of the present invention are admixed with a polyhydric alcohol such as sorbitol, mannitol, inositol, glycerol, xylitol, and polypropylene/ethylene glycol copolymer, as well as various polyethylene glycols (PEG) of molecular weight 200, 400, 1450, 3350, 4000, 6000, and 8000).
  • a polyhydric alcohol such as sorbitol, mannitol, inositol, glycerol, xylitol, and polypropylene/ethylene glycol copolymer, as well as various polyethylene glycols (PEG) of molecular weight 200, 400, 1450, 3350, 4000, 6000, and 8000).
  • PEG polyethylene glycols
  • the liquid formulation of the invention should be substantially isotonic and/or iso-osmolar.
  • An isotonic solution may be defined as a solution that has a concentration of electrolytes, or a combination of electrolytes and non-electrolytes that will exert equivalent osmotic pressure as that into which it is being introduced, here for example in the case of parenteral injection of the formulation, a mammalian tissue.
  • an iso-osmolar solution may be defined as a solution that has a concentration of non-electrolytes that will exert equivalent osmotic pressure as that into which it is being introduced.
  • substantially isotonic means within ⁇ 20% of isotonicity, preferably within ⁇ 10%.
  • substantially iso-osmolar means within ⁇ 20% of iso-osmolality, preferably within ⁇ 10%.
  • the formulated product for injection is included within a container, typically, for example, a vial, cartridge, prefilled syringe or disposable pen.
  • the formulation which best support a unit-dose parenteral lyophilized dosage form is one in which the active ingredient is reasonably stable, with or without adequate buffering capacity to maintain the pH of the solution over the intended shelf life of the reconstituted product.
  • the dosage form should contain a bulking agent to facilitate cake formation.
  • the bulking agent may also act as a tonicifer and/or iso-osmolality modifier upon reconstitution to either facilitate stability of the active ingredient and/or lessen the pain on injection.
  • devices that deliver very small injection volumes may not require the formulation to be isotonic and/or iso-osmolar.
  • a surfactant may also benefit the properties of the cake and/or facilitate reconstitution.
  • These dosage forms include approximately 0.005 to about 0.4%, more specifically from about 0.005 to about 0.02%, or 0.005 to 0.05% (w/v) of the active ingredient. It may not be necessary to include a buffer in the formulation and/or to reconstitute the lyophile with a buffer if the intention is to consume the contents of the container within the stability period established for the reconstituted active ingredient. If a buffer is used, it may be included in the lyophile or in the reconstitution solvent.
  • the formulation and/or the reconstitution solvent may contain individually or collectively approximately 0.02 to 0.5% (w/v) of an acetate, phosphate, citrate or glutamate buffer either alone or in combination to obtain a pH of the final composition of approximately 3.0 to 7.0, more specifically from about pH 4.0 to about 6.0, or from about 4.0 to 5.0.
  • the bulking agent may consist of either approximately 1.0 to 10% (w/v) of a carbohydrate or polyhydric alcohol iso-osmolality modifier (as described above) or up to 0.9% saline or a combination of both leading to a isotonic or iso-osmolar solution in the reconstituted aqueous phase.
  • a surfactant preferably about 0.1 to about 1.0% (w/v) of polysorbate 80 or other non-ionic detergent, may be included.
  • sodium chloride as well as other excipients, may also be present in the lyophilized unit-dosage formulation, if desired. Such excipients, however, must maintain the overall stability of the active ingredient. The formulation will be lyophilized within the validation parameters identified to maintain stability of the active ingredient.
  • the liquid formulation of the invention before lyophilization should be substantially isotonic and/or iso-osmolar either before lyophilization or to enable formation of isotonic and/or iso-osmolar solutions after reconstitution.
  • the formulation should be used within the period established by shelf-life studies on both the lyophilized form and following reconstitution.
  • the lyophilized product is included within a container, typically, for example, a vial. If other containers are used such as a cartridge, pre-filled syringe, or disposable pen, the reconstitution solvent may also be included.
  • the formulation which best supports a multi-dose parenteral lyophilized dosage form is one in which the active ingredient is reasonably stable with adequate buffering capacity to maintain the pH of the solution over the intended “in-use” shelf-life of the product.
  • the dosage form should contain a bulking agent to facilitate cake formation.
  • the bulking agent may also act as a tonicifer and/or iso-osmolality modifier upon reconstitution to either facilitate stability of the active ingredient or lessen the pain on injection or both.
  • devices that deliver very small injection volumes may not require the formulation to be either isotonic and/or iso-osmolar.
  • a preservative is, however, necessary to facilitate multiple use by the patient.
  • These dosage forms include approximately 0 . 005 to about 0.4%, more specifically from about 0.005 to about 0.02%, or from about 0.005 to 0.05% (w/v), respectively of the active ingredient. It may not be necessary to include a buffer in the formulation and/or to reconstitute the lyophile with a buffer if the intention is to consume the contents of the container within the stability period established for the reconstituted active ingredient. If a buffer is used, it may be included in the lyophile or in the reconstitution solvent.
  • the formulation and/or the reconstitution solvent may contain individually or collectively approximately 0.02 to 0.5% (w/v) of an acetate, phosphate, citrate or glutamate buffer either alone or in combination to obtain a pH of the final composition of approximately 3.0 to 7.0, more specifically from about pH 4.0 to about 6.0, or from about 4.0 to 5.0.
  • the bulking agent may consist of either approximately 1.0 to 10% (w/v) of a carbohydrate or a polyhydric alcohol iso-osmolality modifier (preferably mannitol) or up to 0.9% saline, or a combination of both, leading to an isotonic or iso-osmolar solution in the reconstituted aqueous phase.
  • a surfactant preferably about 0.1 to about 1.0% (w/v) of polysorbate 80 or other non-ionic detergent, may be included.
  • an anti-microbial preservative selected from the group consisting of m-cresol, benzyl alcohol, methyl, ethyl, propyl and butyl parabens and phenol (preferably m-cresol) is also present if the formulation is packaged in a multi-use container.
  • Sodium chloride, as well as other excipients may also be present, if desired. Again, however, such excipients must maintain the overall stability of the active ingredient.
  • the formulation should be lyophilized within the validation parameters identified to maintain stability of the active ingredient.
  • the liquid formulation of the invention should be substantially isotonic and/or iso-osmolar either before lyophilization or to enable formation of isotonic and/or iso-osmolar solutions after reconstitution.
  • the formulation should be used within the period established by shelf-life studies on both the lyophilized form and following reconstitution.
  • the lyophilized product is included within a container, typically, for example, a vial. If other containers are used such as a cartridge, pre-filled syringe or disposable pen, the reconstitution solvent may also be included.
  • the formulations that best support oral, nasal, pulmonary and/or intra-tracheal dosage forms may be either preserved or unpreserved liquid formulations and/or dry powder or, for oral administration, solid formulations.
  • the preserved or unpreserved liquid formulations will be essentially identical to the formulations described above under preserved or unpreserved liquid parenteral formulations.
  • the pH of the solution should be about 3.0 to 7.0, with a pH greater than or equal to about 5.0 being most preferred to reduce the potential for bronchoconstriction.
  • the dry powder formulations may contain a bulking agent and/or salts to facilitate particle size formation and appropriate particle size distribution. A surfactant and/or salts may also benefit the properties of the particle morphology and/or facilitate tissue uptake of the active ingredient.
  • dry powder dosage forms can range from 1% to 100% (w/w), respectively of the active ingredient. It may not be necessary to include a bulking agent and/or salts to facilitate particle size formation and/or distribution.
  • the bulking agent and/or salts may consist of either approximately 0 to 99% (w/w) of a carbohydrate or polyhydric alcohol or approximately 0 to 99% salt or a combination of both leading to the preferred particle size and distribution.
  • a surfactant preferably about 0.1 to about 1.0% (w/w) of polysorbate 80 or other non-ionic detergent, may be included.
  • Sodium chloride, as well as other excipients may also be present, if desired. Such excipients, however, must maintain the overall stability of the active ingredient and facilitate the proper level of hydration.
  • formulations that best support nasal and/or intra-tracheal dosage forms may be either preserved or unpreserved liquid dosage formulations described previously.
  • Dissolvable gels and/or patches may be used to facilitate buccal delivery.
  • the gels may be prepared from various types of starch and/or cellulose derivatives.
  • Sublingual delivery may be best supported by liquid formulations similar to those described above as parenteral liquid or parenteral lyophilized formulations after reconstitution except without the need for the dosage form to be an isotonic and/or iso-osmolar solution.
  • Solid dosage forms may be similar to oral solid dosage forms except that they must be readily dissolvable under the tongue.
  • Oral delivery may be best supported by a liquid (gel cap) formulation that is similar to the parenteral liquid formulation except that the solution may be more concentrated and may contain additional additives to facilitate uptake of the active ingredient by the small intestine.
  • Solid dosage forms will contain inert ingredients along with the active ingredient to facilitate tablet formation. These ingredients may include polyhedral alcohols (such as mannitol), carbohydrates, or types of starch, cellulose derivatives, and/or other inert, physiologically compatible materials.
  • the tablet may be enterically coated to minimize digestion in the stomach and thereby facilitate dissolution and uptake further along the alimentary canal.
  • Example 14 a double blind, placebo-controlled single ascending dose study examining the safety, tolerability, and pharmacokinetics of subcutaneous exendin-4 in healthy volunteers has been completed.
  • Five single subcutaneous doses of exendin-4 (0.01, 0.05, 0.1, 0.2 or 0.3 ⁇ g/kg) were studied in 40 healthy male volunteers in the fasting state.
  • Maximum plasma exendin-4 concentrations were achieved between one and two hours post-dose with little difference among the doses examined. Examination of the data indicated a dose dependent increase for C max . There were no serious adverse events reported in this study.
  • exendin-4 was well tolerated at subcutaneous doses up to and including 0.1 ⁇ g/kg. A decrease in plasma glucose concentration was also observed at this dose. At doses of 0.2 ⁇ g/kg and higher, the most commonly observed adverse events were headache, nausea, vomiting, dizziness, and postural hypotension. There was a transient fall in plasma glucose concentration following administration of doses of 0.05 ⁇ g/kg and above.
  • exendin-4 The feasibility of alternate routes of delivery for exendin-4 has been explored by measuring exendin-4 in the circulation in conjunction with observation of a biologic response, such as plasma glucose lowering in diabetic animals, after administration. Passage of exendin-4 has been investigated across several surfaces, the respiratory tract (nasal, tracheal, and pulmonary routes) and the gut (sublingual, gavage and intraduodenal routes). Biologic effect and appearance of exendin-4 in blood have been observed with each route of administration via the respiratory tract, and with sublingual and gavaged peptide via the gastrointestinal tract.
  • a biologic response such as plasma glucose lowering in diabetic animals
  • Intra-tracheal Administration As described herein, intra-tracheal administration of exendin-4 into fasted rats (20 ⁇ g/500 ⁇ L/animal) produced a rise in the mean plasma exendin-4 concentration to 2060 ⁇ 960 ⁇ g/mL within 5-10 minutes after administration. Elevated plasma exendin-4 concentrations were maintained for at least 1 hour after instillation (see FIG. 7 ). In diabetic db/db mice, intra-tracheal instillation of exendin-4 (1 ⁇ g/animal) lowered plasma glucose concentration by 30% while that in the vehicle control group increased by 41% 1.5 hours after treatment. In these animals the mean plasma concentration of exendin-4 was 777 ⁇ 365 ⁇ g/ml at 4.5 hours after treatment (see FIGS. 8 a and 8 b ).
  • IRMA immunoradiometric
  • the t1 ⁇ 2 (defined pragmatically as time for plasma to fall below 50% of Cmax) was 30-60 min for the lowest dose and 60-90 min for the 2 higher doses.
  • biologically effective quantities of exendin-4 are rapidly absorbed via the trachea without evoking apparent respiratory distress.
  • the respiratory tract is a viable route of administration of exendin-4.
  • Pulmonary Administration Increased plasma concentrations of exendin-4 were detected in rats exposed to aerosolized exendin-4. Exposure of rats to approximately 8 ng of aerosolized exendin-4 per mL of atmosphere for 10 minutes resulted in peak plasma exendin-4 concentrations of 300-1900 ⁇ g/mL 5 minutes following treatment (see FIG. 11 ). Similar exposure of diabetic db/db mice to aerosolized exendin-4 lead to a 33% decrease in plasma glucose concentration after 1 hour, when a mean plasma exendin-4 concentration of 170 ⁇ 67 ⁇ g/mL was detected. Diabetic db/db mice in the control group exposed to aerosolized saline recorded no change in plasma glucose (see FIGS. 12 a and 12 b ).
  • Sublingual Administration Sublingual application of exendin-4 (100 ⁇ g/5 ⁇ L/animal) to diabetic db/db mice led to a 15% decrease in plasma glucose concentration one hour after treatment. A 30% increase was observed for the control group receiving saline. The mean exendin-4 plasma level at 60 minutes was 4520 ⁇ 1846 pg/mL (see FIGS. 15 a , 15 b , and 15 c ).
  • exendin-4 can be delivered at bioeffective doses via the sublingual route. Bioavailability and C max were greatest, T max was shortest, and variability of availability was least with the lowest sublingual dose. The lowest sublingual dose resulted in plasma concentrations similar to those that are predicted to be effective in lowering glucose in humans ( ⁇ 50-100 pM).
  • the optimal formulation and mode of administration of compounds of the present application to a patient depend on factors known in the art such as the particular disease or disorder, the desired effect, and the type of patient. While the compounds will typically be used to treat human patients, they may also be used to treat sinilar or identical diseases in other vertebrates such as other primates, farm animals such as swine, cattle and poultry, and sports animals and pets such as horses, dogs and cats.
  • the above amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.). In general, single-coupling cycles were used throughout the synthesis and Fast Moc (HBTU activation) chemistry was employed. Deprotection (Fmoc group removal) of the growing peptide chain was achieved using piperidine.
  • Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
  • the solution containing peptide was applied to a preparative C-18 column and purified (10% to 40% Solvent B in Solvent A over 40 minutes). Purity of fractions was determined isocratically using a C-18 analytical column. Pure fractions were pooled furnishing the above-identified peptide. Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 19.2 minutes.
  • the kidney can play a major role in the elimination of some molecules (drugs, peptides, proteins). For some molecules, this process begins when the kidney filters the blood at the glomerulus to produce the ultrafiltrate described below.
  • the glomerular filter discriminates not only on the basis of molecular weight but also by acting as a negatively charged selective barrier, promoting retention of anionic compounds.
  • the free fraction of molecules in the plasma (not protein bound) with a molecular weight less than 5 kD and an effective radii less than 15 ⁇ are easily filtered. For larger molecular weight molecules they are filtered on a more restrictive and limited basis, principally by molecular size, structure and net charge.
  • the cutoff point for glomerular filtration lies between albumin (67 kD) which is retained and hemoglobin (68 kD) which is filtered.
  • Albumin with an effective radius of about 36 ⁇ is filtered less than 1% at the glomerulus.
  • a molecule travels to the proximal tubule where it is either reabsorbed or it passes on through the loop of Henle to the distal tubule where collecting ducts drain the filtrate into the bladder.
  • Filtered proteins and peptides are typically cleaved by brush border enzymes in the proximal tubule, from where they are efficiently retrieved by sodium/amino cotransporters (scavenging pumps). Otherwise, molecules which are polar, ionized and of large molecular weight will not be reabsorbed. Throughout this process metabolizing enzymes in the renal cortex (proximal tubules) may also degrade the molecule into more polar molecules, thereby increasing the probability for excretion into the urine.
  • peptide hormones for example, amylin, calcitonins
  • vascular ectoenzymes accessible to the plasma, independently of the process of glomerular filtration.
  • rates of peptide clearance from the plasma are similar to the rate of renal plasma flow, which is 3-fold greater than the rate of glomerular filtration.
  • Exendin clearance rates in intact rats were, again, similar to glomerular filtration rates expected in those rats (4.2 mL/min). Taken together these results indicate that very little metabolism occurs systemically and that most of the clearance of exendin 4 is through the kidney via filtration (but not by renal intravascular proteolysis). The low amounts of immunoreactive full-length exendin in the urine are consistent with it being cleaved by brush border enzymes in the proximal tubule after filtration.
  • Absolute or relative hyperglucagonemia is often a feature of, for example, type 1 and type 2 diabetes mellitus, and the suppression of excessive glucagon secretion in these and other conditions described or referred to herein is a potential benefit of therapy using glucagonostatic agents.
  • exendin-4 on glucagon secretion in male anaesthetized Diabetic Fatty Zucker (ZDF) rats was examined. Using an hyperinsulinemic hyperglycemic clamp protocol, factors tending to influence glucagon secretion were held constant.
  • Plasma glucose concentrations were reduced in all doses of exendin-4 compared to PBO although insulin concentrations were not significantly different.
  • the 8 hour mean ⁇ SE changes in plasma glucose AUC from baseline were +391 ⁇ 187, ⁇ 263 ⁇ 108, ⁇ 247 ⁇ 64, ⁇ 336 ⁇ 139, and ⁇ 328 ⁇ 70 mg*hr/dL for the PBO, 0.1, 0.2, 0.3, and 0.4 ⁇ g/kg doses respectively.
  • the 3 hr changes in plasma glucagon were +128.0 ⁇ 19.2, ⁇ 5.6 ⁇ 10.5, ⁇ 29.4 ⁇ 18.6, ⁇ 40.5 ⁇ 24.5, and +6.9 ⁇ 38.6 ⁇ g*hr/mL respectively.
  • the gastric emptying rate was slowed in all doses and the mean total absorbed acetaminophen over 6 hours was reduced by 51%, 50%, 57% and 79% compared to PBO for 0.1, 0.2, 0.3, and 0.4 ⁇ g/kg doses respectively.
  • SC injection of exendin-4 to patients identified no safety issues, was tolerated at doses ⁇ 0.3 ⁇ g/kg, reduced plasma glucose and glucagon and slowed the rate of gastric emptying.
  • exendin 4 a 39 amino acid peptide with a molecular weight of 4187, modifications that increase its size and/or increase its anionic nature will decrease its ability to be filtered by the kidney. Because clearance of exendin 4 is largely by the kidney this will effectively increase its half life.
  • Other properties of PEGylation increased plasma half-life due to evasion of such renal and/or cellular clearance mechanisms that may exist; reduced immunogenicity and antigenicity; increased solubility; resistance to proteolysis; reduced toxicity (avoid dose spike); improved thermal and mechanical stability; improved permeability of the mucus or epithelial layer; and selective control over a specific biological fimction) are also of potential benefit for exendin 4 and exendin agonists.
  • exendin 4 has a molecular weight of approximately 4.2 kD and is anionic in nature with an overall net charge of approximately ⁇ 2 at physiological pH.
  • PEG constituents may be covalently linked to exendin 4 or an analog of exendin 4, for example, with one PEG constituent being preferred.
  • the size of the PEG can vary from a molecular weight of 500 to 20,000, preferably between 5,000 and 12,000.
  • Exendin 4 has two lysines that can be modified by attachment of PEG.
  • the two lysines at positions 12 and 27 were moderately affected by this substitution suggesting that loss of the lysine specific R group side chain (methylene chain plus epsilon-amino group) is tolerated.
  • the two lysine positions are appropriate for PEG attachment (see compounds 1 and 2).
  • the epsilon-amino groups at these positions may be masked thereby increasing the anionic nature of the peptide.
  • H K(PEG) EGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH 2 (204) HGEG K(PEG) FTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH 2 (205) HGEGTFT K(PEG) DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH 2 (206) HGEGTFTSD K(PEG) SKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH 2 (207) HGEGTFTSDL K(PEG) KQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH 2 (208) HGEGTFTSDLSK K(PEG) MEEEAVRLFIEWLKNGGPSSGAPPPS-NH 2 (209)* HGEGTFTSDLSKQME K(PEG) EAVRLFIEWLKNGGPSSGAPPPS-NH 2 (210)* HGEGTFTSDLSKQMEE K(PEG) AVRLFIEWLKNGGPSSGAPPPS-NH
  • the three positions* above normally containing a glutamic acid that were indicated for modification with K(PEG) can also be modified by conjugation to the glutamic side chain carboxyl group, E(PEG).
  • Lys-PEG Another analog in which the Lys-PEG can be added is at the supposed GlyGly turn:
  • Positions 29-39 of exendin-4 may not be critical for the glucose lowering activity as evidenced by AC3177 having nearly equipotent activity to exendin 4, and any of them, alone or in combination, can be substituted for K(PEG) or an equivalent.
  • Exendin-4 is a Circulating, Meal-Related Peptide in the Gila Monster
  • Exendin-4 Decreases Glucagon Secretion During Hyperglycemic Clamps in Diabetic Fatty Zucker Rats
  • Absolute or relative hyperglucagonemia is often a feature of type 1 and type 2 diabetes mellitus, and the suppression of excessive glucagon secretion is a potential benefit of therapy using glucagonostatic agents.
  • ZDF Diabetic Fatty Zucker rats
  • the lower limit of quantitation was 15 pM (63 pg/mL).
  • the estimated t1 ⁇ 2 for exendin-4 was 18-41 min for i.v. bolus, 28-49 for i.v. continuous, 90-216 min for s.c. and 125-174 min for i.p. injection.
  • Bioavailability was 65-76% for s.c. and i.p. injection.
  • Clearance determined from the i.v. infusion was 4-8 mL/min. Both C max and AUC values within each route of administration were proportional to dose. Volume of distribution was 457-867 mL. Clearance and bioavailability were not dose dependent.
  • C max or steady-state plasma concentration; C ss ) is shown in the table below
  • This experiment compares the insulinotropic actions of synthetic exendin-4 and GLP-1 in vivo following an intravenous (i.v.) glucose challenge in rats.
  • Sprague-Dawley rats ( ⁇ 400 g) were anesthetized with halothane and cannulated via the femoral artery and saphenous vein.
  • D-glucose (5.7 mmol/kg, 0.8 ml) was injected i.v.
  • exendin-4 Amplification of glucose-stimulated insulin release by exendin-4 was also tested at infusion rates of 3 and 300 pmol/kg/min and shown to be dose-dependent. Thus, exendin-4 is more potent and/or effective than GLP-1 in amplifyng glucose-stimulated insulin release in intact rats.
  • IRMA sandwich-type immunoradio-metric
  • Assay validation in rat, monkey, dog, rabbit and human plasmas showed inter- and intra-assay coefficients of variation ⁇ 20% and ⁇ 10%, respectively, accuracy of ⁇ 15% with target low, mid and high controls, and lower and upper limits of quantitation of 62.8 and 2512 pg/mL, respectively.
  • Plasma samples from 28-day subcutaneous toxicity evaluations of exendin-4 in rats and monkeys and a Phase I clinical study in normal subjects were evaluated using the IRMA. The C values in the animals studies are shown in the table below. Human samples from subcutaneous administration of 0.05, 0.1, 0.2 and 0.3 ⁇ g/kg yielded C max values of 90, 224, 370 and 587 pg/mL.
  • Exendin-4 was synthesized by solid phase peptide synthesis techniques and compared to synthetic GLP-1 in terms of in vitro binding to, and activation of, GLP-1 receptors, and in vivo in terms of lowering plasma glucose in diabetic dbldb mice.
  • a plasma membrane preparation of a rat insulinoma cell line (RINm5f) that expresses the GLP-1 receptor the peptides were assayed for their ability to bind and displace radiolabeled GLP-1 and for their ability to stimulate the production of cAMP.
  • the relative order of binding potency was found to be GLP-1>exendin-4.
  • Glucose-lowering Binding IC50 (nM) Cyclase EC50 (nM) ED50 ( ⁇ g) GLP-1 0.15 0.28 20.6 Exendin-4 0.66 0.30 0.006
  • This Example tests whether the beneficial effects of exendin-4 in ZDF rats were secondary to changes in food intake. It compares effects obtained with exendin-4 to effects observed in saline-treated matched animals who consumed the same amount of food as was eaten by ZDF rats injected subcutaneously twice daily with 10 ⁇ g exendin-4. Plasma glucose and HbAlc were measured weekly for 6 weeks. One day after the last treatment, animals were anesthetized with halothane and subjected to an hyperinsulinemic (50 mU/kg/min) euglycemic clamp.
  • Another index of insulin sensitivity, plasma lactate concentration differed significantly between treatment groups (P ⁇ 0.02 ANOVA) and was lowest in exendin-4-treated rats.
  • exendin-4 treatment is associated with improvement in glycemic indices and in insulin sensitivity that is partly, but not fully, matched in controls fed the same amount of food, indicating that improvements in metabolic control with exendin-4 in ZDF rats are at least partly due to mechanisms beyond caloric restriction.
  • exendin-4 formulated for subcutaneous injection was evaluated in healthy male volunteers while assessing effects upon plasma glucose and insulin concentrations.
  • Five single subcutaneous doses of exendin-4 (0.01, 0.05, 0.1, 0.2 or 0.3 ⁇ g/kg) were studied in 40 healthy male volunteers in the fasting state.
  • Maximum plasma exendin-4 concentrations were achieved between 1 and 2 hours post-dose with little difference among the doses examined. Examination of the data indicated a dose dependent increase for C max .
  • exendin-4 was well tolerated at subcutaneous doses up to and including 0.1 ⁇ g/kg. A decrease in plasma glucose concentration was also observed at this dose. At doses of 0.2 ⁇ g/kg and higher, the most commonly observed adverse events were headache, nausea, vomiting, dizziness, and postural hypotension. There was a transient fall in plasma glucose concentration following administration of doses of 0.05 ⁇ g/kg and above.
  • Plasma glucose decreased following all doses, except 0.01 ⁇ g/kg, reached a nadir by 30 min and returned back to baseline within 180 min.
  • Subjects receiving 0.3 ⁇ g/kg received a caloric beverage 30 minutes after dosing, precluding comparison of their data.
  • This Example tested the delivery of exendin-4 by means alternative to injection, and examined its ability to traverse mucosal surfaces in sufficient quantities to exert biological effect. Changes in concentration of plasma glucose and of intact synthetic exendin-4 (measured by a 2-site imnunoradiometric assay) were observed in db/db mice administered a saline solution containing differing doses of synthetic exendin-4 via the trachea, via an aerosol mist (pulmonary), via gavage (oral), and under the tongue (sublingual). The same routes of administration, as well as intraduodenally and nasally, were tested in rats, and bioavailability was calculated, for example, for sublingual and intra-tracheal routes.
  • Exendin-4 administered via each of the above routes in mice resulted in significant glucose-lowering activity 1 to 4 hours after administration (db/db mice intra-tracheal P ⁇ 0.02; ob/ob mice intra-tracheal P ⁇ 0.0002; db/db mice aerosol P ⁇ 0.0001; gavage P ⁇ 0.002; sublingual P ⁇ 0.02).
  • Dose-dependent increases in plasma exendin-4 concentration were up to 777 ⁇ 365 ⁇ g/mL (db/db mice intra-tracheal); 170 ⁇ 67 ⁇ g/mL (db/db mice aerosol); 4520 ⁇ 1846 ⁇ g/mL (db/db mice sublingual).
  • exendin-4 concentrations were observed up to 68,682 ⁇ 38,661 pg/mL (intra-tracheal); 1900 ⁇ g/iL (pulmonary); 6757 pg/mL (nasal); 3,862 ⁇ 2,844 pg/mL (sublingual); but no apparent absorption or biological activity when delivered intraduodenally.
  • Bioavailability of exendin-4 in saline was 7.3% at lower doses when delivered via the trachea, where 61-74% of Cmax was observed within 5 min.
  • Kinetics thereafter were similar to those observed after subcutaneous administration. Bioavailability of exendin-4 in saline delivered under the tongue was 3.1-9.6% at lower doses.
  • GLP-1[7-36]NH 2 was purchased from Bachem (Torrance, Calif.). All other peptides were prepared using synthesis methods such as those described therein. All chemicals were of the highest commercial grade.
  • the cAMP SPA imuunoassay was purchased from Amersham. The radioligands were purchased from New England Nuclear (Boston, Mass.). RINm5f cells (American Type Tissue Collection, Rockville, Md.) were grown in DME/F12 medium containing 10% fetal bovine serum and 2 mM L-glutamine. Cells were grown at 37° C. and 5% CO 2 /95% humidified air and medium was replaced every 2 to 3 days. Cells were grown to confluence then harvested and homogenized using on a Polytron homogenizer. Cell homogenates were stored frozen at ⁇ 70° C. until used.
  • Receptor binding was assessed by measuring displacement of [ 125 I]GLP-1 or [ 125 I]exendin(9-39) from RINm5f membranes.
  • Assay buffer contained 5 ⁇ g/ml bestatin, 1 ⁇ g/ml phosphoramidon, 1 mg/ml bovine serum albumin (fraction V), 1 mg/ml bacitracin, and 1 mM MgCl 2 in 20 mM HEPES, pH 7.4.
  • membrane protein (Bradford protein assay) was resuspended in 200 ⁇ l assay buffer and incubated with 60 pM [ 125 I]GLP-1 or [ 125 I]exendin(9-39) and unlabeled peptides for 120 minutes at 23° C. in 96 well plates (Nagle Nunc, Rochester, N.Y.). Incubations were terminated by rapid filtration with cold phosphate buffered saline, pH 7.4, through polyethyleneimine-treated GF/B glass fiber filters (Wallac Inc., Gaithersburg, Md.) using a Tomtec Mach II plate harvester (Wallac Inc., Gaithersburg, Md.). Filters were dried, combined with scintillant, and radioactivity determined in a Betaplate liquid scintillant counter (Wallac Inc.).
  • Peptide samples were run in the assay as duplicate points at 6 dilutions over a concentration range of 10 ⁇ 6 M to 10 ⁇ 12 M to generate response curves.
  • the biological activity of a sample is expressed as an IC 50 value, calculated from the raw data using an iterative curve-fitting program using a 4-parameter logistic equation (Prizm, GraphPAD Software).
  • Assay buffer contained 10 ⁇ M GTP, 0.75 mM ATP, 2.5 mM MgCl 2 , 0.5 mM phosphocreatine, 12.5 U/ml creatine kinase, 0.4 mg/ml aprotinin, 1 ⁇ M IBMX in 50 mM HEPES, pH 7.4.
  • Membranes and peptides were combined in 100 ml of assay buffer in 96 well filter-bottom plates (Millipore Corp., Bedford, Mass.). After 20 minutes incubation at 37° C., the assay was terminated by transfer of supernatant by filtration into a fresh 96 well plate using a Millipore vacuum manifold.
  • mice at least 3 months of age were utilized for the study.
  • the mice were obtained from The Jackson Laboratory and allowed to acclimate for at least one week before use. Mice were housed in groups of ten at 22° C. ⁇ 1° C. with a 12:12 light:dark cycle, with lights on at 6 a.m. All animals were deprived of food for 2 hours before taking baseline blood samples. Approximately 70 ⁇ l of blood was drawn from each mouse via eye puncture, after a light anesthesia with metophane. After collecting baseline blood samples, to measure plasma glucose concentrations, all animals receive subcutaneous injections of either vehicle (10.9% NaCl), exendin-4 or test compound (1 ⁇ g) in vehicle. Blood samples were drawn again, using the same procedure, after exactly one hour from the injections, and plasma glucose concentrations were measured. For each animal, the % change in plasma value, from baseline value, was calculated.
  • mice C57BLKS/J-m-db/db mice, at least 3 months of age were utilized for the study.
  • the mice were obtained from The Jackson Laboratory and allowed to acclimate for at least one week before use. Mice were housed in groups of ten at 22° C. ⁇ 1° C. with a 12:12 light:dark cycle, with lights on at 6 a.m. All animals were deprived of food for 2 hours before taking baseline blood samples. Approximately 70 ⁇ l of blood was drawn from each mouse via eye puncture, after a light anesthesia with metophane. After collecting baseline blood samples, to measure plasma glucose concentrations, all animals receive subcutaneous injections of either vehicle, exendin-4 or test compound in concentrations indicated. Blood samples were drawn again, using the same procedure, after exactly one hour from the injections, and plasma glucose concentrations were measured. For each animal, the % change in plasma value, from baseline value, was calculated and a dose dependent relationship was evaluated using Graphpad Prizmm software.
  • Conscious rats received by gavage 1.5 ml of an acaloric gel containing 1.5% methyl cellulose (M-0262, Sigma Chemical Co, St Louis, Mo.) and 0.05% phenol red indicator.
  • rats were anesthetized using 5% halothane, the stomach exposed and clamped at the pyloric and lower esophageal sphincters using artery forceps, removed and opened into an alkaline solution which was made up to a fixed volume.
  • Stomach content was derived from the intensity of the phenol red in the alkaline solution, measured by absorbance at a wavelength of 560 nm.
  • the stomach and small intestine were both excised and opened into an alkaline solution.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Novel formulations containing exendins, exendin agonists and/or exendin analogs are provided

Description

    RELATED APPLICATIONS
  • This application is a continuation of U.S. application Ser. No. 11/272,488 filed Nov. 10, 2005, which is a continuation-in-part of U.S. application Ser. No. 11/083,730 filed Mar. 18, 2005, issued as U.S. Pat. No. 7,153,825, which is a continuation of U.S. application Ser. No. 09/889,331 filed Dec. 18, 2001, issued as U.S. Pat. No. 6,872,700, which is a §371 of PCT/US00/00942 filed Jan. 14, 2000, claiming priority to U.S. application Ser. No. 60,175,365 filed Jan. 10, 2000, U.S. Application No. 60/132,017 filed Apr. 30, 1999, and U.S. Application No. 60/116,380 filed Jan.14, 1999, the contents of which are hereby incorporated by reference in their entiretics.
    • FIELD OF THE INVENTION
  • The present application relates to novel formulations containing exendins, exendiln agonists and exendin analogs.
    • INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED BY EFS
  • The sequence listing in the present application is being submitted to the electronic filing system, the contents of which are hereby incorporated by reference.
    • BACKGROUND
  • The following description includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art to the presently claimed invention, or relevant, nor that any of the publications specifically or implicitly referenced are prior art.
  • The exendins are peptides that are found in the salivary secretions of the Gila monster and the Mexican Beaded Lizard, reptiles that are endogenous to Arizona and Northern Mexico. Exendin-3 [SEQ ID NO: 1, i.e., His Ser Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser-NH2] is present in the salivary secretions of Heloderma horridum (Mexican Beaded Lizard), and exendin-4 [SEQ ID NO: 2, i.e., His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser-NH2] is present in the salivary secretions of Heloderma suspectum (Gila monster)(Eng, J., et al., J. Biol. Chem., 265:20259-62, 1990; Eng, J., et al., J. Biol. Chem., 267:7402-05, 1992). The amino acid sequence of exendin-3 is shown in FIG. 1. The amino acid sequence of exendin-4 is shown in FIG. 2. Exendin-4 was first thought to be a (potentially toxic) component of the venom. It now appears that exendin-4 is devoid of toxicity, and that it instead is made in salivary glands in the Gila monster.
  • The exendins have some sequence similarity to several members of the glucagon-like peptide family, with the highest homology, 53%, being to GLP-1[7-36]NH2 [SEQ ID NO: 3] (Goke, et al., J. Biol. Chem., 268:19650-55, 1993). GLP-1[7-36]NH2, also sometimes referred to as proglucagon[78-107] or simply “GLP-1” as used most often herein, has an insulinotropic effect, stimulating insulin secretion from pancreatic beta-cells; GLP-1 has also been reported to inhibit glucagon secretion from pancreatic alpha-cells (ørsov, et al., Diabetes, 42:658-61, 1993; D'Alessio, et al., J. Clin. Invest., 97:133-38, 1996). GLP-1 has been reported to inhibit gastric emptying (Willms B, et al., J Clin Endocrinol Metab 81 (1): 327-32, 1996; Wettergren A, et al., Dig Dis Sci 38 (4): 665-73, 1993), and gastric acid secretion (Schjoldager B T, et al., Dig Dis Sci 34 (5): 703-8, 1989; O'Halloran D J, et al., J Endocrinol 126 (1): 169-73, 1990; Wettergren A, et al., Dig Dis Sci 38 (4): 665-73, 1993)). GLP-1[7-37], which has an additional glycine residue at its carboxy terminus, is reported to stimulate insulin secretion in humans (ørskov, et al., Diabetes, 42:658-61, 1993). A transmembrane G-protein adenylate-cyclase-coupled receptor said to be responsible at least in part for the insulinotropic effect of GLP-1 has reportedly been cloned from a beta-cell line (Thorens, Proc. Natl. Acad. Sci. USA 89:8641-45, 1992). GLP-1 has been the focus of significant investigation in recent years due to its reported action on the amplification of stimulated insulin production (Byrne M M, Goke B. Lessons from human studies with glucagon-like peptide-1: Potential of the gut hormone for clinical use. In: Fehmann H C, Goke B. Insulinotropic Gut Hormone Glucagon-Like Peptide 1. Basel, Switzerland: Karger, 1997:219-33).
  • Other reports relate to the inhibition of gastric emptying (Wettergren A, et al., Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man, Dig. Dis. Sci. 1993 April;38(4):665-73), inhibition of glucagon secretion (Creutzfeldt WOC, et al., Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide 1(7-36) amide in type I diabetic patients, Diabetes Care 1996;19(6):580-6), and a purported role in appetite control (Turton M D, et al., A role for glucagon-like peptide-1 in the central regulation of feeding, Nature 1996 January; 379(6560):69-72).
  • GLP-1 has also been reported to restore islet glucose sensitivity in aging rats, restoring their glucose tolerance to that of younger rats (Egan J M, et al., Glucagon-like peptide-1 restores acute-phase insulin release to aged rats, Diabetologia 1997 June;40(Suppl 1):A130). However, the short duration of biological action of GLP-1 in vivo is one feature of the peptide that has hampered its development as a therapeutic agent. Various methods have been tried to prolong the half-life of GLP-1 or GLP-1(7-37), including attempts to alter their amino acid sequence and to deliver them using certain formulations (see, e.g., European Patent Application, entitled “Prolonged Delivery of Peptides,” by Darley, et al., publication number 0 619 322 A2, regarding the inclusion of polyethylene glycol in formulations containing GLP-1 (7-37)).
  • Pharmacological studies have led to reports that exendin-4 can act at GLP-1 receptors on certain insulin-secreting cells, at dispersed acinar cells from guinea pig pancreas, and at parietal cells from stomach; the peptide is also reported to stimulate somatostatin release and inhibit gastrin release in isolated stomachs (Goke, et al., J. Biol. Chem. 268:19650-55, 1993; Schepp, et al., Eur. J. Pharmacol., 69:183-91, 1994; Eissele, et al., Life Sci., 55:629-34, 1994). Exendin-3 and exendin-4 were reportedly found to stimulate cAMP production in, and amylase release from, pancreatic acinar cells (Malhotra, R., et al., Regulatorv Peptides, 41:149-56, 1992; Raufman, et al., J. Biol. Chem. 267:21432-37, 1992; Singh, et al., Regul. Pept. 53:47-59, 1994). Additionally, exendin-4 has a significantly longer duration of action than GLP-1. For example, in one experiment, glucose lowering by exendin-4 in diabetic mice was reported to persist for several hours, and, depending on dose, for up to 24 hours (Eng J. Prolonged effect of exendin-4 on hyperglycemia of db/db mice, Diabetes 1996 May; 45(Suppl 2):152A (abstract 554)). Based on their insulinotropic activities, the use of exendin-3 and exendin-4 for the treatment of diabetes mellitus and the prevention of hyperglycemia has been proposed (Eng, U.S. Pat. No. 5,424,286).
  • The results of an investigation of whether exendins are the species homolog of mammalian GLP-1 was reported by Chen and Drucker who cloned the exendin gene from the Gila monster (J. Biol. Chem. 272(7):4108-15 (1997)). The observation that the Gila monster also has separate genes for proglucagons (from which GLP-1 is processed), that are more similar to mammalian proglucagon than exendin, indicates that exendins are not merely species homologs of GLP-1.
  • To date, agents that serve to delay gastric emptying have generally found a place in medicine as diagnostic aids in gastrointestinal radiological examinations. For example, glucagon is a polypeptide hormone that is produced by the alpha cells of the pancreatic islets of Langerhans. It is a hyperglycemic agent that mobilizes glucose by activating hepatic glycogenolysis. It can to a lesser extent stimulate the secretion of pancreatic insulin. Glucagon is used in the treatment of insulin-induced hypoglycemia, for example, when administration of glucose intravenously is not possible. However, as glucagon reduces the motility of the gastro-intestinal tract it is also used as a diagnostic aid in gastrointestinal radiological examinations. Glucagon has also been used in several studies to treat various painful gastrointestinal disorders associated with spasm. Daniel, et al. (Br. Med. J., 3:720, 1974) reported quicker symptomatic relief of acute diverticulitis in patients treated with glucagon compared with those who had been treated with analgesics or antispasmodics. A review by Glauser, et al. (J. Am. Coll. Emergency Physns, 8:228, 1979) described relief of acute esophageal food obstruction following glucagon therapy. In another study, glucagon significantly relieved pain and tenderness in 21 patients with biliary tract disease compared with 22 patients treated with placebo (M. J. Stower, et al., Br. J. Surg., 69:591-2, 1982).
  • Methods for regulating gastrointestinal motility using amylin agonists are described in commonly owned International Application No. PCT/US94/10225, published Mar. 16, 1995, as WO 1995/007098.
  • Methods for regulating gastrointestinal motility using exendin agonists are described in commonly owned U.S. Pat. No. 6,858,576 (i.e., U.S. patent application Ser. No. 08/908,867, filed Aug. 8, 1997 entitled “Methods for Regulating Gastrointestinal Motility,” which application is a continuation-in-part of U.S. patent application Ser. No. 08/694,954, filed Aug. 8, 1996).
  • Methods for reducing food intake using exendin agonists are described in commonly owned U.S. Pat. No. 5,956,026 (i.e., U.S. patent application Ser. No. 09/003,869, filed Jan. 7, 1998, entitled “Use of Exendin and Agonists Thereof for the Reduction of Food Intake,” which claims the benefit of U.S. Provisional Application No. 60/034,905 filed Jan. 7, 1997, 60/055,404 filed Aug. 7, 1997, 60/065,442 filed Nov. 14, 1997 and 60/066,029 filed Nov. 14, 1997).
  • Novel exendin agonist compounds are described in commonly owned PCT Application Serial No. PCT/US98/16387 filed Aug. 6, 1998, entitled “Novel Exendin Agonist Compounds,” published as WO 99/07404, which claims the benefit of U.S. Patent Application Ser. No. 60/055,404, filed Aug. 8, 1997.
  • Other novel exendin agonists are described in commonly owned PCT Application Serial No. PCT/US98/24210, filed Nov. 13, 1998, entitled “Novel Exendin Agonist Compounds,” published as WO 99/25727, which claims the benefit of U.S. Provisional Application No. 60/065,442 filed Nov. 14, 1997.
  • Still other novel exendin agonists are described in commonly owned PCT Application Serial No. PCT/US98/24273, filed Nov. 13, 1998, entitled “Novel Exendin Agonist Compounds,” published as WO 99/25728, which claims the benefit of U.S. Provisional Application No. 60/066,029 filed Nov. 14, 1997.
  • Other recent advances in exendin related technology are described in WO 99/40788 (i.e., U.S. Provisional Patent Application Ser. No. 60/075,122, filed Feb. 13, 1998, entitled “Inotropic and Diuretic Effects of Exendin and GLP-1”) and in WO 00/41546 and WO 00/41548 (i.e., U.S. Provisional Patent Application Ser. No. 60/116,380, filed Jan. 14, 1998, entitled “Novel Exendin Agonist Formulations and Methods of Administration Thereof”).
  • Polyethylene glycol (PEG) modification of therapeutic peptides and proteins may yield both advantages and disadvantages. While PEG modification may lead to improved circulation time, reduced antigenicity and immunogenicity, improved solubility, resistance to proteolysis, improved bioavailability, reduced toxicity, improved stability, and easier formulation of peptides (See, Francis et al., International Journal of Hematology, 68:1-18, 1998) problems with PEGylation in most cases is substantial reduction in bioactivity. Id. In addition, most methods involve use of linkers that have several types of adverse effects including immunogenicity, instability, toxicity, and reactivity. Id.
  • Glucagonoma (tumor of glucagon-secreting cells) produces, in addition to glucose intolerance, a skin condition, necrolytic migratory erythema. This is a raised scaly red rash, sometimes blistering and eventually crusting, localized to the face, abdomen, extremities and perineum. It can also be associated with inflamation of the tongue and mouth, and diseased nails and thining of the hair. The condition is reported to respond to octreotide, a glucagonostatic hormone analog. The compounds described herein are also useful as glucagonastatic agents and thus in the treatment of this disease, which was was first described in 1966 (Kaplan, L. M. Endocrine Tumors of the Gastrointestinal Tract and Pancreas. Ch 262, p1392: In Harrison's Principles of Internal Medicine, 12th Edition. McGraw-Hill Inc, New York, 1991). The compounds described herein that are useful for lowering glucagon levels and/or suppressing glucagon secretion include exendin, exendin agonists, and modified exendins and exendin agonists and related formulations, and dosage formulations.
  • The contents of the above-identified articles, patents, and patent applications, and all other documents mentioned or cited herein, are hereby incorporated by reference in their entirety. Applicants reserve the right to physically incorporate into this application any and all materials and information from any such articles, patents, patent applications, or other documents mentioned or cited herein.
    • SUMMARY OF THE INVENTION
  • According to one aspect, the present invention provides novel exendin agonist compound formulations and dosages thereof exhibiting advantageous properties that include effects in slowing gastric emptying and lowering plasma glucose levels. Thus, this aspect of the invention includes formulations of exendins and exendin agonists that comprise an exendin or exendin agonist mixed together with a buffer (preferably an acetate buffer), an iso-osmolality modifier (preferably mannitol), and optionally containing a preservative (preferably m-cresol), said formulation having a pH of between about 3.0 and about 7.0 (preferably between about 4.0 and about 5.0).
  • Additional formulations within the scope of the invention include a parenteral liquid dosage form, a lyophilized unit-dosage form, a lyophilized multi-use dosage form, and modifications of these dosage forms that are useful in the oral, nasal, buccal, sublingual, intra-tracheal, and pulmonary delivery of exendins and exendin agonists.
  • Thus, the invention includes parenteral liquid dosage forms that comprise approximately 0.005 to about 0.4%, more specifically from about 0.005 to about 0.02%, or from about 0.005 to about 0.05% (w/v), respectively of the active ingredient in an aqueous system along with approximately 0.02 to 0.5% (w/v) of an acetate, phosphate, citrate or glutamate or similar buffer either alone or in combination to obtain a pH of the final composition of approximately 3.0 to 7.0, more specifically from about pH 4.0 to about 6.0, or from about 4.0 to 5.0, as well as either approximately 1.0 to 10% (w/v) of a carbohydrate or polyhydric alcohol iso-osmolality modifier (preferably mannitol) or up to about 0.9% saline or a combination of both leading to an isotonic or an iso-osmolar solution in an aqueous continuous phase. Approximately 0.005 to 1.0% (w/v) of an anti-microbial preservative selected from the group consisting of m-cresol, benzyl alcohol, methyl, ethyl, propyl and butyl parabens and phenol is also present if the formulation is packaged in a multi-use container. A sufficient amount of water for injection is added to obtain the desired concentration of solution. Sodium chloride, as well as other excipients, may also be present, if desired. Such excipients, however, must maintain the overall stability of the active ingredient. Useful polyhydric alcohols include such compounds as sorbitol, mannitol, glycerol, and polyethylene glycols (PEGs). The polyhydric alcohols and the carbohydrates will also be effective in stabilizing protein against denaturation caused by elevated temperature and by freeze-thaw or freeze-drying processes. Suitable carbohydrates include galactose, arabinose, lactose or any other carbohydrate which does not have an adverse affect on a diabetic patient, if intended for that use, i.e., the carbohydrate is not metabolized to form large concentrations of glucose in the blood. Preferably, the peptides of the present invention are admixed with a polyhydric alcohol such as sorbitol, mannitol, inositol, glycerol, xylitol, and polypropylene/ethylene glycol copolymer, as well as various polyethylene glycols (PEG) of molecular weight 200, 400, 1450, 3350, 4000, 6000, and 8000). Mannitol is the preferred polyhydric alcohol.
  • The lyophilized unit-dose formulations of the present invention are also stable, but need not be isotonic and/or iso-osmolar. They include active ingredient(s), a bulking agent to facilitate cake formation (which may also act as a tonicifer and/or iso-osmolality modifier upon reconstitution to either facilitate stability of the active ingredient and/or lessen the pain on injection), and may also include a surfactant that benefits the properties of the cake and/or facilitates reconstitution. The lyophilized unit-dose formulations of the present invention include approximately 0.005 to about 0.4%, more specifically from about 0.005 to about 0.02%, or 0.005 to 0.05% (w/v) of the active ingredient. It may not be necessary to include a buffer in the formulation and/or to reconstitute the lyophile with a buffer if the intention is to consume the contents of the container within the stability period established for the reconstituted active ingredient. If a buffer is used, it may be included in the lyophile or in the reconstitution solvent. Therefore, the formulation and/or the reconstitution solvent may contain individually or collectively approximately 0.02 to 0.5% (w/v) of an acetate, phosphate, citrate or glutamate buffer either alone or in combination to obtain a pH of the final composition of approximately 3.0 to 7.0, more specifically from about pH 4.0 to about 6.0, or from about 4.0 to 5.0. The bulking agent may consist of either approximately 1.0 to 10% (w/v) of a carbohydrate or polyhydric alcohol iso-osmolality modifier (as described above) or up to 0.9% saline or a combination of both leading to a isotonic or iso-osmolar solution in the reconstituted aqueous phase. A surfactant, preferably about 0.1 to about 1.0% (w/v) of polysorbate 80 or other non-ionic detergent, may be included. As noted above, sodium chloride, as well as other excipients, may also be present in the lyophilized unit-dosage formulation, if desired. The liquid formulation of the invention prior to lyophilization will be substantially isotonic and/or iso-osmolar either before lyophilization or to enable formation of isotonic and/or iso-osmolar solutions after reconstitution.
  • The invention also includes lyophilized and liquid multi-dose formulations. As with the parenteral liquid and lyophilized unit-dosage formulations described above, the lyophilized multi-unit-dosage form should contain a bulking agent to facilitate cake formation. A preservative is included to facilitate multiple use by the patient. These dosage forms include approximately 0.005 to about 0.4%, more specifically from about 0.005 to about 0.02%, or from about 0.005 to 0.05% (w/v), respectively of the active ingredient. If a buffer is used, it may be included in the lyophile or in the reconstitution solvent, and the formulation and/or the reconstitution solvent may contain individually or collectively approximately 0.02 to 0.5% (w/v) of an acetate, phosphate, citrate or glutamate buffer either alone or in combination to obtain a pH of the final composition of approximately 3.0 to 7.0, more specifically from about pH 4.0 to about 6.0, or from about 4.0 to 5.0. The bulking agent may consist of either approximately 1.0 to 10% (w/v) of a carbohydrate or a polyhydric alcohol iso-osmolality modifier (preferably mannitol) or up to 0.9% saline, or a combination of both, leading to an isotonic or iso-osmolar solution in the reconstituted aqueous phase. A surfactant, preferably about 0.1 to about 1.0% (w/v) of polysorbate 80 or other non-ionic detergent, may be included. Approximately 0.005 to 1.0% (w/v) of an anti-microbial preservative selected from the group consisting of m-cresol, benzyl alcohol, methyl, ethyl, propyl and butyl parabens and phenol (preferably m-cresol) is also present if the formulation is packaged in a multi-use container. Sodium chloride, as well as other excipients, may also be present, if desired. The liquid formulation of the invention should be substantially isotonic and/or iso-osmolar either before lyophilization or to enable formation of isotonic and/or iso-osmolar solutions after reconstitution.
  • The invention further includes solid dosage forms useful for oral, buccal, sublingual, intra-tracheal, nasal, and pulmonary delivery. The formulations that best support pulmonary and/or intra-tracheal dosage forms may be either preserved or unpreserved liquid formulations and/or dry powder formulations. The preserved or unpreserved liquid formulations will be essentially identical to the formulations described above under preserved or unpreserved liquid parenteral formulations. The pH of the solution should be about 3.0 to 7.0, more specifically from about 4.0 to 6.0, or from about 4.0 to 5.0, with a pH greater than or equal to about 5.0 being most preferred to reduce the potential for bronchoconstriction. The dry powder formulations may contain a bulking agent and/or salts to facilitate particle size formation and appropriate particle size distribution. A surfactant and/or salts may also benefit the properties of the particle morphology and/or facilitate tissue uptake of the active ingredient. Dry powder dosage forms can range from 1% to 100% (w/w), respectively of the active ingredient. It may not be necessary to include a bulking agent and/or salts to facilitate particle size formation and/or distribution. The bulking agent and/or salts may consist of either approximately 0 to 99% (w/w) of a carbohydrate or polyhydric alcohol or approximately 0 to 99% salt or a combination of both leading to the preferred particle size and distribution. A surfactant, preferably about 0.1 to about 1.0% (w/w) of polysorbate 80 or other non-ionic detergent, may be included. Sodium chloride, as well as other excipients, may also be present, if desired. Such excipients, however, will maintain the overall stability of the active ingredient and facilitate the proper level of hydration.
  • Also within the scope of the invention is the formulation comprising up to 50 mg/ml of an exendin or an exendin agonist in 30 mM acetate buffer (pH about 4.5) and mannitol, with or without a preservative.
  • Further within the scope of the invention are preferred dosages for exendins and exendin agonists when given by injection, and when given by other routes. Thus, formulations for exendin and exendin agonists having comparable potency are provided for the administration by injection of from about 0.1 to about 0.5 μg per kilogram, given one to three times per day. Typically, for the patient with diabetes who weighs in the range from about 70 kilograms (average for the type 1 diabetic) to about 90 kilograms (average for the type 2 diabetic), for example, this will result in the total administration of about 10 to about 120 μg per day in single or divided doses. If administered in divided doses, the doses are preferably administered two or three times per day, and more preferably, two times per day.
  • Oral dosages according to the present invention will include from about 50 to about 100 times the active ingredient, i.e., from about 500 to about 12,000 μg per day in single or divided doses, preferably from about 500 to about 5,000 μg per day. Pulmonary dosages according to the present invention will include from about 10 to about 100 times the active ingredient, i.e., from about 100 to about 12,000 μg per day in single or divided doses, preferably about 500 to 1000 μg per day. Nasal, buccal and sublingual dosages according to the present invention will also include from about 10 to about 100 times the active ingredient, i.e., from about 100 to about 12,000 μg per day in single or divided doses.
  • Preferred dosages for nasal administration are from about 10-1000 to about 1200-12,000 μg per day, for buccal administration from about 10-1000 to about 1200-12,000 μg per day, and for sublingual administration from about 10-1000 to about 1200-8,000 μg per day. Sublingual dosages are preferably smaller than buccal dosages. Administration dosages for exendin agonists having less than or greater than the potency of exendin-4 are increased or decreased as appropriate from those described above and elsewhere herein.
  • Also included within the scope of the present invention are methods of administration of said novel exendin agonist compound formulations and dosages by delivery means alternative to subcutaneous injection or intravenous infusion, including, for example, by nasal delivery, pulmonary delivery, oral delivery, intra-tracheal delivery, sublingual delivery, and buccal delivery.
  • According to another aspect, the present invention provides novel exendin agonist compound formulations and dosages, and methods for the administration thereof, that are useful in treating diabetes (including type 1 and type 2 diabetes), obesity, and other conditions that will benefit from the administration of a therapy that can slow gastric emptying, lowering plasma glucose levels, and reduce food intake.
  • Preferred exendins or exendin agonists for use include:
  • exendin-4 (1-30)
    [SEQ ID NO: 4,
    i.e., His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser
    Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile
    Glu Trp Leu Lys Asn Gly Gly];
    exendin-4 (1-30) amide
    [SEQ ID NO: 5,
    i.e., His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser
    Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile
    Glu Trp Leu Lys Asn Gly Gly-NH2];
    exendin-4 (1-28) amide
    [SEQ ID NO: 6,
    i.e., His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser
    Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile
    Glu Trp Leu Lys Asn-NH2];
    14Leu,25Phe exendin-4 amide
    [SEQ ID NO: 7,
    i.e., His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser
    Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile
    Glu Phe Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala
    Pro Pro Pro Ser-NH2];
    14Leu,25Phe exendin-4 (1-28) amide
    [SEQ ID NO: 8,
    i.e., His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser
    Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile
    Glu Phe Leu Lys Asn-NH2];
    and
    14Leu,22Ala,25Phe exendin-4 (1-28) amide
    [SEQ ID NO: 9,
    i.e., His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser
    Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Ala Ile
    Glu Phe Leu Lys Asn-NH2].
    • Definitions
  • In accordance with the present invention and as used herein, the following terms are defined to have the following meanings, unless explicitly stated otherwise.
  • The term “amino acid” refers to natural amino acids, unnatural amino acids, and amino acid analogs, all in their D and L stereoisomers if their structure allow such stereoisomeric forms. Natural amino acids include alanine (Ala), arginine (Arg), asparagine (Asn), aspartic acid (Asp), cysteine (Cys), glutamine (Gln), glutamic acid (Glu), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), Lysine (Lys), methionine (Met), phenylalanine (Phe), proline (Pro), serine (Ser), threonine (Thr), typtophan (Trp), tyrosine (Tyr) and valine (Val). Unnatural amino acids include, but are not limited to azetidinecarboxylic acid, 2-aminoadipic acid, 3-aminoadipic acid, beta-alanine, aminopropionic acid, 2-aminobutyric acid, 4-aminobutyric acid, 6-aminocaproic acid, 2-aminoheptanoic acid, 2-aminoisobutyric acid, 3-aminoisbutyric acid, 2-aminopimelic acid, tertiary-butylglycine, 2,4-diaminoisobutyric acid, desmosine, 2,2′-diaminopimelic acid, 2,3-diaminopropionic acid, N-ethylglycine, N-ethylasparagine, homoproline, hydroxylysine, allo-hydroxylysine, 3-hydroxyproline, 4-hydroxyproline, isodesmosine, allo-isoleucine, N-methylalanine, N-methylglycine, N-methylisoleucine, N-methylpentylglycine, N-methylvaline, naphthalanine, norvaline, norleucine, ornithine, pentylglycine, pipecolic acid and thioproline. Amino acid analogs include the natural and unnatural amino acids which are chemically blocked, reversibly or irreversibly, or modified on their N-terminal amino group or their side-chain groups, as for example, methionine sulfoxide, methionine sulfone, S-(carboxymethyl)-cysteine, S-(carboxymethyl)-cysteine sulfoxide and S-(carboxymethyl)-cysteine sulfone.
  • The term “amino acid analog” refers to an amino acid wherein either the C-terminal carboxy group, the N-terminal amino group or side-chain functional group has been chemically codified to another functional group. For example, aspartic acid-(beta-methyl ester) is an amino acid analog of aspartic acid; N-ethylglycine is an amino acid analog of glycine; or alanine carboxamide is an amino acid analog of alanine.
  • The term “amino acid residue” refers to radicals having the structure: (1) —C(O)—R—NH—, wherein R typically is —CH(R′)—, wherein R′ is an amino acid side chain, typically H or a carbon containing substitutent;
  • or (2)
  • Figure US20080249018A1-20081009-C00001
  • wherein p is 1, 2 or 3 representing the azetidinecarboxylic acid, proline or pipecolic acid residues, respectively.
  • The term “lower” referred to herein in connection with organic radicals such as alkyl groups defines such groups with up to and including about 6, preferably up to and including 4 and advantageously one or two carbon atoms. Such groups may be straight chain or branched chain.
  • “Pharmaceutically acceptable salt” includes salts of the compounds of the present invention derived from the combination of such compounds and an organic or inorganic acid. In practice the use of the salt form amounts to use of the base form. The compounds of the present invention are useful in both free base and salt form, with both forms being considered as being within the scope of the present invention.
  • In addition, the following abbreviations stand for the following: “ACN” or “CH3CN” refers to acetonitrile. “Boc”, “tBoc” or “Thoc” refers to t-butoxy carbonyl. “DCC” refers to N,N′-dicyclohexylcarbodiimide. “Fmoc” refers to fluorenylmethoxycarbonyl. “HBTU” refers to 2-(1H-benzotriazol-1-yl)-1,1,3,3,-tetramethyluronium hexaflurophosphate. “HOBt” refers to 1-hydroxybenzotriazole monohydrate. “homoP” or hPro” refers to homoproline. “MeAla” or “Nme” refers to N-methylalanine. “naph” refers to naphthylalanine. “pG” or pGly” refers to pentylglycine. “tBuG” refers to tertiary-butylglycine. “ThioP” or tPro” refers to thioproline. “3Hyp” refers to 3-hydroxyproline. “4Hyp” refers to 4-hydroxyproline. “NAG” refers to N-alkylglycine. “NAPG” refers to N-alkylpentylglycine. “Norval” refers to norvaline. “Norleu” refers to norleucine.
  • Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 depicts the amino acid sequence for exendin-3 [SEQ ID NO: 1].
  • FIG. 2 depicts the amino acid sequence for exendin-4 [SEQ ID NO: 2].
  • FIG. 3 depicts the amino acid sequences for certain exendin agonist compounds useful in the present invention [SEQ ID NOs: 10 to 40].
  • FIG. 4 depicts the amino acid sequences for certain compounds of the present invention, Compounds 1-174.
  • FIG. 5 is a graph showing the effect of functional nephrectomy on exendin-4 clearance.
  • FIG. 6 is a graph showing the terminal decay of exendin-4 plasma levels in nephrectomized and sham subjects.
  • FIG. 7 depicts the plasma levels of exendin-4 in rats after intra-tracheal administration.
  • FIG. 8A depicts the plasma exendin-4 concentration after intra-tracheal instillation in db/db mice.
  • FIG. 8B depicts the effect of intra-tracheal administration of exendin-4 on plasma glucose in db/db mice.
  • FIGS. 9A and 9B depict the effect of intra-tracheal administration of exendin-4 on plasma glucose in ob/ob mice.
  • FIG. 10A depicts the plasma exendin-4 concentration after intra-tracheal instillation into rats.
  • FIG. 10B depicts the bioavailability of exendin-4 following intra-tracheal instillation into rats.
  • FIG. 11 depicts plasma exendin-4 concentrations in rats exposed to aerosolized exendin-4 (8 ng/ml) for 10 minutes.
  • FIG. 12A depicts the effect of ten minutes of exposure to aerosolized exendin-4 on plasma glucose in db/db mice.
  • FIG. 12B depicts the plasma exendin-4 concentration after ten minutes of exposure of db/db mice to aerosolized exendin-4.
  • FIG. 13 depicts plasma exendin-4 concentrations in rats after intra-nasal administration of exendin-4.
  • FIG. 14 depicts the effect of intra-gastric administration of exendin-4 on plasma glucose in db/db mice.
  • FIG. 15A depicts the plasma exendin-4 concentration after sublingual administration to db/db mice.
  • FIG. 15B depicts the effect of sublingual administration of exendin-4 on plasma glucose in db/db mice.
  • FIG. 15C depicts the plasma exendin-4 concentration after sublingual administration to rats.
  • FIG. 15D depicts the bioavailability of exendin-4 after sublingual administration.
  • FIG. 15E depicts the Cmax of sublingual exendin-4.
    •  DETAILED DESCRIPTION OF THE INVENTION
  • The present invention relates to relates to methods of suppressing and/or lowering glucagon in a subject, comprising the administration of an exendin, an exendin agonist, or a modified exendin or exendin agonist having an exendin or exendin agonist peptide linked to one or more polyethylene glycol polymers or other compound useful to increase molecular weight. Such methods are useful, for example, in the treatment of hyperglucagonemia and other conditions in which lower levels of glucagon or suppresion of glucagon secretion are of benefit. Such conditions include, but are not limited to, glucagonoma and necrolytic migratory erythema.
    • Modified Exendins And Exendin Agonists
  • The modified exendins and exendin agonists of the present invention include, for example, one or more PEG polymers linked to an exendin or exendin agonist, such as a naturally occurring exendin, a synthetic exendin or an exendin agonist.
    • Exendin-4
  • Exendin-4 is a naturally occurring peptide isolated from the salivary secretions of the Gila monster. Animal testing of exendin-4 has shown that its ability to lower blood glucose persists for several hours. Exendin-4, a 39-amino acid polypeptide, is synthesized using solid phase synthesis as described herein, and this synthetic material has been shown to be identical to that of native exendin-4.
  • As described herein, the nonclinical pharmacology of exendin-4 has been studied. In the brain, exendin-4 binds principally to the area postrema and nucleus tractus solitarius region in the hindbrain and to the subfornical organ in the forebrain. Exendin-4 binding has been observed in the rat and mouse brain and kidney. The structures to which exendin-4 binds in the kidney are unknown.
  • Various experiments have compared the biologic actions of exendin-4 and GLP-1 and demonstrated a more favorable spectrum of properties for exendin-4. A single subcutaneous dose of exendin-4 lowered plasma glucose in db/db (diabetic) and ob/ob (diabetic obese) mice by up to 40%. In Diabetic Fatty Zucker (ZDF) rats, 5 weeks of treatment with exendin-4 lowered HbA,, (a measure of glycosylated hemoglobin used to evaluate plasma glucose levels) by up to 41%. Insulin sensitivity was also improved by 76% following 5 weeks of treatment in obese ZDF rats. In glucose intolerant primates, dose-dependent decreases in plasma glucose were also observed.
  • An insulinotropic action of exendin-4 has also been observed in rodents, improving insulin response to glucose by over 100% in non-fasted Harlan Sprague Dawley (HSD) rats, and by up to ˜10-fold in non-fasted db/db mice. Higher pretreatment plasma glucose concentrations were associated with greater glucose-lowering effects. Thus the observed glucose lowering effect of exendin-4 appears to be glucose-dependent, and minimal if animals are already euglycemic.
  • Exendin-4 dose dependently slowed gastric emptying in HSD rats and was -90-fold more potent than GLP-1 for this action. Exendin-4 has also been shown to reduce food intake in NII/Sw (Swiss) mice following peripheral administration, and was at least 1000 times more potent than GLP-1 for this action. Exendin-4 reduced plasma glucagon concentrations by approximately 40% in anesthetized ZDF rats during hyperinsulinemic, hyperglycemic clamp conditions, but did not affect plasma glucagon concentrations during euglycemic conditions in normal rats. Exendin-4 has been shown to dose-dependently reduce body weight in obese ZDF rats, while in lean ZDF rats, the observed decrease in body weight appears to be transient.
  • Through effects on lowering glucagon and supressing glucagon secretion, exendins, exendin agonists, and modified exendins or exendin agonists containing exendin-4, for example, will be useful in people who would benefit from lowered glucagon, for example, people with glucagonoma and necrolytic migratory erythema, and people with diabetes whether or not they retain the ability to secrete insulin. See Example 5.
  • The toxicology of exendin-4 has been investigated in single-dose studies in mice, rats and monkeys, repeated-dose (up to 28 consecutive daily doses) studies in rats and monkeys and in vitro tests for mutagenicity and chromosomal alterations. To date, no deaths have occurred, and there have been no observed treatment-related changes in hematology, clinical chemistry, or gross or microscopic tissue changes. Exendin-4 was demonstrated to be non-mutagenic, and did not cause chromosomal aberrations at the concentrations tested (up to 5000 μg/mL).
  • In support of the investigation of the nonclinical pharmacokinetics and metabolism of exendin-4, a number of immunoassays have been developed. A radioimmunoassay with limited sensitivity (˜100pM) was used in initial pharmacokinetic studies. A two-site IRMA assay for exendin-4 was subsequently validated with a lower limit of quantitation of 15 pM. The bioavailability of exendin-4, given subcutaneously, was found to be approximately 50-80% using the radioimmunoassay. This was similar to that seen following intraperitoneal administration (48-60%). Peak plasma concentrations (Cma.) occurred between 30 and 43 minutes (Tmax). Both Cmax and AUC values were monotonically related to dose. The apparent terminal half-life for exendin-4 given subcutaneously was approximately 90-110 minutes. This was significantly longer than the 14-41 minutes seen following intravenous dosing. Similar results were obtained using the IRMA assay. Degradation studies with exendin-4 compared to GLP-1 indicate that exendin-4 is relatively resistant to degradation.
    • Exendin Agonists
  • The structure activity relationship (SAR) of exendin was investigated for structures that may relate to the antidiabetic activity of exendin, for its stability to metabolism, and for improvement of its physical characteristics, especially as it pertains to peptide stability and to amenability to alternative delivery systems, and various exendin agonist peptide compounds have been invented. Exendin agonists include exendin peptide analogs in which one or more naturally occurring amino acids are eliminated or replaced with another amino acid(s). Preferred exendin agonists are agonist analogs of exendin-4. Particularly preferred exendin agonists include those described in commonly owned WO 99/07404 (i.e., PCT Application Serial No. PCT/US98/16387 filed Aug. 6, 1998, entitled “Novel Exendin Agonist Compounds,” which claims the benefit of U.S. Patent Application Ser. No. 60/055,404, filed Aug. 8, 1997); commonly owned WO 99/25727 (i.e., PCT Application Serial No. PCT/US98/24210, filed Nov. 13, 1998, entitled “Novel Exendin Agonist Compounds,” which claims the benefit of U.S. Provisional Application No. 60/065,442 filed Nov. 14, 1997); and commonly owned WO 99/25728 (i.e., PCT Application Serial No. PCT/US98/24273, filed Nov. 13, 1998, entitled “Novel Exendin Agonist Compounds,” which claims the benefit of U.S. Provisional Application No. 60/066,029 filed Nov. 14, 1997), all of which are incorporated herein by reference in their entirety, including any drawings.
  • Activity as exendin agonists can be indicated, for example, by activity in the assays described below. Effects of exendins or exendin agonists on gastric motility and gastric emptying can be identified, evaluated, or screened for, using the methods described herein, or other art-known or equivalent methods for determining gastric motility. Negative receptor assays or screens for exendin agonist compounds or candidate exendin agonist compounds, such as an amylin receptor assay/screen using an amylin receptor preparation as described in U.S. Pat. No. 5,264,372, issued Nov. 23, 1993, the contents of which are incorporated herein by reference, one or more calcitonin receptor assays/screens using, for example, T47D and MCF7 breast carcinoma cells, which contain calcium receptors coupled to the stimulation of adenyl cyclase activity, and/or a CGRP receptor assay/screen using, for example, SK-N-MC cells.
  • One such method for use in identifying or evaluating the ability of a compound to slow gastric motility, involves: (a) bringing together a test sample and a test system, the test sample containing one or more test compounds, the test system containing a system for evaluating gastric motility, the system being characterized in that it exhibits, for example, elevated plasma glucose in response to the introduction to the system of glucose or a meal; and, (b) determining the presence or amount of a rise in plasma glucose in the system. Positive and/or negative controls may be used as well.
  • Also included within the scope of the present invention are pharmaceutically acceptable salts of the compounds of formula (I-VIII) and pharmaceutical compositions including said compounds and salts thereof.
    • Formula I
  • Exendin agonist compounds also include those described in U.S. Provisional Application No. 60/065,442 (i.e., priority application to WO 99/25727) including compounds of the formula (I) [SEQ ID NO: 41]:
  • Xaa1 Xaa2 Xaa3 Gly Xaa5 Xaa6 Xaa7 Xaa8 Xaa9 Xaa10
    Xaa11 Xaa12 Xaa13 Xaa14 Xaa15 Xaa16 Xaa17 Ala
    Xaa19 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 Xaa25 Xaa26
    Xaa27 Xaa28-Z1;
    • wherein
    • Xaa1 is His, Arg or Tyr;
    • Xaa2 is Ser, Gly, Ala or Thr;
    • Xaa3 is Ala, Asp or Glu;
    • Xaa5 is Ala or Thr;
    • Xaa6 is Ala, Phe, Tyr or naphthylalanine;
    • Xaa7 is Thr or Ser;
    • Xaa8 is Ala, Ser or Thr;
    • Xaa9 is Asp or Glu;
    • Xaa10 is Ala, Leu, Ile, Val, pentylglycine or Met;
    • Xaa11 is Ala or Ser;
    • Xaa12 is Ala or Lys;
    • Xaa13 is Ala or Gln;
    • Xaa14 is Ala, Leu, Ile, pentylglycine, Val or Met;
    • Xaa15 is Ala or Glu;
    • Xaa16 is Ala or Glu;
    • Xaa17 is Ala or Glu;
    • Xaa19 is Ala or Val;
    • Xaa20 is Ala or Arg;
    • Xaa21 is Ala or Leu;
    • Xaa22 is Ala, Phe, Tyr or naphthylalanine;
    • Xaa23 is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met;
    • Xaa24 is Ala, Glu or Asp;
    • Xaa25 is Ala, Trp, Phe, Tyr or naphthylalanine;
    • Xaa26 is Ala or Leu;
    • Xaa27 is Ala or Lys;
    • Xaa28 is Ala or Asn;
    • Z1 is OH,
  • NH2,
  • Gly-z2,
  • Gly Gly-Z2,
  • Gly Gly Xaa31-Z2,
  • Gly Gly Xaa31 Ser-Z2,
  • Gly Gly Xaa31 Ser Ser-Z2,
  • Gly Gly Xaa31 Ser Ser Gly-Z2,
  • Gly Gly Xaa31 Ser Ser Gly Ala-Z2,
  • Gly Gly Xaa31 Ser Ser Gly Ala Xaa36-Z2,
  • Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37-Z2 or
  • Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37 Xaa38-Z2;
  • Xaa31, Xaa36, Xaa37 and Xaa38 are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine or N-alkylalanine; and
  • Z2 is OH or NH2; provided that no more than three of Xaa3, Xaa5, Xaa6, Xaa8, Xaa10, Xaa11, Xaa12, Xaa13, Xaa14, Xaa15, Xaa16, Xaa17, Xaa19, Xaa20, Xaa21, Xaa24, Xaa25, Xaa26, Xaa27 and Xaa28 are Ala.
  • Preferred N-alkyl groups for N-alkylglycine, N-alkylpentylglycine and N-alkylalanine include lower alkyl groups preferably of 1 to about 6 carbon atoms, more preferably of 1 to 4 carbon atoms.
  • Preferred exendin agonist compounds include those wherein Xaa, is His or Tyr. More preferably Xaa1 is His.
  • Preferred are those compounds wherein Xaa2 is Gly.
  • Preferred are those compounds wherein Xaa14 is Leu, pentylglycine or Met.
  • Preferred compounds are those wherein Xaa25 is Trp or Phe.
  • Preferred compounds are those where Xaa6 is Phe or naphthylalanine; Xaa22 is Phe or naphthylalamnne and Xaa23 is Ile or Val.
  • Preferred are compounds wherein Xaa31, Xaa36, Xaa37 and Xaa38 are independently selected from Pro, homoproline, thioproline and N-alkylalanine.
  • Preferably Z1 is NH2.
  • Preferably Z2 is NH2.
  • According to one aspect, preferred are compounds of formula (I) wherein Xaa1 is His or Tyr, more preferably His; Xaa2 is Gly; Xaa6 is Phe or naphthylalanine; Xaa14 is Leu, pentylglycine or Met; Xaa22 is Phe or naphthylalanine; Xaa23 is Ile or Val; Xaa31, Xaa36, Xaa37 and Xaa38 are independently selected from Pro, homoproline, thioproline or N-alkylalanine. More preferably Z1 is —NH2.
  • According to an especially preferred aspect, especially preferred compounds include those of formula (I) wherein: Xaa1 is His or Arg; Xaa2 is Gly or Ala; Xaa3 is Asp or Glu; Xaa5 is Ala or Thr; Xaa6 is Ala, Phe or nephthylalaine; Xaa7 is Thr or Ser; Xaa8 is Ala, Ser or Thr; Xaa9 is Asp or Glu; Xaa10 is Ala, Leu or pentylglycine; Xaa11 is Ala or Ser; Xaa12 is Ala or Lys; Xaa13 is Ala or Gln; Xaa14 is Ala, Leu or pentylglycine; Xaa15 is Ala or Glu; Xaa16 is Ala or Glu; Xaa17 is Ala or Glu; Xaa19 is Ala or Val; Xaa20 is Ala or Arg; Xaa21 is Ala or Leu; Xaa22 is Phe or naphthylalanine; Xaa23 is Ile, Val or tert-butylglycine; Xaa24 is Ala, Glu or Asp; Xaa25 is Ala, Trp or Phe; Xaa26 is Ala or Leu; Xaa27 is Ala or Lys; Xaa28 is Ala or Asn; Z1 is —OH, —NH2, Gly-Z2, Gly Gly-Z2, Gly Gly Xaa31-Z2, Gly Gly Xaa31 Ser-Z2, Gly Gly Xaa31 Ser Ser-Z2, Gly Gly Xaa31 Ser Ser Gly-Z2, Gly Gly Xaa31 Ser Ser Gly Ala-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37 Xaa38-Z2; Xaa31, Xaa36, Xaa37 and Xaa38 being independently Pro homoproline, thioproline or N-methylalanine; and Z2 being —OH or —NH2; provided that no more than three of Xaa3, Xaa5, Xaa6, Xaa8, Xaa10, Xaa11, Xaa12, Xaa13, Xaa14, Xaa15, Xaa16, Xaa17, Xaa19, Xaa20, Xaa21, Xaa24, Xaa25, Xaa26, Xaa27 and Xaa28 are Ala. Especially preferred compounds include those set forth in PCT application Serial No. PCT/US98/24210, filed Nov. 13, 1998, entitled “Novel Exendin Agonist Compounds” identified therein as compounds 2-23.
  • According to an especially preferred aspect, provided are compounds where Xaa14 is Leu, Ile, Val or pentylglycine, more preferably Leu or pentylglycine, and Xaa25 is Phe, Tyr or naphthylalanine, more preferably Phe or naphthylalanine. These compounds will be less susceptive to oxidative degration, both in vitro and in vivo, as well as during synthesis of the compound.
    • Formula II
  • Exendin agonist compounds also include those described in U.S. Provisional Application No. 60/066,029 (i.e., priority application to WO 99/25728) including compounds of the formula (II) [SEQ ID NO: 42]:
  • Xaa1 Xaa2 Xaa3 Xaa4 Xaa5 Xaa6 Xaa7 Xaa8 Xaa9 Xaa10
    Xaa11 Xaa12 Xaa13 Xaa14 Xaa15 Xaa16 Xaa17 Ala
    Xaa19 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 Xaa25 Xaa26
    Xaa27 Xaa28-Z1;
    • wherein
    • Xaa1 is His, Arg, Tyr, Ala, Norval, Val or Norleu;
    • Xaa2 is Ser, Gly, Ala or Thr;
    • Xaa3 is Ala, Asp or Glu;
    • Xaa4 is Ala, Norval, Val, Norleu or Gly;
    • Xaa5 is Ala or Thr;
    • Xaa6 is Ala, Phe, Tyr or naphthylalanine;
    • Xaa7 is Thr or Ser;
    • Xaa8 is Ala, Ser or Thr;
    • Xaa9 is Ala, Norval, Val, Norleu, Asp or Glu;
    • Xaa10 is Ala, Leu, Ile, Val, pentylglycine or Met;
    • Xaa11 is Ala or Ser;
    • Xaa12 is Ala or Lys;
    • Xaa13 is Ala or Gln;
    • Xaa14 is Ala, Leu, Ile, pentylglycine, Val or Met;
    • Xaa15 is Ala or Glu;
    • Xaa16 is Ala or Glu;
    • Xaa17 is Ala or Glu;
    • Xaa19 is Ala or Val;
    • Xaa20 is Ala or Arg;
    • Xaa21 is Ala or Leu;
    • Xaa22 is Phe, Tyr or naphthylalanine;
    • Xaa23 is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met;
    • Xaa24 is Ala, Glu or Asp;
    • Xaa25 is Ala, Trp, Phe, Tyr or naphthylalanine;
    • Xaa26 is Ala or Leu;
    • Xaa27 is Ala or Lys;
    • Xaa28 is Ala or Asn;
    • Z1 is OH,
  • NH2,
  • Gly-Z2,
  • Gly Gly-Z2,
  • Gly Gly Xaa31-Z2,
  • Gly Gly Xaa31 Ser-Z2,
  • Gly Gly Xaa31 Ser Ser-Z2,
  • Gly Gly Xaa31 Ser Ser Gly-Z2,
  • Gly Gly Xaa31 Ser Ser Gly Ala-Z2,
  • Gly Gly Xaa31 Ser Ser Gly Ala Xaa36-Z2,
  • Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37-Z2,
  • Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37 Xaa3g-Z2 or
  • Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37 Xaa38 Xaa39-Z2;
  • wherein Xaa31, Xaa36, Xaa37 and Xaa38 are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine or N-alkylalanine;
  • Xaa39 is Ser or Tyr; and
  • Z2 is OH or NH2;
  • provided that no more than three of Xaa3, Xaa4, Xaa5, Xaa6, Xaa8, Xaa9, Xaa10, Xaa11, Xaa12, Xaa13, Xaa14, Xaa15, Xaa16, Xaa17, Xaa19, Xaa20, Xaa21, Xaa24, Xaa25, Xaa26, Xaa27 and Xaa28 are Ala; and provided also that, if Xaa1 is His, Arg or Tyr, then at least one of Xaa3, Xaa4 and Xaa9 is Ala.
  • Preferred N-alkyl groups for N-alkylglycine, N-alkylpentylglycine and N-alkylalanine include lower alkyl groups preferably of 1 to about 6 carbon atoms, more preferably of 1 to 4 carbon atoms.
  • Suitable compounds of formula (II) include those described in WO 99/25728 (i.e., application Serial No. PCT/US98/24273, filed Nov. 13, 1998, entitled “Novel Exendin Agonist Compounds”), identified therein in Examples 1-89 (“Compounds 1-89,” respectively), as well as those corresponding compounds identified therein in Examples 104 and 105.
  • Preferred such exendin agonist compounds include those wherein Xaa1 is His, Ala or Norval. More preferably Xaa1 is His or Ala. Most preferably Xaa1 is His.
  • Preferred are those compounds of formula (II) wherein Xaa2 is Gly.
  • Preferred are those compounds of formula (II) wherein Xaa3 is Ala.
  • Preferred are those compounds of formula (II) wherein Xaa4 is Ala.
  • Preferred are those compounds of formula (II) wherein Xaa9 is Ala.
  • Preferred are those compounds of formula (II) wherein Xaa14 is Leu, pentylglycine or Met.
  • Preferred compounds of formula (II) are those wherein Xaa25 is Trp or Phe.
  • Preferred compounds of formula (II) are those where Xaa6 is Ala, Phe or naphthylalanine; Xaa22 is Phe or naphthylalanihe; and Xaa23 is Ile or Val.
  • Preferred are compounds of formula (II) wherein Xaa31, Xaa36, Xaa37 and Xaa38 are independently selected from Pro, homoproline, thioproline and N-alkylalanine.
  • Preferably Z1 is —NH2.
  • Preferably Z2 is —NH2.
  • According to one aspect, preferred are compounds of formula (II) wherein Xaa1 is Ala, His or Tyr, more preferably Ala or His; Xaa2 is Ala or Gly; Xaa6 is Phe or naphthylalanine; Xaa14 is Ala, Leu, pentylglycine or Met; Xaa22 is Phe or naphthylalamne; Xaa23 is Ile or Val; Xaa31, Xaa36, Xaa37 and Xaa38 are independently selected from Pro, homoproline, thioproline or N-alkylalanine; and Xaa39 is Ser or Tyr, more preferably Ser. More preferably Z1 is —NH2.
  • According to an especially preferred aspect, especially preferred compounds include those of formula (II) wherein: Xaa1 is His or Ala; Xaa2 is Gly or Ala; Xaa3 is Ala, Asp or Glu; Xaa4 is Ala or Gly; Xaa5 is Ala or Thr; Xaa6 is Phe or naphthylalanine; Xaa7 is Thr or Ser; Xaa8 is Ala, Ser or Thr; Xaa9 is Ala, Asp or Glu; Xaa10 is Ala, Leu or pentylglycine; Xaa11 is Ala or Ser; Xaa12 is Ala or Lys; Xaa13 is Ala or Gln; Xaa14 is Ala, Leu, Met or pentylglycine; Xaa15 is Ala or Glu; Xaa16 is Ala or Glu; Xaa17 is Ala or Glu; Xaa19 is Ala or Val; Xaa20 is Ala or Arg; Xaa21 is Ala or Leu; Xaa22 is Phe or naphthylalanine; Xaa23 is Ile, Val or tert-butylglycine; Xaa24 is Ala, Glu or Asp; Xaa25 is Ala, Trp or Phe; Xaa26 is Ala or Leu; Xaa27 is Ala or Lys; Xaa28 is Ala or Asn; Z1 is —OH, —NH2, Gly-Z2, Gly Gly-Z2, Gly Gly Xaa31-Z2, Gly Gly Xaa31 Ser-Z2, Gly Gly Xaa31 Ser Ser-Z2, Gly Gly Xaa31 Ser Ser Gly-Z2, Gly Gly Xaa31 Ser Ser Gly Ala-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37 Xaa38-Z2 or Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37 Xaa38 Xaa39-Z2; Xaa31, Xaa36, Xaa37 and Xaa38 being independently Pro homoproline, thioproline or N-methylalanine; and Z2 being —OH or —NH2; provided that no more than three of Xaa3, Xaa5, Xaa6, Xaa8, Xaa10, Xaa11, Xaa12, Xaa13, Xaa14, Xaa15, Xaa16, Xaa17, Xaa19, Xaa20, Xaa21, Xaa24, Xaa25, Xaa26, Xaa27 and Xaa28 are Ala; and provided also that if Xaa1 is His, Arg or Tyr, then at least one of Xaa3, Xaa4 and Xaa9 is Ala. Especially preferred compounds of formula (II) include those described in WO 99/25728 (i.e., application Serial No. PCT/US98/24273, filed Nov. 13, 1998, entitled “Novel Exendin Agonist Compounds”) as having the amino acid sequence of SEQ ID NOs: 5-93 therein.
  • According to an especially preferred aspect, provided are compounds of formula (II) where Xaa14 is Ala, Leu, Ile, Val or pentylglycine, more preferably Leu or pentylglycine, and Xaa25 is Ala, Phe, Tyr or naphthylalanine, more preferably Phe or naphthylalanine. These compounds will be less susceptible to oxidative degration, both in vitro and in vivo, as well as during synthesis of the compound.
    • Formula III
  • Also within the scope of the present invention are narrower genera of compounds having peptides of various lengths, for example genera of compounds which do not include peptides having a length of 28, 29 or 30 amino acid residues, respectively. Additionally, the present invention includes narrower genera of compounds described in PCT application Serial No. PCT/US98/24210, filed Nov. 13, 1998, entitled “Novel Exendin Agonist Compounds,” published as WO 99/25727, and having particular amino acid sequences, for example, compounds of the formula (III) [SEQ ID NO: 43]:
  • Xaa1 Xaa2 Xaa3 Gly Xaa5 Xaa6 Xaa7 Xaa8 Xaa9 Xaa10
    Xaa11 Xaa12 Xaa13 Xaa14 Xaa15 Xaa16 Xaa17 Ala
    Xaa18 Xaa19 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 Xaa25
    Xaa26 Xaa27 Xaa28-Z1;
    • wherein
    • Xaa1 is His or Arg;
    • Xaa2 is Gly or Ala;
    • Xaa3 is Ala, Asp or Glu;
    • Xaa5 is Ala or Thr;
    • Xaa6 is Ala, Phe or naphthylalanine;
    • Xaa7 is Thr or Ser;
    • Xaa8 is Ala, Ser or Thr;
    • Xaa9 is Asp or Glu;
    • Xaa10 is Ala, Leu or pentylglycine;
    • Xaa11 is Ala or Ser;
    • Xaa12 is Ala or Lys;
    • Xaa13 is Ala or Gln;
    • Xaa14 is Ala, Leu or pentylglycine;
    • Xaa15 is Ala or Glu,;
    • Xaa16 is Ala or Glu;
    • Xaa17 is Ala or Glu;
    • Xaa19 is Ala or Val;
    • Xaa20 is Ala or Arg;
    • Xaa21 is Ala or Leu;
    • Xaa22 is Phe or naphthylalanine;
    • Xaa23 is Ile, Val or tert-butylglycine;
    • Xaa24 is Ala, Glu or Asp;
    • Xaa25 is Ala, Trp, or Phe;
    • Xaa26 is Ala or Leu;
    • Xaa27 is Ala or Lys;
    • Xaa28 is Ala or Asn;
    • Z1 is OH,
  • NH2,
  • Gly-Z2,
  • Gly Gly -Z2,
  • Gly Gly Xaa31-Z2,
  • Gly Gly Xaa31 Ser-Z2,
  • Gly Gly Xaa31 Ser Ser-Z2,
  • Gly Gly Xaa31 Ser Ser Gly-Z2,
  • Gly Gly Xaa31 Ser Ser Gly Ala-Z2,
  • Gly Gly Xaa31 Ser Ser Gly Ala Xaa36-Z2,
  • Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37-Z2 or
  • Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37 Xaa38-Z2;
  • Xaa31, Xaa36, Xaa37 and Xaa38 are independently selected from the group consisting of Pro, homoproline, thioproline and N-methylylalanine; and
  • Z2 is OH or NH2;
  • provided that no more than three of Xaa3, Xaa5, Xaa6, Xaag, Xaa10, Xaa11, Xaa12, Xaa13, Xaa14, Xaa15, Xaa16, Xaa17, Xaa19, Xaa20, Xaa21, Xaa24, Xaa25, Xaa26, Xaa27 and Xaa28 are Ala; and pharmaceutically acceptable salts thereof.
    • Formula IV
  • Additionally, the present invention includes narrower genera of peptide compounds described in PCT Application Serial No. PCT/US98/24273, filed Nov. 13, 1998, entitled “Novel Exendin Agonist Compounds,” published as WO 99/25728, as having particular amino acid sequences, for example, compounds of the formula [IV] [SEQ ID NO: 44]:
  • Xaa1 Xaa2 Xaa3 Xaa5 Xaa5 Xaa6 Xaa7 Xaa8 Xaa9 Xaa10
    Xaa11 Xaa12 Xaa13 Xaa14 Xaa15 Xaa16 Xaa17 Ala
    Xaa18 Xaa19 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 Xaa25
    Xaa26 Xaa27 Xaa28-Z1;
    • wherein
    • Xaa1 is His or Ala;
    • Xaa2 is Gly or Ala;
    • Xaa3 is Ala, Asp or Glu;
    • Xaa4 is Ala or Gly;
    • Xaa5 is Ala or Thr;
    • Xaa6 is Ala, Phe or naphthylalanme;
    • Xaa7 is Thr or Ser.;
    • Xaa8 is Ala, Ser or Thr;
    • Xaa9 is Ala, Asp or Glu;
    • Xaa10 is Ala, Leu or pentylglycine;
    • Xaa11 is Ala or Ser;
    • Xaa12 is Ala or Lys;
    • Xaa13 is Ala or Gln;
    • Xaa14 is Ala, Leu, Met or pentylglycine;
    • Xaa15 is Ala or Glu;
    • Xaa16 is Ala or Glu;
    • Xaa17 is Ala or Glu;
    • Xaa19 is Ala or Val;
    • Xaa20 is Ala or Arg;
    • Xaa21 is Ala or Leu;
    • Xaa22 is Phe or naphthylalanine;
    • Xaa23 is Ile, Val or tert-butylglycine;
    • Xaa24 is Ala, Glu or Asp;
    • Xaa25 is Ala, Trp or Phe;
    • Xaa26 is Ala or Leu;
    • Xaa27 is Ala or Lys;
    • Xaa28 is Ala or Asn;
    • Z1 is OH,
  • NH2,
  • Gly-Z2,
  • Gly Gly-Z2
  • Gly Gly Xaa31-Z2,
  • Gly Gly Xaa31 Ser-Z2,
  • Gly Gly Xaa31 Ser Ser-Z2,
  • Gly Gly Xaa31 Ser Ser Gly-Z2,
  • Gly Gly Xaa31 Ser Ser Gly Ala-Z2,
  • Gly Gly Xaa31 Ser Ser Gly Ala Xaa36-Z2,
  • Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37-Z2
  • Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37 Xaa38-Z2
  • Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37 Xaa38 Ser-Z2;
  • Xaa31, Xaa36, Xaa37 and Xaa38 are independently Pro, homoproline, thioproline, or N-methylalanine; and
  • Z2 is -OH or —NH2;
  • provided that no more than three of Xaa3, Xaa5, Xaa6, Xaa8, Xaa10, Xaa11, Xaa12, Xaa13, Xaa14, Xaa15, Xaa16, Xaa17, Xaa19, Xaa20, Xaa21, Xaa24, Xaa25, Xaa26, Xaa27, and Xaa28 are Ala; and provided that, if Xaa, is His then at least one of Xaa3, Xaa4 and Xaa9 is Ala; and pharmaceutically acceptable salts thereof.
  • Preferred compounds of formula (IV) include those wherein Xaa1 is His or Ala.
  • Preferably, Xaa1 is His.
  • Preferred compounds of formula (IV) include those wherein Xaa2 is Gly.
  • Preferred compounds of formula (IV) include those wherein Xaa4 is Ala.
  • Preferred compounds of formula (IV) include those wherein Xaa9 is Ala.
  • Preferred compounds of formula (IV) include those wherein Xaa14 is Leu, pentylglycine or Met.
  • Preferred compounds of formula (IV) include those wherein Xaa25 is Trp or Phe.
    • Xaa14 is Ala, Leu, Ile, pentylglycine, Val or Met;
    • Xaa15 is Ala or Glu;
    • Xaa16 is Ala or Glu;
    • Xaa17 is Ala or Glu;
    • Xaa19 is Ala or Val;
    • Xaa20 is Ala or Arg;
    • Xaa21 is Ala, Leu or Lys-NHε—R where R is Lys, Arg, C1-C10 straight chain or branched alkanoyl or cycloalkylalkanoyl;
    • Xaa22 is Phe, Tyr or naphthylalanine;
    • Xaa23 is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met;
    • Xaa24 is Ala, Glu or Asp;
    • Xaa25 is Ala, Trp, Phe, Tyr or naphthylalanine;
    • Xaa26 is Ala or Leu;
    • X1 is Lys Asn, Asn Lys, Lys-NHε—R Asn, Asn Lys-NHε—R, Lys-NHε—R Ala, Ala Lys-NHε—R where R is Lys, Arg, C1-C10 straight chain or branched alkanoyl or cycloalkylalkanoyl
    • Z1 is OH,
  • NH2,
  • Gly-Z2,
  • Gly Gly-Z2,
  • Gly Gly Xaa31-Z2,
  • Gly Gly Xaa31 Ser-Z2,
  • Gly Gly Xaa31 Ser Ser-Z2,
  • Gly Gly Xaa31 Ser Ser Gly-Z2,
  • Gly Gly Xaa31 Ser Ser Gly Ala-Z2,
  • Gly Gly Xaa31 Ser Ser Gly Ala Xaa36-Z2,
  • Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37-Z2 or
  • Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37 Xaa38-Z2;
  • wherein
  • Xaa31, Xaa36, Xaa37 and Xaa38 are independently selected from the group consisting of Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine and N-alkylalanine; and
  • Z2 is —OH or —NH2;
  • provided that no more than three of Xaa3, Xaa5, Xaa6, Xaa8, Xaa10, Xaa11, Xaa12, Xaa13, Xaa14, Xaa15, Xaa16, Xaa17, Xaa19, Xaa20, Xaa21, Xaa24, Xaa25, and Xaa26 are Ala. Also within the scope of the present invention are pharmaceutically acceptable salts of the compound of formula (V) and pharmaceutical compositions including said compounds and salts thereof.
  • Preferred exendin agonist compounds of formula (V) include those wherein Xaa1 is His, Tyr or 4-imidazopropionyl. More preferably Xaa1 is His.
  • Preferred are those compounds of formula (V) wherein Xaa1 is 4-midazopropionyl.
  • Preferred are those compounds of formula (V) wherein Xaa2 is Gly.
  • Preferred compounds of formula (V) are those wherein Xaa14 is Leu, pentylglycine or Met.
  • Preferred compounds of formula (V) are those wherein Xaa25 is Trp or Phe.
  • According to one aspect, preferred are compounds of formula (V) wherein Xaa6 is Phe or naphthylalanine; and Xaa22 is Phe or naphthylalanine; and Xaa23 is Ile or Val. More preferably, Z1 is —NH2. According to one aspect, especially preferred are such compounds of formula (V) wherein Xaa31, Xaa36, Xaa37 and Xaa38 are independently selected from the group consisting of Pro, homoproline, thioproline and N-alkylalanine. More preferred, Z2 is —NH2.
  • Preferred compounds of formula (V) include those wherein X1 is Lys Asn, Lys-NHε—R Asn, or Lys-NHε—R Ala where R is Lys, Arg, C1-C10 straight chain or branched alkanoyl. Preferred compounds of formula (V) include compounds described in PCT application Serial No. PCT/US98/24210, filed Nov. 13, 1998, entitled “Novel Exendin Agonist Compounds,” published as WO 99/25727, and identified therein as Compound Nos. 62-69.
  • Preferred are those compounds of formula (V) wherein Xaa2 is Gly.
  • Preferred are those compounds of formula (V) wherein Xaa3 is Ala.
  • Preferred are those compounds of formula (V) wherein Xaa9 is Ala.
  • Preferred are those compounds of formula (V) wherein Xaa14 is Leu, pentylglycine or Met.
  • Preferred compounds of formula (V) are those wherein Xaa25 is Trp or Phe.
  • Preferred compounds of formula (V) are those where Xaa6 is Ala, Phe or naphthylalanine; Xaa22 is Phe or naphthylalanine; and Xaa23 is Ile or Val.
  • Preferred are compounds of formula (V) wherein Xaa3l, Xaa36, Xaa37 and Xaa38 are independently selected from Pro, homoproline, thioproline and N-alkylalanine.
  • Preferably Z1 is —NH2.
  • Preferably Z2 is —NH2.
  • According to one aspect, preferred are compounds of formula (V) wherein Xaa1 is Ala, His or Tyr, more preferably Ala or His; Xaa2 is Ala or Gly; Xaa6 is Phe or naphthylalanine; Xaa14 is Ala, Leu, pentylglycine or Met; Xaa22 is Phe or naphthylalanine; Xaa23 is Ile or Val; Xaa31, Xaa36, Xaa37 and Xaa38 are independently selected from Pro, homoproline, thioproline or N-alkylalanine. More preferably Z1 is —NH2.
  • According to an especially preferred aspect, especially preferred compounds include those of formula (V) wherein: Xaa1 is His or Ala; Xaa2 is Gly or Ala; Xaa3 is Ala, Asp or Glu; Xaa5 is Ala or Thr; Xaa6 is Phe or naphthylalanine; Xaa7 is Thr or Ser; Xaa8 is Ala, Ser or Thr; Xaa9 is Ala, Asp or Glu; Xaa10 is Ala, Leu or pentylglycine; Xaa1 is Ala or Ser; Xaa12 is Ala or Lys; Xaa13 is Ala or Gln; Xaa14 is Ala, Leu, Met or pentylglycine; Xaa15 is Ala or Glu; Xaa16 is Ala or Glu; Xaa17 is Ala or Glu; Xaa19 is Ala or Val; Xaa20 is Ala or Arg; Xaa21 is Ala or Leu; Xaa22 is Phe or naphthylalanine; Xaa23 is Ile, Val or tert-butylglycine; Xaa24 is Ala, Glu or Asp; Xaa25 is Ala, Trp or Phe; Xaa26 is Ala or Leu; Xaa27 is Ala or Lys; Xaa28 is Ala or Asn; Z1 is —OH, —NH2, Gly-Z2, Gly Gly-Z2, Gly Gly Xaa31-Z2, Gly Gly Xaa31 Ser-Z2, Gly Gly Xaa31 Ser Ser-Z2, Gly Gly Xaa31 Ser Ser Gly-Z2, Gly Gly Xaa31 Ser Ser Gly Ala-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37 Xaa38-Z2 or Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37 Xaa38 Xaa39-Z2; Xaa3i, Xaa36, Xaa37 and Xaa38 being independently Pro homoproline, thioproline or N-methylalanine; and Z2 being —OH or —NH2; provided that no more than three of Xaa3, Xaa5, Xaa6, Xaa8, Xaa10, Xaa11, Xaa12, Xaa13, Xaa14, Xaa15, Xaa16, Xaa17, Xaa19, Xaa20, Xaa21, Xaa24, Xaa25, Xaa26, Xaa27 and Xaa28 are Ala; and provided also that, if Xaa1 is His, Arg or Tyr, then at least one of Xaa3, and Xaa9 is Ala. Especially preferred compounds of formula (V) include those described in PCT application Serial No. PCT/US98/24210, filed Nov. 13, 1998, entitled “Novel Exendin Agonist Compounds,” published as WO 99/25727, and having the amino acid sequences identified therein as SEQ ID NOs: 5-93.
  • According to an especially preferred aspect, provided are compounds of formula (V) where Xaa14 is Ala, Leu, Ile, Val or pentylglycine, more preferably Leu or pentylglycine, and Xaa25 is Ala, Phe, Tyr or naphthylalamnne, more preferably Phe or naphthylalanine. These compounds will be less susceptible to oxidative degration, both in vitro and in vivo, as well as during synthesis of the compound.
    • Formula VI
  • Also provided are peptide compounds described in PCT Application Serial No. PCT/US98/24273, filed Nov. 13, 1998, entitled “Novel Exendin Agonist Compounds,” published as WO 99/25728, including compounds of the formula (VI) [SEQ ID NO: 46]:
  • Xaa1 Xaa2 Xaa3 Xaa4 Xaa5 Xaa6 Xaa7 Xaa8 Xaa9 Xaa10
    Xaa11 Xaa12 Xaa13 Xaa14 Xaa15 Xaa16 Xaa17 Ala
    Xaa19 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 Xaa25 Xaa26
    X1-Z1;
    • wherein
    • Xaa1 is His, Arg, Tyr, Ala, Norval, Val, Norleu or 4-imidazopropionyl;
    • Xaa2 is Ser, Gly, Ala or Thr;
    • Xaa3 is Ala, Asp or Glu;
    • Xaa4 is Ala, Norval, Val, Norleu or Gly;
    • Xaa5 is Ala or Thr;
    • Xaa6 is Ala, Phe, Tyr or naphthylalanine;
    • Xaa7 is Thr or Ser;
    • Xaa8 is Ala, Ser or Thr;
    • Xaa9 is Ala, Norval, Val, Norleu, Asp or Glu;
    • Xaa10 is Ala, Leu, Ile, Val, pentylglycine or Met;
    • Xaa11 is Ala or Ser;
    • Xaa12 is Ala or Lys;
    • Xaa13 is Ala or Gln;
    • Xaa14 is Ala, Leu, Ile, pentylglycine, Val or Met;
    • Xaa15 is Ala or Glu;
    • Xaa16 is Ala or Glu;
    • Xaa17 is Ala or Glu;
    • Xaa19 is Ala or Val;
    • Xaa20 is Ala or Arg;
    • Xaa21 is Ala, Leu or Lys-NHε—R where R is Lys, Arg, C1-10 straight chain or branched alkanoyl or cycloalleyl-alkanoyl;
    • Xaa22 is Phe, Tyr or naphthylalanine;
    • Xaa23 is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met;
    • Xaa24 is Ala, Glu or Asp;
    • Xaa25 is Ala, Trp, Phe, Tyr or naphthylalanine;
    • Xaa26 is Ala or Leu;
    • X1 is Lys Asn, Asn Lys, Lys-NHε—R Asn, Asn Lys-NHε—R, Lys-NHε—R Ala, Ala Lys-NHε—R where R is Lys, Arg, C1-C10 straight chain or branched alkanoyl or cycloalkylalkanoyl
    • Z1 is OH,
  • NH2,
  • Gly-Z2,
  • Gly Gly-Z2,
  • Gly Gly Xaa31-Z2,
  • Gly Gly Xaa31 Ser-Z2,
  • Gly Gly Xaa31 Ser Ser-Z2,
  • Gly Gly Xaa31 Ser Ser Gly-Z2,
  • Gly Gly Xaa31 Ser Ser Gly Ala-Z2,
  • Gly Gly Xaa31 Ser Ser Gly Ala Xaa36-Z2,
  • Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37-Z2,
  • Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37 Xaa38-Z2 or
  • Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37 Xaa38 Xaa39-Z2;
  • wherein Xaa31, Xaa36, Xaa37 and Xaa38 are independently selected from the group consisting of Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine and N-alkylalanine;
  • Xaa31 is Ser or Tyr; and
  • Z2 is —OH or —NH2;
  • provided that no more than three of Xaa3, Xaa4, Xaa5, Xaa6, Xaa8, Xaa9, Xaa10, Xaa11, Xaa12, Xaa13, Xaa14, Xaa15, Xaa16, Xaa17, Xaa19, Xaa20, Xaa21, Xaa24, Xaa25, Xaa26, are Ala; and provided also that, if Xaa1 is His, Arg, Tyr, or 4-imidazopropionyl then at least one of Xaa3, Xaa4 and Xaa9 is Ala.
  • Preferred compounds of formula (VI) include those wherein Xaa1 is His, Ala, Norval or 4-imidazopropionyl. Preferably, Xaa1 is His, or 4-imidazopropionyl or Ala, more preferably His or 4-imidazopropionyl.
  • Preferred compounds of formula (VI) include those wherein Xaa2 is Gly.
  • Preferred compounds of formula (VI) include those wherein Xaa4 is Ala.
  • Preferred compounds of formula (VI) include those wherein Xaa9 is Ala.
  • Preferred compounds of formula (VI) include those wherein Xaa14 is Leu, pentylglycine or Met.
  • Preferred compounds of formula (VI) include those wherein Xaa25 is Trp or Phe.
  • Preferred compounds of formula (VI) include those wherein Xaa6 is Ala, Phe or naphthylalanine; Xaa22 is Phe or naphthylalanine; and Xaa23 is Ile or Val.
  • Preferred compounds of formula (VI) include those wherein Z1 is —NH2.
  • Preferred compounds of formula (VI) include those wherein Xaa31, Xaa36, Xaa37 and Xaa38 are independently selected from the group consisting of Pro, homoproline, thioproline and N-alkylalanine.
  • Preferred compounds of formula (VI) include those wherein Xaa39 is Ser or Tyr, preferably Ser.
  • Preferred compounds of formula (VI) include those wherein Z2 is —NH2.
  • Preferred compounds of formula (VI) include those 42 wherein Z1 is —NH2.
  • Preferred compounds of formula (VI) include those wherein Xaa21 is Lys-NHε—R where R is Lys, Arg, C1-C10 straight chain or branched alkanoyl.
  • Preferred compounds of formula (VI) include those wherein X1 is Lys Asn, Lys-NHε—R Asn, or Lys-NHε—R Ala where R is Lys, Arg, C1-C10 straight chain or branched alkanoyl.
  • Preferred compounds of formula (VI) include those described in PCT Application Serial No. PCT/US98/24273, filed Nov. 13, 1998, entitled “Novel Exendin Agonist Compounds,” published as WO 99/25728, as having an amino acid sequence selected from those identified therein as SEQ ID NOs: 95-110.
    • Formula VII
  • Compounds particularly useful according to the present invention are exendin agonist compounds described in U.S. patent application Ser. No. 09/003,869, filed Jan. 7, 1998, entitled “Use of Exendins And Agonists Thereof For The Reduction of Food Intake,” issued as U.S. Pat. No. 5,956,026, including compounds of the formula (VII) [SEQ ID NO: 47]:
  • Xaa1 Xaa2 Xaa3 Gly Thr Xaa6 Xaa7 Xaa8 Xaa9 Xaa10
    Ser Lys Gln Xaa14 Glu Glu Glu Ala Val Arg Leu
    Xaa22 Xaa23 Xaa24 Xaa25 Leu Lys Asn Gly Gly Xaa31
    Ser Ser Gly Ala Xaa36 Xaa37 Xaa38 Xaa39-Z

    wherein Xaa1 is His, Arg or Tyr; Xaa2 is Ser, Gly, Ala or Thr; Xaa3 is Asp or Glu; Xaa6 is Phe, Tyr or naphthalanine; Xaa7 is Thr or Ser; Xaa8 is Ser or Thr; Xaa9 is Asp or Glu; Xaa10 is Leu, Ile, Val, pentylglycine or Met; Xaa14 is Leu, Ile, pentylglycine, Val or Met; Xaa22 is Phe, Tyr or naphthalanine; Xaa23 is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met; Xaa24 is Glu or Asp; Xaa25 is Trp, Phe, Tyr, or naphthylalanine; Xaa31, Xaa36, Xaa37 and Xaa3s are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine or N-alkylalanine; Xaa39 is Ser, Thr or Tyr; and Z is OH or NH2; with the proviso that the compound does not have the formula of either SEQ ID NOs: 1 or 2. Preferred N-alkyl groups for N-alkylglycine, N-alkylpentylglycine and N-alkylalanine include lower alkyl groups preferably of 1 to about 6 carbon atoms, more preferably of 1 to 4 carbon atoms. Suitable compounds include those having amino acid sequences of SEQ ID NOs: 10 to 40. Also useful in the present invention are pharmaceutically acceptable salts of the compounds of formula (VII).
  • Preferred exendin agonist compounds include those wherein Xaa1 is His or Tyr. More preferably Xaa1 is His.
  • Preferred are those compounds wherein Xaa2 is Gly.
  • Preferred are those compounds wherein Xaa14 is Leu, pentylglycine or Met.
  • Preferred compounds include those wherein Xaa25 is Trp or Phe.
  • Also preferred are compounds where Xaa6 is Phe or naphthalanine; Xaa23 is Ile or Val and Xaa31, Xaa36, Xaa37 and Xaa38 are independently selected from Pro, homoproline, thioproline or N-alkylalanine. Preferably N-alkylalanine has a N-alkyl group of 1 to about 6 carbon atoms.
  • According to an especially preferred aspect, Xaa36, Xaa37 and Xaa38 are the same anmno acid reside.
  • Preferred are compounds wherein Xaa39 is Ser or Tyr, more preferably Ser.
  • Preferably Z is —NH2.
  • According to one aspect, preferred are compounds of formula (VII) wherein Xaa1 is His or Tyr, more preferably His; Xaa2 is Gly; Xaa6 is Phe or naphthalanine; Xaa14 is Leu, pentylglycine or Met; Xaa22 is Phe or naphthalanine; Xaa23 is Ile or Val; Xaa31, Xaa36, Xaa37 and Xaa38 are independently selected from Pro, homoproline, thioproline or N-alkylalanine; and Xaa39 is Ser or Tyr, more preferably Ser. More preferably Z is —NH2.
  • According to an especially preferred aspect, especially preferred compounds include those of formula (VII) wherein: Xaa1 is His or Arg; Xaa2 is Gly; Xaa3 is Asp or Glu; Xaa6 is Phe or napthylalanine; Xaa7 is Thr or Ser; Xaa8 is Ser or Thr; Xaa9 is Asp or Glu; Xaa10 is Leu or pentylglycine; Xaa14 is Leu or pentylglycine; Xaa22 is Phe or naphthylalanine; Xaa23 is Ile, Val or t-butyltylglycine; Xaa24 is Glu or Asp; Xaa25 is Trp or Phe; Xaa31, Xaa36, Xaa37, and Xaa38 are independently Pro, homoproline, tluoproline, or N-methylalanine; Xaa39 is Ser or Tyr: and Z is —OH or —NH2; with the proviso that the compound does not have the formula of either SEQ ID NOs: 1 or 2. More preferably Z is —NH2. Especially preferred compounds include those having the amino acid sequence of SEQ ID NOs: 10, 11, 22, 23, 24, 27, 29, 36, 37 and 40.
  • According to an especially preferred aspect, provided are compounds where Xaa14 is Leu, Ile, Val or pentylglycine, more preferably Leu or pentylglycine, and Xaa25 is Phe, Tyr or naphthylalanine, more preferably Phe or naphthylalanine. These compounds are believed to exhibit advantageous duration of action and to be less subject to oxidative degration, both in vitro and in vivo, as well as during synthesis of the compound.
    • Formula VIII
  • Also provided are compounds described in PCT Application Serial No. PCT/US98/16387, filed Aug. 6, 1998, entitled “Novel Exendin Agonist Compounds,” published as WO 99/07404, including compounds of the formula (VIII) [SEQ ID NO: 48]:
  • Xaa1 Xaa2 Xaa3 Gly Thr Xaa6 Xaa7 Xaa8 Xaa9 Xaa10
    Ser Lys Gln Xaa14 Glu Glu Glu Ala Val Arg Leu
    Xaa22 Xaa23 Xaa24 Xaa25 Leu X1 Gly Gly Xaa31 Ser
    Ser Gly Ala Xaa36 Xaa37 Xaa38 Xaa39-Z

    wherein Xaa1 is His, Arg, Tyr or 4-imidazopropionyl; Xaa2 is Ser, Gly, Ala or Thr; Xaa3 is Asp or Glu; Xaa6 is Phe, Tyr or naphthylalanine; Xaa7 is Thr or Ser; Xaa8 is Ser or Thr; Xaa9 is Asp or Glu; Xaa10 is Leu, Ile, Val, pentylglycine or Met; Xaa14 is Leu, Ile, pentylglycine, Val or Met; Xaa22 is Phe, Tyr or naphthylalanine; Xaa23 is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met; Xaa24 is Glu or Asp; Xaa25 is Trp, Phe, Tyr, or naphthylalanine; X1 is Lys Asn, Asn Lys, Lys-NHε—R Asn, Asn Lys-NHε—R where R is Lys, Arg, C1-C10 straight chain or branched alkanoyl or cycloalkylalkanoyl; Xaa31, Xaa36, Xaa37 and Xaa38 are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine or N-alkylalanine; Xaa39 is Ser, Thr or Tyr; and Z is —OH or —NH2; with the proviso that the compound does not have the formula of either SEQ ID NOs: 1 or 2. Suitable compounds of formula (VIII) include compounds described in PCT Application Serial No. PCT/US98/16387, filed Aug. 6, 1998, entitled “Novel Exendin Agonist Compounds,” published as WO 99/07404, having the amino acid sequences of SEQ ID NOs: 37-40 therein.
  • Preferred exendin agonist compounds of formula (VIII) include those wherein Xaa1 is His, Tyr or 4-imidazopropionyl. More preferably, Xaa1 is His or 4-imidazopropionyl.
  • Preferred are those compounds of formula (VIII) wherein Xaa2 is Gly.
  • Preferred are those compounds of formula (VIII) wherein Xaa,4 is Leu, pentylglycine or Met.
  • Preferred are those compounds of formula (VIII) wherein Xaa25 is Trp or Phe.
  • Preferred are those compounds of formula (VIII) wherein X1 is Lys Asn, or Lys-NHε—R Asn, where R is Lys, Arg, C1-C10 straight chain or branched alkanoyl.
  • Also preferred are compounds of formula (VIII) wherein Xaa6 is Phe or naphthylalanine; Xaa22 is Phe or naphthylalanme; Xaa23 is Ile or Val and Xaa3l, Xaa36, Xaa37 and Xaa38 are independently selected from Pro, homoproline, thioproline or N-alkylalanine. According to an especially preferred aspect, Xaa39 is Ser or Tyr. Preferred are those such compounds wherein Xaa39 is Ser. Preferably, Z is —NH2.
  • According to one preferred aspect, preferred are compounds of formula (VIII) wherein Xaa6 is Phe or naphthylalanine; Xaa22 is Phe or naphthylalanine; Xaa23 is Ile or Val, X1 is Lys Asn, or Lys-NHεR Asn, where R is Lys, Arg, C1-C10 straight chain or branched alkanoyl and Xaa31, Xaa36, Xaa37 and Xaa38 are independently selected from Pro, homoproline, thioproline or N-alkylalanine.
    • Preparation of Modified Exendins And Exendin Agonists
  • The modified exendins and exendin agonists of the present invention may be made by linking one or more polyethylene glycol polymers to an exendin or exendin agonist. The synthesis of exendins and exendin agonists is thus described first, followed by methodology for linking the polyethylene glycol polymer(s) to the exendin or exendin agonist.
    • Preparation of Exendins And Exendin Agonists
  • Exendins and exendin agonist compounds such as exendin analogs and exendin derivatives, described herein may be prepared through peptide purification as described in, for example, Eng, et al., J. Biol. Chem. 265:20259-62, 1990; and Eng, et al., J. Biol. Chem. 267:7402-05, 1992, hereby incorporated by reference herein. Alternatively, exendins and exendin agonist peptides may be prepared by methods known to those skilled in the art, for example, as described in Raufman, et al. (J. Biol. Chem. 267:21432-37, 1992), hereby incorporated by reference herein, using standard solid-phase peptide synthesis techniques and preferably an automated or semiautomated peptide synthesizer. The compounds that constitute active ingredients of the formulations and dosages of the present invention may be prepared using standard solid-phase peptide synthesis techniques and preferably an automated or semiautomated peptide synthesizer. Typically, using such techniques, an α-N-carbamoyl protected amino acid and an amino acid attached to the growing peptide chain on a resin are coupled at room temperature in an inert solvent such as dimethylformamide, N-methylpyrrolidinone or methylene chloride in the presence of coupling agents such as dicyclohexylcarbodiimide and 1-hydroxybenzotriazole in the presence of a base such as diisopropylethylamine. The α-N-carbamoyl protecting group is removed from the resulting peptide-resin using a reagent such as trifluoroacetic acid or piperidine, and the coupling reaction repeated with the next desired N-protected amino acid to be added to the peptide chain. Suitable N-protecting groups are well known in the art, with t-butyloxycarbonyl (tBoc) and fluorenyhnethoxycarbonyl (Fmoc) being preferred herein.
  • The solvents, amino acid derivatives and 4-methylbenzhydryl-amine resin used in the peptide synthesizer may be purchased from Applied Biosystems Inc. (Foster City, Calif.). The following side-chain protected amino acids may be purchased from Applied Biosystems, Inc.: BSD-112344.1-Arg(Pmc), Boc-Thr(Bzl), Fmoc-Thr(t-Bu), Boc-Ser(Bzl), Fmoc-Ser(t-Bu), Boc-Tyr(BrZ), Fmoc-Tyr(t-Bu), Boc-Lys(Cl-Z), Fmoc-Lys(Boc), Boc-Glu(Bzl), Fmoc-Glu(t-Bu), Fmoc-His(Trt), Fmoc-Asn(Trt), and Fmoc-Gln(Trt). Boc-His(BOM) may be purchased from Applied Biosystems, Inc. or Bachem Inc. (Torrance, Calif.). Anisole, dimethylsulfide, phenol, ethanedithiol, and thioanisole may be obtained from Aldrich Chemical Company (Milwaukee, Wis.). Air Products and Chemicals (Allentown, Pa.) supplies HF. Ethyl ether, acetic acid and methanol may be purchased from Fisher Scientific (Pittsburgh, Pa.).
  • Solid phase peptide synthesis may be carried out with an automatic peptide synthesizer (Model 430A, Applied Biosystems Inc., Foster City, Calif.) using the NMP/HOBt (Option 1) system and tBoc or Fmoc chemistry (see, Applied Biosystems User's Manual for the ABI 430A Peptide Synthesizer, Version 1.3B Jul. 1, 1988, section 6, pp. 49-70, Applied Biosystems, Inc., Foster City, Calif.) with capping. Boc-peptide-resins may be cleaved with HF (−50° C. to 0° C., 1 hour). The peptide may be extracted from the resin with alternating water and acetic acid, and the filtrates lyophilized. The Fmoc-peptide resins may be cleaved according to standard methods (Introduction to Cleavage Techniques, Applied Biosystems, Inc., 1990, pp. 6-12). Peptides may also be assembled using an Advanced Chem Tech Synthesizer (Model MPS 350, Louisville, Ky.).
  • Peptides may be purified by RP-HPLC (preparative and analytical) using a Waters Delta Prep 3000 system. A C4, C8 or C18 preparative column (10 μ, 2.2×25 cm; Vydac, Hesperia, Calif.) may be used to isolate peptides, and purity may be determined using a C4, C8 or C18 analytical column (5 μ, 0.46×25 cm; Vydac). Solvents (A=0.1% TFA/water and B=0.1% TFA/CH3CN) may be delivered to the analytical column at a flowrate of 1.0 ml/min and to the preparative column at 15 ml/min. Amino acid analyses may be performed on the Waters Pico Tag system and processed using the Maxima program. Peptides may be hydrolyzed by vapor-phase acid hydrolysis (115° C., 20-24 h). Hydrolysates may be derivatized and analyzed by standard methods (Cohen, et al., The Pico Tag Method: A Manual of Advanced Techniques for Amino Acid Analysis, pp. 11-52, Millipore Corporation, Milford, Mass. (1989)). Fast atom bombardment analysis may be carried out by M-Scan, Incorporated (West Chester, Pa.). Mass calibration may be performed using cesium iodide or cesium iodide/glycerol. Plasma desorption ionization analysis using time of flight detection may be carried out on an Applied Biosystems Bio-Ion 20 mass spectrometer. Electrospray mass spectroscopy may be carried and on a VG-Trio machine.
  • Peptide active ingredient compounds useful in the formulations and dosages of the invention may also be prepared using recombinant DNA techniques, using methods now known in the art. See, eg., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2d Ed., Cold Spring Harbor (1989). Alternatively, such compounds may be prepared by homogeneous phase peptide synthesis methods. Non-peptide compounds useful in the present invention may be prepared by art-known methods. For example, phosphate- containing amino acids and peptides containing such amino acids, may be prepared using methods known in the art. See, e.g., Bartlett and Landen, Biorg. Chem. 14:356-377 (1986).
    • Conjugation of Polyethylene Glycol Polymers
  • There are several strategies for coupling PEG to peptides/proteins. See, Francis, Int. J. Hematology 68:1 (1998); Gombotz, Bioconjugate Chem. 6:150 (1995); and Delgado, Crit. Rev. Therap. Drug Carrier Sys. 9:249 (1992) all of which are incorporated herein by reference in their entirety. Those skilled in the art, therefore, will be able to utilize such well-known techniques for linking one or more polethylene glycol polymers to the exendins and exendin agonists described herein. Suitable polethylene glycol polymers typically are commercially available or may be made by techniqueswell know to those skilled in the art. The polyethylene glycol polymers preferably have molecular weights between 500 and 20,000 and may be branched or straight chain polymers.
  • The attachment of a PEG on an intact peptide or protein can be accomplished by coupling to amino, carboxyl or thiol groups. These groups will typically be the N and C termini and on the side chains of such naturally occurring amino acids as lysine, aspartic acid, glutamic acid and cysteine. Since exendin 4 and other exendins and exendin agonists can be prepared by solid phase peptide chemistry techniques, a variety of moieties containing diamino and dicarboxylic groups with orthogonal protecting groups can be introduced for conjugation to PEG.
  • The present invention also provides for conjugation of an exendin or exendin agonist to one or more polymers other than polyethylene glycol which can regulate kidney clearance in a manner similar to polyethylene glycol. Examples of such polymers include albumin and gelatin. See, Gombotz and Pettit, Bioconjugate Chem., 6:332-351, 1995, which is incorporated herein by reference in its entirety.
    • Utility
  • The formulations and dosages described herein are useful in view of their pharmacological properties. In particular, the compounds described herein possess activity as agents to reduce glucagon levels and suppress glucagon secretion, as evidenced by the ability to lower glucagon levels in animals and humans. They can be used to treat conditions or diseases that can be alleviated by reducing glucagon levels and suppressing glucagon secretion.
  • The compounds referenced above may form salts with various inorganic and organic acids and bases. Such salts include salts prepared with organic and inorganic acids, for example, HCl, HBr, H2SO4, H3PO4, trifluoroacetic acid, acetic acid, formic acid, methanesulfonic acid, toluenesulfonic acid, maleic acid, fuimaric acid and camphorsulfonic acid. Salts prepared with bases include ammonium salts, alkali metal salts, e.g., sodium and potassium salts, and alkali earth salts, e.g., calcium and magnesium salts. Acetate, hydrochloride, and trifluoroacetate salts are preferred. The salts may be formed by conventional means, as by reacting the free acid or base forms of the product with one or more equivalents of the appropriate base or acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is then removed in vacuo or by freeze-drying or by exchanging the ions of an existing salt for another ion on a suitable ion exchange resin.
    • Formulation and Administration
  • Exendin and exendin agonist formulations and dosages of the invention are useful in view of their exendin-like effects, and may conveniently be provided in the form of formulations suitable for parenteral (including intravenous, intramuscular and subcutaneous) administration. Also described herein are formulations and dosages useful in alternative delivery routes, including oral, nasal, buccal, sublingual and pulmonary.
  • The feasibility of alternate routes of delivery for exendin-4 has been explored by measuring exendin-4 in the circulation in conjunction with observation of a biologic response, such as plasma glucose lowering in diabetic animals, after administration. Passage of exendin-4 has been investigated across several surfaces, the respiratory tract (nasal, tracheal and pulmonary routes) and the gut (sublingual, gavage and intraduodenal routes). Biologic effect and appearance of exendin-4 in blood have been observed with each route of administration via the respiratory tract, and with sublingual and gavaged peptide via the gastrointestinal tract. Intra-tracheal administration, nasal administration, administration via the gut, and sublingual administration have all been described.
  • In some cases, it will be convenient to provide a modified exendin or exendin agonist and another anti-glucagon agent, such as an amylin or an amylin agonist, in a single composition or solution for administration together. In other cases, it may be more advantageous to administer another anti-glucagon agent separately from the exendin, exendin agonist, or modified exendin or exendin agonist. In yet other cases, it may be beneficial to provide an exendin, exendin agonist, or modified exendin or exendin agonist either co-formulated or separately with other glucagon lowering agents such as amylin. A suitable administration format may best be determined by a medical practitioner for each patient individually. Suitable pharmaceutically acceptable carriers and their formulation are described in standard formulation treatises, e.g., Remington's Pharmaceutical Sciences by E. W. Martin. See also Wang, Y. J. and Hanson, M. A. “Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers,” Journal of Parenteral Science and Technology, Technical Report No. 10, Supp. 42:2S (1988).
  • Compounds useful in the invention can be provided as parenteral compositions for injection or infusion. They can, for example, be suspended in an inert oil, suitably a vegetable oil such as sesame, peanut, olive oil, or other acceptable carrier. Preferably, they are suspended in an aqueous carrier, for example, in an isotonic buffer solution at a pH of about 3.0 to about 7.0, more specifically from about 4.0 to 6.0, and preferably from about 4.0 to about 5.0. These compositions may be sterilized by conventional sterilization techniques, or may be sterile filtered. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH buffering agents. Useful buffers include for example, sodium acetate/acetic acid buffers. A form of repository or “depot” slow release preparation may be used so that therapeutically effective amounts of the preparation are delivered into the bloodstream over many hours or days following transdermal injection or delivery.
  • The desired isotonicity may be accomplished using sodium chloride or other pharmaceutically acceptable agents such as dextrose, boric acid, sodium tartrate, propylene glycol, polyols (such as mannitol and sorbitol), or other inorganic or organic solutes. Sodium chloride is preferred particularly for buffers containing sodium ions.
  • The claimed compounds can also be formulated as pharmaceutically acceptable salts (e.g., acid addition salts) and/or complexes thereof. Pharmaceutically acceptable salts are non-toxic salts at the concentration at which they are administered. The preparation of such salts can facilitate the pharmacological use by altering the physical-chemical characteristics of the composition without preventing the composition from exerting its physiological effect. Examples of useful alterations in physical properties include lowering the melting point to facilitate transmucosal administration and increasing the solubility to facilitate the administration of higher concentrations of the drug.
  • Pharmaceutically acceptable salts include acid addition salts such as those containing sulfate, hydrochloride, phosphate, sulfamate, acetate, citrate, lactate, tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, cyclohexylsulfamate and quinate. Pharmaceutically acceptable salts can be obtained from acids such as hydrochloric acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, and quinic acid. Such salts may be prepared by, for example, reacting the free acid or base forms of the product with one or more equivalents of the appropriate base or acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is then removed in vacuo or by freeze-drying or by exchanging the ions of an existing salt for another ion on a suitable ion exchange resin.
  • Carriers or excipients can also be used to facilitate administration of the compound. Examples of carriers and excipients include calcium carbonate, calcium phosphate, various sugars such as lactose, glucose, or sucrose, or types of starch, cellulose derivatives, gelatin, vegetable oils, polyethylene glycols and physiologically compatible solvents. The compositions or pharmaceutical composition can be administered by different routes including intravenously, intraperitoneal, subcutaneous, and intramuscular, orally, topically, or transmucosally.
  • If desired, solutions of the above compositions may be thickened with a thickening agent such as methylcellulose. They may be prepared in emulsified form, either water in oil or oil in water. Any of a wide variety of pharmaceutically acceptable emulsifying agents may be employed including, for example, acacia powder, a non-ionic surfactant (such as a Tween), or an ionic surfactant (such as alkali polyether alcohol sulfates or sulfonates, e.g., a Triton).
  • Compositions useful in the invention are prepared by mixing the ingredients following generally accepted procedures. For example, the selected components may be simply mixed in a blender or other standard device to produce a concentrated mixture which may then be adjusted to the final concentration and viscosity by the addition of water or thickening agent and possibly a buffer to control pH or an additional solute to control tonicity.
  • Other pharmaceutically acceptable carriers and their formulation are described in standard formulation treatises, e.g., Remington's Pharmaceutical Sciences by E. W. Martin. See also Wang, Y. J. and Hanson, M. A. “Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers,” Journal of Parenteral Science and Technology, Technical Report No. 10, Supp. 42:2S (1988).
  • For use by the physician, the compounds will be provided in dosage unit form containing an amount of an exendin, exendin agonist, or modified exendin or exendin agonist, with or without another anti-glucagon agent. Therapeutically effective amounts of an exendin, exendin agonist, or modified exendin or exendin agonist for use in the control of glucagon and in conditions in which glucagon levels are beneficially lowered or regulated are those that decrease post-prandial blood glucagon levels as desired. In diabetic or glucose intolerant individuals, plasma glucagon levels may be higher than in normal individuals. In such individuals, beneficial reduction or “smoothing” of post-prandial blood glucagon levels, may be obtained. As will be recognized by those in the field, an effective amount of therapeutic agent will vary with many factors including the age and weight of the patient, the patient's physical condition, the glucagon level or level of inhibition of glucagon suppression to be obtained, and other factors.
  • Such pharmaceutical compositions are useful in causing glucagon to be lowered in a subject and may be used as well in other disorders where lowered or suppressed glucagon is beneficially reduced.
  • The effective daily anti-glucagon dose of the compounds will typically be in the range of 0.01 or 0.03 to about 5 mg/day, preferably about 0.01 or 0.5 to 2 mg/day and more preferably about 0.01 or 0.1 to 1 mg/day, for a 70 kg patient, administered in a single or divided doses. The exact dose to be administered is determined by the attending clinician and is dependent upon where the particular compound lies within the above quoted range, as well as upon the age, weight and condition of the individual. Administration should begin at the first sign of symptoms or shortly after diagnosis of, for example, diabetes mellitus as manifested by elevated glucagon. Administration may be by injection, preferably subcutaneous or intramuscular. Orally active compounds may be taken orally, however dosages should be increased 5-10 fold.
  • Generally, in treating or preventing elevated, inappropriate, or undesired post-prandial blood glucagon levels, the compounds of this invention may be administered to patients in need of such treatment in a dosage ranges similar to those given above, however, the compounds are administered more frequently, for example, one, two, or three times a day. Particularly preferred are the exendin and exendin agonist formulations and dosages and routes of administration thereof described commonly owned WO 00/41546 and WO 00/41548 (i.e., claiming priority to U.S. Provisional Application 60/116,380, entitled “Novel Exendin Agonist Formulations And Methods Of Administration Thereof,” filed Jan. 14, 1999 (and the corresponding PCT application claiming priority from it that was filed on Jan. 14, 2000, Serial No. [not yet assigned]), and U.S. Provisional Application 60/[not yet assigned], entitled “Use of Exendins and Agonists Thereof for Modulation of Triglyceride Levels and Treatment of Dyslipidemia,” filed Jan. 4, 1999), from which this application claims priority and the disclosures of which have been incorporated by referenced in their entirety as if fully set forth herein.
  • A form of repository or “depot” slow release preparation may be used so that therapeutically effective amounts of the preparation are delivered into the bloodstream over many hours or days following transdermal injection or other form of delivery.
  • The effective daily doses of the compounds are described. The exact dose to be administered may be determined by the attending clinician and may be further dependent upon the efficacy of the particular exendin or exendin agonist compound used, as well as upon the age, weight and condition of the individual. The optimal mode of administration of compounds of the present application to a patient depend on factors known in the art such as the particular disease or disorder, the desired effect, and the type of patient. While the compounds will typically be used to treat human patients, they may also be used to treat similar or identical diseases in other vertebrates such as other primates, farm animals such as swine, cattle and poultry, and sports animals and pets such as horses, dogs and cats.
  • In particular, the formulation which best supports a parenteral liquid dosage form is one in which the active ingredient(s) is stable with adequate buffering capacity to maintain the pH of the solution over the intended shelf life of the product. The dosage form should be either an isotonic and/or an iso-osmolar solution to either facilitate stability of the active ingredient or lessen the pain on injection or both. Devices that deliver very small injection volumes, however, may not require that the formulation be either isotonic and/or iso-osmolar. If the dosage form is packaged as a unit-dose, then a preservative may be included but is not required. If, however, the dosage form is packaged in a multi-use container, then a preservative is necessary.
  • These dosage forms include approximately 0.005 to about 0.4%, more specifically from about 0.005 to about 0.02%, or from about 0.005 to about 0.05% (w/v), respectively of the active ingredient in an aqueous system along with approximately 0.02 to 0.5% (w/v) of an acetate, phosphate, citrate or glutamate or similar buffer either alone or in combination to obtain a pH of the final composition of approximately 3.0 to 7.0, more 30 specifically from about pH 4.0 to about 6.0, or from about 4.0 to 5.0, as well as either approximately 1.0 to 10% (w/v) of a carbohydrate or polyhydric alcohol iso-osmolality modifier (preferably maunitol) or up to about 0.9% saline or a combination of both leading to an isotonic or an iso-osmolar solution in an aqueous continuous phase. Approximately 0.005 to 1.0% (w/v) of an anti-microbial preservative selected from the group consisting of m-cresol, benzyl alcohol, methyl ethyl, propyl and butyl parabens and phenol is also present if the formulation is packaged in a multi-use container. A sufficient amount of water for injection is added to obtain the desired concentration of solution. Sodium chloride, as well as other excipients, may also be present, if desired. Such excipients, however, must maintain the overall stability of the active ingredient.
  • Polyhydric alcohols and carbohydrates share the same feature in their backbones, i.e., —CHOH—CHOH—. The polyhydric alcohols include such compounds as sorbitol, mannitol, glycerol, and polyethylene glycols (PEGs). These compounds are straight-chain molecules. The carbohydrates, such as mannose, ribose, trehalose, maltose, glycerol, inositol, glucose and lactose, on the other hand, are cyclic molecules that may contain a keto or aldehyde group. These two classes of compounds will also be effective in stabilizing protein against denaturation caused by elevated temperature and by freeze-thaw or freeze-drying processes. Suitable carbohydrates include galactose, arabinose, lactose or any other carbohydrate which does not have an adverse affect on a diabetic patient, i.e., the carbohydrate is not metabolized to form large concentrations of glucose in the blood. Such carbohydrates are well known in the art as suitable for diabetics.
  • Preferably, the peptides of the present invention are admixed with a polyhydric alcohol such as sorbitol, mannitol, inositol, glycerol, xylitol, and polypropylene/ethylene glycol copolymer, as well as various polyethylene glycols (PEG) of molecular weight 200, 400, 1450, 3350, 4000, 6000, and 8000). Mannitol is the preferred polyhydric alcohol.
  • The liquid formulation of the invention should be substantially isotonic and/or iso-osmolar. An isotonic solution may be defined as a solution that has a concentration of electrolytes, or a combination of electrolytes and non-electrolytes that will exert equivalent osmotic pressure as that into which it is being introduced, here for example in the case of parenteral injection of the formulation, a mammalian tissue. Similarly, an iso-osmolar solution may be defined as a solution that has a concentration of non-electrolytes that will exert equivalent osmotic pressure as that into which it is being introduced. As used herein, “substantially isotonic” means within ±20% of isotonicity, preferably within ±10%. As used herein, “substantially iso-osmolar” means within ±20% of iso-osmolality, preferably within ±10%. The formulated product for injection is included within a container, typically, for example, a vial, cartridge, prefilled syringe or disposable pen.
  • The formulation which best support a unit-dose parenteral lyophilized dosage form is one in which the active ingredient is reasonably stable, with or without adequate buffering capacity to maintain the pH of the solution over the intended shelf life of the reconstituted product. The dosage form should contain a bulking agent to facilitate cake formation. The bulking agent may also act as a tonicifer and/or iso-osmolality modifier upon reconstitution to either facilitate stability of the active ingredient and/or lessen the pain on injection. As noted above, devices that deliver very small injection volumes may not require the formulation to be isotonic and/or iso-osmolar. A surfactant may also benefit the properties of the cake and/or facilitate reconstitution.
  • These dosage forms include approximately 0.005 to about 0.4%, more specifically from about 0.005 to about 0.02%, or 0.005 to 0.05% (w/v) of the active ingredient. It may not be necessary to include a buffer in the formulation and/or to reconstitute the lyophile with a buffer if the intention is to consume the contents of the container within the stability period established for the reconstituted active ingredient. If a buffer is used, it may be included in the lyophile or in the reconstitution solvent. Therefore, the formulation and/or the reconstitution solvent may contain individually or collectively approximately 0.02 to 0.5% (w/v) of an acetate, phosphate, citrate or glutamate buffer either alone or in combination to obtain a pH of the final composition of approximately 3.0 to 7.0, more specifically from about pH 4.0 to about 6.0, or from about 4.0 to 5.0. The bulking agent may consist of either approximately 1.0 to 10% (w/v) of a carbohydrate or polyhydric alcohol iso-osmolality modifier (as described above) or up to 0.9% saline or a combination of both leading to a isotonic or iso-osmolar solution in the reconstituted aqueous phase. A surfactant, preferably about 0.1 to about 1.0% (w/v) of polysorbate 80 or other non-ionic detergent, may be included. As noted above, sodium chloride, as well as other excipients, may also be present in the lyophilized unit-dosage formulation, if desired. Such excipients, however, must maintain the overall stability of the active ingredient. The formulation will be lyophilized within the validation parameters identified to maintain stability of the active ingredient.
  • The liquid formulation of the invention before lyophilization should be substantially isotonic and/or iso-osmolar either before lyophilization or to enable formation of isotonic and/or iso-osmolar solutions after reconstitution. The formulation should be used within the period established by shelf-life studies on both the lyophilized form and following reconstitution. The lyophilized product is included within a container, typically, for example, a vial. If other containers are used such as a cartridge, pre-filled syringe, or disposable pen, the reconstitution solvent may also be included.
  • As with the parenteral liquid and lyophilized uint-dosage formulations described above, the formulation which best supports a multi-dose parenteral lyophilized dosage form is one in which the active ingredient is reasonably stable with adequate buffering capacity to maintain the pH of the solution over the intended “in-use” shelf-life of the product. The dosage form should contain a bulking agent to facilitate cake formation. The bulking agent may also act as a tonicifer and/or iso-osmolality modifier upon reconstitution to either facilitate stability of the active ingredient or lessen the pain on injection or both. Again, devices that deliver very small injection volumes may not require the formulation to be either isotonic and/or iso-osmolar. A preservative is, however, necessary to facilitate multiple use by the patient.
  • These dosage forms include approximately 0.005 to about 0.4%, more specifically from about 0.005 to about 0.02%, or from about 0.005 to 0.05% (w/v), respectively of the active ingredient. It may not be necessary to include a buffer in the formulation and/or to reconstitute the lyophile with a buffer if the intention is to consume the contents of the container within the stability period established for the reconstituted active ingredient. If a buffer is used, it may be included in the lyophile or in the reconstitution solvent. Therefore, the formulation and/or the reconstitution solvent may contain individually or collectively approximately 0.02 to 0.5% (w/v) of an acetate, phosphate, citrate or glutamate buffer either alone or in combination to obtain a pH of the final composition of approximately 3.0 to 7.0, more specifically from about pH 4.0 to about 6.0, or from about 4.0 to 5.0. The bulking agent may consist of either approximately 1.0 to 10% (w/v) of a carbohydrate or a polyhydric alcohol iso-osmolality modifier (preferably mannitol) or up to 0.9% saline, or a combination of both, leading to an isotonic or iso-osmolar solution in the reconstituted aqueous phase. A surfactant, preferably about 0.1 to about 1.0% (w/v) of polysorbate 80 or other non-ionic detergent, may be included. Approximately 0.005 to 1.0% (w/v) of an anti-microbial preservative selected from the group consisting of m-cresol, benzyl alcohol, methyl, ethyl, propyl and butyl parabens and phenol (preferably m-cresol) is also present if the formulation is packaged in a multi-use container. Sodium chloride, as well as other excipients, may also be present, if desired. Again, however, such excipients must maintain the overall stability of the active ingredient. The formulation should be lyophilized within the validation parameters identified to maintain stability of the active ingredient. The liquid formulation of the invention should be substantially isotonic and/or iso-osmolar either before lyophilization or to enable formation of isotonic and/or iso-osmolar solutions after reconstitution. The formulation should be used within the period established by shelf-life studies on both the lyophilized form and following reconstitution. The lyophilized product is included within a container, typically, for example, a vial. If other containers are used such as a cartridge, pre-filled syringe or disposable pen, the reconstitution solvent may also be included.
  • The formulations that best support oral, nasal, pulmonary and/or intra-tracheal dosage forms may be either preserved or unpreserved liquid formulations and/or dry powder or, for oral administration, solid formulations. The preserved or unpreserved liquid formulations will be essentially identical to the formulations described above under preserved or unpreserved liquid parenteral formulations. The pH of the solution should be about 3.0 to 7.0, with a pH greater than or equal to about 5.0 being most preferred to reduce the potential for bronchoconstriction. The dry powder formulations may contain a bulking agent and/or salts to facilitate particle size formation and appropriate particle size distribution. A surfactant and/or salts may also benefit the properties of the particle morphology and/or facilitate tissue uptake of the active ingredient.
  • These dry powder dosage forms can range from 1% to 100% (w/w), respectively of the active ingredient. It may not be necessary to include a bulking agent and/or salts to facilitate particle size formation and/or distribution. The bulking agent and/or salts may consist of either approximately 0 to 99% (w/w) of a carbohydrate or polyhydric alcohol or approximately 0 to 99% salt or a combination of both leading to the preferred particle size and distribution. A surfactant, preferably about 0.1 to about 1.0% (w/w) of polysorbate 80 or other non-ionic detergent, may be included. Sodium chloride, as well as other excipients, may also be present, if desired. Such excipients, however, must maintain the overall stability of the active ingredient and facilitate the proper level of hydration.
  • The formulations that best support nasal and/or intra-tracheal dosage forms may be either preserved or unpreserved liquid dosage formulations described previously.
  • Dissolvable gels and/or patches may be used to facilitate buccal delivery. The gels may be prepared from various types of starch and/or cellulose derivatives.
  • Sublingual delivery may be best supported by liquid formulations similar to those described above as parenteral liquid or parenteral lyophilized formulations after reconstitution except without the need for the dosage form to be an isotonic and/or iso-osmolar solution. Solid dosage forms may be similar to oral solid dosage forms except that they must be readily dissolvable under the tongue.
  • Oral delivery may be best supported by a liquid (gel cap) formulation that is similar to the parenteral liquid formulation except that the solution may be more concentrated and may contain additional additives to facilitate uptake of the active ingredient by the small intestine. Solid dosage forms will contain inert ingredients along with the active ingredient to facilitate tablet formation. These ingredients may include polyhedral alcohols (such as mannitol), carbohydrates, or types of starch, cellulose derivatives, and/or other inert, physiologically compatible materials. The tablet may be enterically coated to minimize digestion in the stomach and thereby facilitate dissolution and uptake further along the alimentary canal.
    • Clinical Studies
  • As described in Example 14 below, a double blind, placebo-controlled single ascending dose study examining the safety, tolerability, and pharmacokinetics of subcutaneous exendin-4 in healthy volunteers has been completed. Five single subcutaneous doses of exendin-4 (0.01, 0.05, 0.1, 0.2 or 0.3 μg/kg) were studied in 40 healthy male volunteers in the fasting state. Maximum plasma exendin-4 concentrations were achieved between one and two hours post-dose with little difference among the doses examined. Examination of the data indicated a dose dependent increase for Cmax. There were no serious adverse events reported in this study.
  • In the healthy male volunteers that participated in this study, exendin-4 was well tolerated at subcutaneous doses up to and including 0.1 μg/kg. A decrease in plasma glucose concentration was also observed at this dose. At doses of 0.2 μg/kg and higher, the most commonly observed adverse events were headache, nausea, vomiting, dizziness, and postural hypotension. There was a transient fall in plasma glucose concentration following administration of doses of 0.05 μg/kg and above.
    • Alternate Routes of Delivery
  • The feasibility of alternate routes of delivery for exendin-4 has been explored by measuring exendin-4 in the circulation in conjunction with observation of a biologic response, such as plasma glucose lowering in diabetic animals, after administration. Passage of exendin-4 has been investigated across several surfaces, the respiratory tract (nasal, tracheal, and pulmonary routes) and the gut (sublingual, gavage and intraduodenal routes). Biologic effect and appearance of exendin-4 in blood have been observed with each route of administration via the respiratory tract, and with sublingual and gavaged peptide via the gastrointestinal tract.
  • Intra-tracheal Administration—As described herein, intra-tracheal administration of exendin-4 into fasted rats (20 μg/500 μL/animal) produced a rise in the mean plasma exendin-4 concentration to 2060±960 μg/mL within 5-10 minutes after administration. Elevated plasma exendin-4 concentrations were maintained for at least 1 hour after instillation (see FIG. 7). In diabetic db/db mice, intra-tracheal instillation of exendin-4 (1 μg/animal) lowered plasma glucose concentration by 30% while that in the vehicle control group increased by 41% 1.5 hours after treatment. In these animals the mean plasma concentration of exendin-4 was 777±365 μg/ml at 4.5 hours after treatment (see FIGS. 8 a and 8 b).
  • In diabetic ob/ob mice, intra-tracheal instillation of exendin-4 (1 μg/animal) decreased plasma glucose concentration to 43% of the pre-treatment level after 4 hours while that in the vehicle control group was not changed (see FIGS. 9 a and 9 b).
  • Nine overnight-fasted male Sprague Dawley rats (age 96-115 days, weight 365-395, mean 385 g) were anesthetized with halothane, tracheotomized, and catheterized via the femoral artery. At t=0 min, 30L of saline in which was dissolved 2.1 ρg (n=3), 21 μg (n=3) or 210 μg of exendin-4 was instilled into the trachea beyond the level of intubation. Blood samples were taken after 5, 10, 20, 30, 60, 90, 120, 150, 180, 240, 300 and 360 min, centrifuged and plasma stored at −20° C. for subsequent immunoradiometric (IRMA) assay directed to N-terminal and C-terminal epitopes of the intact exendin-4 molecule. Following intra-tracheal administration, 61-74% of peak plasma concentration was observed within 5 min. Tmax occurred between 20 and 30 min after administration. AUC and Cmax were proportional to dose. At a dose of 2.1μg (1.5 nmol/kg), resulting in plasma concentrations of ˜50 pM (where glucose-lowering effects in man are observed), bioavailability was 7.3%. The coefficient of variation was 44%. At higher doses, bioavailability was slightly lower, and the CV was higher (see FIGS. 10 a and 10 b). Via the tracheal route of administration, the t½ (defined pragmatically as time for plasma to fall below 50% of Cmax) was 30-60 min for the lowest dose and 60-90 min for the 2 higher doses. In summary, biologically effective quantities of exendin-4 are rapidly absorbed via the trachea without evoking apparent respiratory distress. The respiratory tract is a viable route of administration of exendin-4.
  • Pulmonary Administration—Increased plasma concentrations of exendin-4 were detected in rats exposed to aerosolized exendin-4. Exposure of rats to approximately 8 ng of aerosolized exendin-4 per mL of atmosphere for 10 minutes resulted in peak plasma exendin-4 concentrations of 300-1900 μg/mL 5 minutes following treatment (see FIG. 11). Similar exposure of diabetic db/db mice to aerosolized exendin-4 lead to a 33% decrease in plasma glucose concentration after 1 hour, when a mean plasma exendin-4 concentration of 170±67 μg/mL was detected. Diabetic db/db mice in the control group exposed to aerosolized saline recorded no change in plasma glucose (see FIGS. 12 a and 12 b).
  • Nasal administration—Application of exendin-4 into the nasal cavity of rats led to a rise in plasma concentrations. Peak values of 300 μg/mL and 6757 μg/mL were detected 10 minutes after administration of 1 μg and 100 μg exendin-4 (dissolved in 2 μL saline), respectively (see FIG. 13).
  • Administration via the Gut—Male db/db mice (approximately 50 g body wt.) were fasted for 2 h and before and after an intra-gastric administration of saline or exendin-4 (exendin-4). A 9% decrease in plasma glucose concentration was observed with 1 mg/200 μl/animal and a 15% decrease was observed with 3 mg/200 μl/animal, compared with a 10% increase plasma glucose in the controls one hour after treatment (see FIG. 14).
  • Sublingual Administration—Sublingual application of exendin-4 (100 μg/5 μL/animal) to diabetic db/db mice led to a 15% decrease in plasma glucose concentration one hour after treatment. A 30% increase was observed for the control group receiving saline. The mean exendin-4 plasma level at 60 minutes was 4520±1846 pg/mL (see FIGS. 15 a, 15 b, and 15 c).
  • Eight Sprague Dawley rats (˜300 g) were briefly anesthetized with metophane while a solution containing 10 μg/3 μL (n=4) or 100 μg/3 μL (n=4) was pipetted under the tongue. Blood samples were subsequently collected from the topically anesthetized tail and assayed for exendin-4 by IRMA. Plasma concentrations had begun to rise by 3 min after administration and were maximal 10 min and 30 min after administration (10 μg and 100 μg doses, respectively). Plasma exendin-4 concentration subsequently remained above the lower limit of quantitation (LLOQ) beyond 5 hours. Area-under-the-curve to the end of each experiment was calculated by the trapezoidal method. Two numbers were derived, one derived from total immunoreactivity, the other derived from the increment above the non-zero value present at t=0. These values were compared to historical intravenous bolus data in the same animal model to obtain, respectively, high and low estimates of bioavailability. For the IOgg dose, sublingual bioavailability was 3.1-9.6%, and for a 100 μg dose, bioavailability was lower at 1.3-1.5%. Variability of AUC was greatest in the first hour after administration (CV 74% and 128% for 10 and 100 μg doses). For the 5-hour integral, coefficient of variation of the AUC was 20% and 64%, respectively. Peak plasma concentration (Cmax) occurred as rapidly after sublingual administration as after subcutaneous administration (Tmax ˜30 min). Cmax after sublingual administration of 10 μg exendin-4 was 1.5% that after an intravenous bolus, but 14.5% of that obtained after a subcutaneous bolus. Cmax after sublingual administration of 100 μg exendin-4 was only 0.29% of that observed after an intravenous bolus, and 6.1% of that obtained after a subcutaneous bolus (see FIGS. 15 d and 15 e). Thus, exendin-4 can be delivered at bioeffective doses via the sublingual route. Bioavailability and Cmax were greatest, Tmax was shortest, and variability of availability was least with the lowest sublingual dose. The lowest sublingual dose resulted in plasma concentrations similar to those that are predicted to be effective in lowering glucose in humans (˜50-100 pM).
  • The optimal formulation and mode of administration of compounds of the present application to a patient depend on factors known in the art such as the particular disease or disorder, the desired effect, and the type of patient. While the compounds will typically be used to treat human patients, they may also be used to treat sinilar or identical diseases in other vertebrates such as other primates, farm animals such as swine, cattle and poultry, and sports animals and pets such as horses, dogs and cats.
  • To assist in understanding the present invention the following Examples are included which describe the results of a series of experiments. The experiments relating to this invention should not, of course, be construed as specifically limiting the invention and such variations of the invention, now known or later developed, which would be within the purview of one skilled in the art are considered to fall within the scope of the invention as described herein and hereinafter claimed.
    • EXAMPLE 1 Preparation of Exendin-3
  • [SEQ ID NO: 1]
    His Ser Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys
    Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
    Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro
    Pro Pro Ser-NH2
  • The above amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.). In general, single-coupling cycles were used throughout the synthesis and Fast Moc (HBTU activation) chemistry was employed. Deprotection (Fmoc group removal) of the growing peptide chain was achieved using piperidine. Final deprotection of the completed peptide resin was achieved using a mixture of triethylsilane (0.2 mL), ethanedithiol (0.2 mL), anisole (0.2 mL), water (0.2 mL) and trifluoroacetic acid (15 mL) according to standard methods (Introduction to Cleavage Techniques, Applied Biosystems, Inc.) The peptide was precipitated in ether/water (50 mL) and centrifuged. The precipitate was reconstituted in glacial acetic acid and lyophilized. The lyophilized peptide was dissolved in water). Crude purity was about 75%.
  • Used in purification steps and analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
  • The solution containing peptide was applied to a preparative C-18 column and purified (10% to 40% Solvent B in Solvent A over 40 minutes). Purity of fractions was determined isocratically using a C-18 analytical column. Pure fractions were pooled furnishing the above-identified peptide. Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 19.2 minutes.
    • EXAMPLE 2 Preparation of Exendin-4
  • [SEQ ID NO: 2]
    His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys
    Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
    Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro
    Pro Pro Ser-NH2
  • The above amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Exendin-3 as describe in Example 1. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 36% to 46% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 14.9 minutes. Electrospray Mass Spectrometry (M): calculated 4186.6; found 4186.0 to 4186.8 (four lots).
    • EXAMPLE 3 Clearance by the Kidney
  • The kidney can play a major role in the elimination of some molecules (drugs, peptides, proteins). For some molecules, this process begins when the kidney filters the blood at the glomerulus to produce the ultrafiltrate described below. The glomerular filter discriminates not only on the basis of molecular weight but also by acting as a negatively charged selective barrier, promoting retention of anionic compounds. The free fraction of molecules in the plasma (not protein bound) with a molecular weight less than 5 kD and an effective radii less than 15 Å are easily filtered. For larger molecular weight molecules they are filtered on a more restrictive and limited basis, principally by molecular size, structure and net charge. The cutoff point for glomerular filtration lies between albumin (67 kD) which is retained and hemoglobin (68 kD) which is filtered. Albumin, with an effective radius of about 36 Å is filtered less than 1% at the glomerulus.
  • Once in the glomerulus a molecule travels to the proximal tubule where it is either reabsorbed or it passes on through the loop of Henle to the distal tubule where collecting ducts drain the filtrate into the bladder. Filtered proteins and peptides are typically cleaved by brush border enzymes in the proximal tubule, from where they are efficiently retrieved by sodium/amino cotransporters (scavenging pumps). Otherwise, molecules which are polar, ionized and of large molecular weight will not be reabsorbed. Throughout this process metabolizing enzymes in the renal cortex (proximal tubules) may also degrade the molecule into more polar molecules, thereby increasing the probability for excretion into the urine. Many peptide hormones (for example, amylin, calcitonins) are degraded by passage through the renal circulation, presumably by vascular ectoenzymes accessible to the plasma, independently of the process of glomerular filtration. In those examples, rates of peptide clearance from the plasma are similar to the rate of renal plasma flow, which is 3-fold greater than the rate of glomerular filtration.
  • Studies performed to identify plasma circulating metabolites of exendin-4 yielded very little evidence of proteolytic degradation; following large intravenous doses in animals, HPLC analysis of plasma showed only the presence of intact exendin, and negligible appearance of “daughter” peaks indicative of the buildup of degradation products. This is in contrast to other peptides studied (for example amylin and GLP-1) where the disappearance of the “parent” HPLC peak was associated with the appearance of “daughter” HPLC peaks, subsequently identified as subpeptide degradants. The absence of plasma degradants of exendin indicates little or no proteolysis at any site, including the renal circulation. Any clearance by the kidney, then, is via non-proteolytic means, namely filtration or active excretion (as occurs with para-amino hippurate).
  • Initial measurements of exendin clearance in man (120-130 mL/min), monkeys (˜9 mL/min) and rats (3.2-4.4 mL/min) matched reported glomerular filtration rates in those species. To test whether renal filtration could be the principal mode of exendin elimination, studies were performed in overnight fasted nephrectomized male rats infused with exendin at a constant rate. Steady-state plasma levels of exendin-4 were greatly increased in nephrectomized rats compared to rats with their kidneys intact. This data indicated that the kidney was responsible for at least 80% of the clearance of exendin 4 (see FIGS. 5 and 6). Exendin clearance rates in intact rats were, again, similar to glomerular filtration rates expected in those rats (4.2 mL/min). Taken together these results indicate that very little metabolism occurs systemically and that most of the clearance of exendin 4 is through the kidney via filtration (but not by renal intravascular proteolysis). The low amounts of immunoreactive full-length exendin in the urine are consistent with it being cleaved by brush border enzymes in the proximal tubule after filtration.
    • EXAMPLE 4 Exendin-4 Decreases Glucagon Secretion
  • During Hyperglycemic Clamps in Diabetic Fatty Zucker Rats
  • Absolute or relative hyperglucagonemia is often a feature of, for example, type 1 and type 2 diabetes mellitus, and the suppression of excessive glucagon secretion in these and other conditions described or referred to herein is a potential benefit of therapy using glucagonostatic agents. In this Example, the effect of exendin-4 on glucagon secretion in male anaesthetized Diabetic Fatty Zucker (ZDF) rats was examined. Using an hyperinsulinemic hyperglycemic clamp protocol, factors tending to influence glucagon secretion were held constant. Plasma glucose was clamped at ˜34 mM 60 min before beginning intravenous infusions of saline (n=7) or exendin-4 (0.21 μg +2.1 μg/mL/h; n=7). Plasma glucagon concentration measured prior to these infusions were similar in both groups (306±30 pM versus 252±32 pM, respectively; n.s.).
  • Mean plasma glucagon concentration in exendin-4 infused rats was nearly half of that in saline-infused rats in the final 60 minutes of the clamp (165±18 pM versus 298±26 pM, respectively; P<0.002). The hyperglycemic clamp protocol also enabled measurement of insulin sensitivity. Glucose infusion rate during the clamp was increased by 111±7% in exendin-4-treated versus control rats (P<0.001). In other words, exendin-4 exhibited a glucagonostatic effect in ZDF rats during hyperglycemic clamp studies, an effect that will be of therapeutic benefit in diabetic humans.
    • EXAMPLE 5 Metabolic Effects of Exendin-4 on Glucagon Secretion in People with Type 2 Diabetes
  • In this Example, the safety, tolerability, and efficacy of synthetic exendin-4 was evaluated in 8 male non-insulin using patients with type 2 diabetes who had discontinued other antidiabetic therapy for a minimum of 7 days. Each patient received subcutaneous (SC) injections of placebo (PBO) and 0.1, 0.2, and 0.3 μg/kg exendin-4 48 hours apart in a single-blind, dose-rising, placebo controlled crossover design. Five patients also received a 0.4 μg/kg dose. Plasma glucose, insulin and glucagon concentrations were assessed fasting and in response to a 7 Kcal/kg Sustacal® challenge administered at the time of exendin-4/PBO injection. Gastric emptying was evaluated by measuring serum acetaminophen concentrations following a 20 mg/kg oral dose of liquid acetaminophen administered with the Sustacal®. No safety issues were identified based upon reported adverse events, EKG and safety lab monitoring. Doses of 0.3 and 0.4 μg/kg elicited a dose-dependent increase in nausea; vomiting occurred at the highest dose.
  • Plasma glucose concentrations were reduced in all doses of exendin-4 compared to PBO although insulin concentrations were not significantly different. The 8 hour mean±SE changes in plasma glucose AUC from baseline were +391±187, −263±108, −247±64, −336±139, and −328±70 mg*hr/dL for the PBO, 0.1, 0.2, 0.3, and 0.4 μg/kg doses respectively. The 3 hr changes in plasma glucagon were +128.0±19.2, −5.6±10.5, −29.4±18.6, −40.5±24.5, and +6.9±38.6 μg*hr/mL respectively. The gastric emptying rate was slowed in all doses and the mean total absorbed acetaminophen over 6 hours was reduced by 51%, 50%, 57% and 79% compared to PBO for 0.1, 0.2, 0.3, and 0.4 μg/kg doses respectively. In summary, SC injection of exendin-4 to patients identified no safety issues, was tolerated at doses <0.3 μg/kg, reduced plasma glucose and glucagon and slowed the rate of gastric emptying. These observations support the use of exendin for the treatment of conditions that would benefit from reduced glucagon levels and/or suppression of glucagon, including but not limited to type 1 and type 2 diabetes.
    • EXAMPLE 6 PEG Modified Exendin-4
  • In the case of exendin 4, a 39 amino acid peptide with a molecular weight of 4187, modifications that increase its size and/or increase its anionic nature will decrease its ability to be filtered by the kidney. Because clearance of exendin 4 is largely by the kidney this will effectively increase its half life. Other properties of PEGylation (increased plasma half-life due to evasion of such renal and/or cellular clearance mechanisms that may exist; reduced immunogenicity and antigenicity; increased solubility; resistance to proteolysis; reduced toxicity (avoid dose spike); improved thermal and mechanical stability; improved permeability of the mucus or epithelial layer; and selective control over a specific biological fimction) are also of potential benefit for exendin 4 and exendin agonists.
  • In particular, because we have observed multiple pharmacologies (likely representing multiple receptor subtypes), different spectra of biological activities of exendin 4 may be selected by putting a PEG group at appropriate positions. Loss or alteration of bioactivity has been reported for PEGylated proteins which may be due to the presence of the PEG chains themselves, the particular site occupied by the PEG chain, or the coupling conditions having an adverse effect on the protein.
  • Primary considerations for PEG modification in terms of filtration at the kidney of exendin and exendin agonists are size and charge. Unmodified, exendin 4 has a molecular weight of approximately 4.2 kD and is anionic in nature with an overall net charge of approximately −2 at physiological pH. One, two or three PEG constituents may be covalently linked to exendin 4 or an analog of exendin 4, for example, with one PEG constituent being preferred. The size of the PEG can vary from a molecular weight of 500 to 20,000, preferably between 5,000 and 12,000.
  • Many of the methods for covalent attachment of PEG take advantage of the epsilon-amnino group on lysine. Exendin 4 has two lysines that can be modified by attachment of PEG. An alanine scan of AC3177 (Leu14, Phe25I-28 exendin-4), a shortened analog of exendin 4, revealed positions that are sensitive to substitution by alanine. The two lysines at positions 12 and 27 were moderately affected by this substitution suggesting that loss of the lysine specific R group side chain (methylene chain plus epsilon-amino group) is tolerated. With regard to the full-length peptide, exendin 4, the two lysine positions are appropriate for PEG attachment (see compounds 1 and 2). In addition, depending on the chemistry used to conjugate the PEG, the epsilon-amino groups at these positions may be masked thereby increasing the anionic nature of the peptide.
  • (201)
    HGEGTFTSDLSK(PEG)QMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2
    (202)
    HGEGTFTSDLSKQMEEEAVRLFIEWLK(PEG)NGGPSSGAPPPS-NH2
  • Based on the results of the alanine scan, other likely positions that may be modified by insertion of a Lys-PEG or equivalent, for example, are:
  • (203)
    HK(PEG)EGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2
    (204)
    HGEGK(PEG)FTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2
    (205)
    HGEGTFTK(PEG)DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2
    (206)
    HGEGTFTSDK(PEG)SKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2
    (207)
    HGEGTFTSDLK(PEG)KQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2
    (208)
    HGEGTFTSDLSKK(PEG)MEEEAVRLFIEWLKNGGPSSGAPPPS-NH2
    (209)*
    HGEGTFTSDLSKQMEK(PEG)EAVRLFIEWLKNGGPSSGAPPPS-NH2
    (210)*
    HGEGTFTSDLSKQMEEK(PEG)AVRLFIEWLKNGGPSSGAPPPS-NH2
    (211)
    HGEGTFTSDLSKQMEEEAK(PEG)RLFIEWLKNGGPSSGAPPPS-NH2
    (212)
    HGEGTFTSDLSKQMEEEAVRK(PEG)FIEWLKNGGPSSGAPPPS-NH2
    (213)*
    HGEGTFTSDLSKQMEEEAVRLFIK(PEG)WLKNGGPSSGAPPPS-NH2
    (214)
    HGEGTFTSDLSKQMEEEAVRLFIEK(PEG)LKNGGPSSGAPPPS-NH2
    (215)
    HGEGTFTSDLSKQMEEEAVRLFIEWLKK(PEG)GGPSSGAPPPS-NH2
  • The three positions* above normally containing a glutamic acid that were indicated for modification with K(PEG) can also be modified by conjugation to the glutamic side chain carboxyl group, E(PEG).
  • Another analog in which the Lys-PEG can be added is at the supposed GlyGly turn:
  • (216)
    HGEGTFTSDLSKQMEEEAVRLFIEWLKNK(PEG)GPSSGAPPPS-NH2
    (217)
    HGEGTFTSDLSKQMEEEAVRLFIEWLKNGK(PEG)PSSGAPPPS-NH2
  • Positions 29-39 of exendin-4 may not be critical for the glucose lowering activity as evidenced by AC3177 having nearly equipotent activity to exendin 4, and any of them, alone or in combination, can be substituted for K(PEG) or an equivalent.
    • EXAMPLE 7 Exendin-4 is a Circulating, Meal-Related Peptide in the Gila Monster
  • This experiment investigated whether exendin-4 has a metabolic role in the Gila monster lizard itself. To investigate whether exendin-4 appeared in the blood of the Gila monster in response to feeding, blood was sampled from one animal fasted for 7 weeks, before and 30 min after ingestion of a small rat. Plasma was assayed for full-length exendin-4 using an immunoradiometric assay with monoclonal antibody pairs directed to epitopes at N- and C-termini of exendin-4. Fasting plasma exendin-4 concentration was 76 pg/mL, near the lower limit of quantitation. After eating, this value rose 300-fold to 23,120 pg/mL.
  • In a second experiment, serial samples were taken from two animals fasted five weeks before and after ingestion of one or two small rats (47-49 g). Plasma exendin-4 concentration rose 23-to 36-fold (to 4860, 8340 pg/mL) immediately after eating, consistent with a direct passage of exendin-4 from the salivary gland to blood. After eating a second rat (t=30 min), plasma exendin-4 concentration in one Gila rose further to 27,209 pg/mL. Plasma exendin-4 concentration decayed with a tV of 5.00 and 5.33 hours, respectively. In conclusion, exendin-4, known to originate from the salivary gland of the Gila monster, appears in high concentration in the blood immediately after eating. This may represent a meal-related signal to inhibit further eating and promote nutrient storage.
    • EXAMPLE 8 Exendin-4 Decreases Glucagon Secretion During Hyperglycemic Clamps in Diabetic Fatty Zucker Rats
  • Absolute or relative hyperglucagonemia is often a feature of type 1 and type 2 diabetes mellitus, and the suppression of excessive glucagon secretion is a potential benefit of therapy using glucagonostatic agents. In this Example, the effect of exendin-4 on glucagon secretion in male anaesthetized Diabetic Fatty Zucker (ZDF) rats was examined. Using an hyperinsulinemic hyperglycemic clamp protocol, factors tending to influence glucagon secretion were held constant. Plasma glucose was clamped at ˜34 mM 60 min before beginning intravenous infusions of saline (n=7) or exendin-4 (0.21 μg+2.1 μg/mL/h; n-7). Plasma glucagon concentration measured before these infusions were similar in both groups (306±30 pM versus 252±32 pM, respectively; n.s.).
  • Mean plasma glucagon concentration in exendin-4 infused rats was nearly half of that in saline-infused rats in the final 60 minutes of the clamp (165±18 pM versus 298±26 pM, respectively; P<0.002). The hyperglycemic clamp protocol also enabled measurement of insulin sensitivity. Glucose infusion rate during the clamp was increased by 111±7% in exendin-4-treated versus control rats (P<0.001). In other words, exendin-4 exhibited a glucagonostatic effect in ZDF rats during hyperglycemic clamp studies, an effect that will be of therapeutic benefit in diabetic humans.
    • EXAMPLE 9 Pharmacokinetics of Exendin-4 in the Rat
  • Following Intravenous, Subcutaneous and Intraperitoneal Administration This Example describes work to define the plasma pharmacokinetics of exendin-4 in rats (˜350 g body weight each) following 2.1, 21, 210 μg/rat i.v. bolus, s.c. and i.p. administration and 2.1, 21, 210 μg/hr/rat i.v. infusion (3 hr). Serial samples of plasma (˜120 μL) were assayed using a validated immunoradiometric assay (IRMA). This sandwich-type assay uses mouse-based monoclonal antibodies that react with exendin-4 but do not react with GLP-1 or tested metabolites of exendin-4 or GLP-1. The lower limit of quantitation was 15 pM (63 pg/mL). The estimated t½ for exendin-4 was 18-41 min for i.v. bolus, 28-49 for i.v. continuous, 90-216 min for s.c. and 125-174 min for i.p. injection. Bioavailability was 65-76% for s.c. and i.p. injection. Clearance determined from the i.v. infusion was 4-8 mL/min. Both Cmax and AUC values within each route of administration were proportional to dose. Volume of distribution was 457-867 mL. Clearance and bioavailability were not dose dependent. Cmax (or steady-state plasma concentration; Css) is shown in the table below
  • Cmax or Css (nM)
    Route IV bolus IV infusion Subcutaneous IP
    Dose
     2.1 μg  2.9 ± 0.4 1.1 ± 0.1 0.56 ± 0.12 0.26 ± 0.04
     21 μg 70 ± 3  19 ± 1.9 4.1 ± 1.5 3.9 ± 1  
    210 μg 645 ± 12 262 ± 60  28 ± 4  35 ± 6 
    • EXAMPLE 10 Comparison of the Insulinotropic Actions of Exendin-4 and GLP-1 During an Intravenous Glucose Challenge in Rats
  • This experiment compares the insulinotropic actions of synthetic exendin-4 and GLP-1 in vivo following an intravenous (i.v.) glucose challenge in rats. Sprague-Dawley rats (˜400 g) were anesthetized with halothane and cannulated via the femoral artery and saphenous vein. Following a 90-min recovery period, saline or peptide (30 pmol/kg/min each) was administered i.v. (1ml/h for 2 hours; n=4-5 for each group). Thirty min after infusion commenced, D-glucose (5.7 mmol/kg, 0.8 ml) was injected i.v. In saline-treated, exendin-4-treated and GLP-1-treated rats, plasma glucose concentrations were similar before injection (9.3±0.3, 9.7±0.3, 10.3±0.4 mM), increased by similar amounts after glucose injection (21.7, 21.3, 23.7 mM), and resulted in a similar 60-min glucose AUC (987±39, 907±30, 1096±68 mM*mm, respectively). That is, the glycemic stimulus was similar in each treatment group. Plasma insulin concentration in saline-treated rats increased 3.3-fold with the glucose challenge (230±53 to a peak of 765±188 pM). With exendin-4 infuision, the increase in plasma insulin concentration was 6.8-fold (363±60 to 2486±365 pM). With GLP-1 the increase in plasma insulin concentration was 2.9-fold (391±27 to 1145±169 pM), which was similar to that obtained in saline-treated rats. The 60-min insulin AUC in saline-treated rats was 24±6 nM·min, was increased 2.8-fold in exendin-treated rats (67±8 nM·min; P<0.003 versus saline; P<0.02 versus GLP-1) and by 20% in GLP-1-treated rats (n.s. versus saline). Amplification of glucose-stimulated insulin release by exendin-4 was also tested at infusion rates of 3 and 300 pmol/kg/min and shown to be dose-dependent. Thus, exendin-4 is more potent and/or effective than GLP-1 in amplifyng glucose-stimulated insulin release in intact rats.
    • EXAMPLE 11 Development and Validation of an Immunoradiometric Assay (IRMA) for the quantitation of Exendin-4 in Plasma and its Application to Preclinical Toxicity and Phase I Clinical Evaluations
  • A sensitive and specific sandwich-type immunoradio-metric (IRMA) assay was developed for quantitation of plasma exendin-4 concentration using synthetic exendin-4 as the immunogen. One mouse-derived monoclonal antibody recognizes a C-terminal epitope on exendin-4 (capture antibody) but does not cross-react with GLP-1. The second antibody (detector antibody labeled with 1251 ) recognizes an N-terminal epitope on exendin-4 and GLP-1, and requires a terminal histidine for binding. Thus, the assay as a whole does not detect GLP-1(7-36)NH2, GLP-1(7-36)COOH or exendin(3-39). Assay validation in rat, monkey, dog, rabbit and human plasmas showed inter- and intra-assay coefficients of variation <20% and <10%, respectively, accuracy of ±15% with target low, mid and high controls, and lower and upper limits of quantitation of 62.8 and 2512 pg/mL, respectively. Plasma samples from 28-day subcutaneous toxicity evaluations of exendin-4 in rats and monkeys and a Phase I clinical study in normal subjects were evaluated using the IRMA. The C values in the animals studies are shown in the table below. Human samples from subcutaneous administration of 0.05, 0.1, 0.2 and 0.3 μg/kg yielded Cmax values of 90, 224, 370 and 587 pg/mL.
  • Cmax (pg/mL)
    Dose (μg/kg)
    10 100 1000
    Rat 7,000 127,000 1,180,000
    Monkey 20,000 170,000 1,890,000
    • EXAMPLE 12 Comparison of GLP-1 Receptor Binding/Activating and Glucose-Lowering Effects of GLP-1 and Exendin-4
  • Exendin-4 was synthesized by solid phase peptide synthesis techniques and compared to synthetic GLP-1 in terms of in vitro binding to, and activation of, GLP-1 receptors, and in vivo in terms of lowering plasma glucose in diabetic dbldb mice. In a plasma membrane preparation of a rat insulinoma cell line (RINm5f) that expresses the GLP-1 receptor, the peptides were assayed for their ability to bind and displace radiolabeled GLP-1 and for their ability to stimulate the production of cAMP. The relative order of binding potency was found to be GLP-1>exendin-4. The relative order of cyclase activation was GLP-1=exendin-4. Affinities, as shown in the table below, differ over a 4-to 5-fold range. In contrast, in vivo glucose lowering potency differed over a 3430-fold range. Exendin-4 was 3430-fold more potent than GLP-1. The in vivo potency of exendin-4 does not match potency at the GLP-1 receptor, and is likely the culmination of an aggregate of properties.
  • Glucose-lowering
    Binding IC50 (nM) Cyclase EC50 (nM) ED50 (μg)
    GLP-1 0.15 0.28 20.6
    Exendin-4 0.66 0.30 0.006
    • EXAMPLE 13 Comparison of Glycemic Indices and Insulin Sensitivity in Pair-Fed and Exendin-4 Treated Diabetic Fatty Zucker Rats
  • This Example tests whether the beneficial effects of exendin-4 in ZDF rats were secondary to changes in food intake. It compares effects obtained with exendin-4 to effects observed in saline-treated matched animals who consumed the same amount of food as was eaten by ZDF rats injected subcutaneously twice daily with 10 μg exendin-4. Plasma glucose and HbAlc were measured weekly for 6 weeks. One day after the last treatment, animals were anesthetized with halothane and subjected to an hyperinsulinemic (50 mU/kg/min) euglycemic clamp. Changes in HbAlc over 6 weeks differed between treatment groups (P<0.001 ANOVA), increasing in ad lib fed (n=5) and pair fed (n=5) rats, but decreasing in exendin-4-treated rats (n=5). Similarly, changes in plasma glucose differed between treatment groups (P<0.002 ANOVA), increasing in ad lib fed and pair fed ZDF rats, and decreasing in ZDF rats treated with exendin-4. In the final hour of a 3-hour clamp protocol, glucose infusion rate in exendin-4-treated rats tended to be higher than in pair fed (+105%) and ad lib fed (+20%) controls, respectively (10.14±1.43 n=5, 8.46±0.87 n=4, 4.93±2.02 mg/kg/min n=3; n.s. P=0.09 ANOVA). Another index of insulin sensitivity, plasma lactate concentration, differed significantly between treatment groups (P<0.02 ANOVA) and was lowest in exendin-4-treated rats. Thus, exendin-4 treatment is associated with improvement in glycemic indices and in insulin sensitivity that is partly, but not fully, matched in controls fed the same amount of food, indicating that improvements in metabolic control with exendin-4 in ZDF rats are at least partly due to mechanisms beyond caloric restriction.
    • EXAMPLE 14 Clinical Studies and the Stimulation of Endogenous Insulin Secretion by Subcutaneous Synthetic Exendin-4 in Healthy Overnight Fasted Volunteers
  • In a double blind, placebo-controlled single ascending dose clinical trial to explore safety and tolerability and pharmacokinetics of synthetic exendin-4, exendin-4 formulated for subcutaneous injection was evaluated in healthy male volunteers while assessing effects upon plasma glucose and insulin concentrations. Five single subcutaneous doses of exendin-4 (0.01, 0.05, 0.1, 0.2 or 0.3 μg/kg) were studied in 40 healthy male volunteers in the fasting state. Maximum plasma exendin-4 concentrations were achieved between 1 and 2 hours post-dose with little difference among the doses examined. Examination of the data indicated a dose dependent increase for Cmax. There were no serious adverse events reported in this study and in the healthy male volunteers that participated in this study, exendin-4 was well tolerated at subcutaneous doses up to and including 0.1 μg/kg. A decrease in plasma glucose concentration was also observed at this dose. At doses of 0.2 μg/kg and higher, the most commonly observed adverse events were headache, nausea, vomiting, dizziness, and postural hypotension. There was a transient fall in plasma glucose concentration following administration of doses of 0.05 μg/kg and above.
  • Forty healthy, lean (mean BMI (±SE) 22.7±1.2) subjects aged 18-40 years were randomly assigned to 5 groups. Within each group of 8 subjects, 6 were assigned to exendin-4 and 2 to placebo (PBO). Exendin-4 (0.01, 0.05, 0.1, 0.2 or 0.3 μg/kg) or placebo was administered following an overnight fast and plasma exendin4, glucose and insulin concentrations monitored along with safety and tolerability. No safety issues were observed. Doses <0.1 μg/kg were tolerated as well as PBO whereas 0.2 and 0.3 μg/kg elicited a dose-dependent increase in nausea and vomiting. Peak plasma exendin-4 concentrations rose dose-dependently and following 0.1 μg/kg, exendin-4 immunoreactivity persisted for 360 min. Plasma glucose decreased following all doses, except 0.01 μg/kg, reached a nadir by 30 min and returned back to baseline within 180 min. Subjects receiving 0.3 μg/kg received a caloric beverage 30 minutes after dosing, precluding comparison of their data. Mean change in plasma glucose (0-180 min): 0.03±0.07, −0.07±0.08, −0.38±0.14, −0.85±0.13 and −0.83±0.23 mmol/L for PBO, 0.01, 0.05, 0.1, and 0.2 μg/kg respectively; P<0.02 versus PBO. The lowest plasma glucose recorded was 3.4 mmol/L. Corresponding mean changes in plasma insulin (0-120 min) were 0.43±0.59, 2.37±0.58, 2.28±0.66, 4.91±1.23, and 14.00±3.34 μU/mL; P<0.01 versus PBO for the 0.1 and 0.2 μg/kg groups. Thus, in healthy, overnight fasted volunteers, subcutaneous injection of exendin-4 (1) presented no safety issues, (2) was well-tolerated at doses ≦0.1 ρg/kg, (3) led to exendin-4 immunoreactivity in plasma for up to 6 hrs, (4) increased plasma insulin and lowered plasma glucose in a dose-dependent manner without inducing hypoglycemia.
    • EXAMPLE 15 Effectiveness of Alternative Delivery of Exendin-4 in Rodents
  • This Example tested the delivery of exendin-4 by means alternative to injection, and examined its ability to traverse mucosal surfaces in sufficient quantities to exert biological effect. Changes in concentration of plasma glucose and of intact synthetic exendin-4 (measured by a 2-site imnunoradiometric assay) were observed in db/db mice administered a saline solution containing differing doses of synthetic exendin-4 via the trachea, via an aerosol mist (pulmonary), via gavage (oral), and under the tongue (sublingual). The same routes of administration, as well as intraduodenally and nasally, were tested in rats, and bioavailability was calculated, for example, for sublingual and intra-tracheal routes. Exendin-4 administered via each of the above routes in mice resulted in significant glucose-lowering activity 1 to 4 hours after administration (db/db mice intra-tracheal P<0.02; ob/ob mice intra-tracheal P<0.0002; db/db mice aerosol P<0.0001; gavage P<0.002; sublingual P<0.02). Dose-dependent increases in plasma exendin-4 concentration were up to 777±365 μg/mL (db/db mice intra-tracheal); 170±67 μg/mL (db/db mice aerosol); 4520±1846 μg/mL (db/db mice sublingual). Similarly, in rats, exendin-4 concentrations were observed up to 68,682±38,661 pg/mL (intra-tracheal); 1900 μg/iL (pulmonary); 6757 pg/mL (nasal); 3,862±2,844 pg/mL (sublingual); but no apparent absorption or biological activity when delivered intraduodenally. Bioavailability of exendin-4 in saline was 7.3% at lower doses when delivered via the trachea, where 61-74% of Cmax was observed within 5 min. Kinetics thereafter were similar to those observed after subcutaneous administration. Bioavailability of exendin-4 in saline delivered under the tongue was 3.1-9.6% at lower doses. These studies support the delivery of exendin-4 and peptide agonist analogs thereof in biologically effective quantities via convenient non-injectable routes.
    • EXAMPLES 16 TO 20 Reagents Used
  • GLP-1[7-36]NH2 (GLP-1) was purchased from Bachem (Torrance, Calif.). All other peptides were prepared using synthesis methods such as those described therein. All chemicals were of the highest commercial grade. The cAMP SPA imuunoassay was purchased from Amersham. The radioligands were purchased from New England Nuclear (Boston, Mass.). RINm5f cells (American Type Tissue Collection, Rockville, Md.) were grown in DME/F12 medium containing 10% fetal bovine serum and 2 mM L-glutamine. Cells were grown at 37° C. and 5% CO2/95% humidified air and medium was replaced every 2 to 3 days. Cells were grown to confluence then harvested and homogenized using on a Polytron homogenizer. Cell homogenates were stored frozen at −70° C. until used.
    • EXAMPLE 16 GLP-1 Receptor Binding Studies
  • Receptor binding was assessed by measuring displacement of [125I]GLP-1 or [125I]exendin(9-39) from RINm5f membranes. Assay buffer contained 5 μg/ml bestatin, 1 μg/ml phosphoramidon, 1 mg/ml bovine serum albumin (fraction V), 1 mg/ml bacitracin, and 1 mM MgCl2 in 20 mM HEPES, pH 7.4. To measure binding, 30 μg membrane protein (Bradford protein assay) was resuspended in 200 μl assay buffer and incubated with 60 pM [125I]GLP-1 or [125I]exendin(9-39) and unlabeled peptides for 120 minutes at 23° C. in 96 well plates (Nagle Nunc, Rochester, N.Y.). Incubations were terminated by rapid filtration with cold phosphate buffered saline, pH 7.4, through polyethyleneimine-treated GF/B glass fiber filters (Wallac Inc., Gaithersburg, Md.) using a Tomtec Mach II plate harvester (Wallac Inc., Gaithersburg, Md.). Filters were dried, combined with scintillant, and radioactivity determined in a Betaplate liquid scintillant counter (Wallac Inc.).
  • Peptide samples were run in the assay as duplicate points at 6 dilutions over a concentration range of 10−6M to 10−12M to generate response curves. The biological activity of a sample is expressed as an IC50 value, calculated from the raw data using an iterative curve-fitting program using a 4-parameter logistic equation (Prizm, GraphPAD Software).
    • EXAMPLE 17 Cyclase Activation Study
  • Assay buffer contained 10 μM GTP, 0.75 mM ATP, 2.5 mM MgCl2, 0.5 mM phosphocreatine, 12.5 U/ml creatine kinase, 0.4 mg/ml aprotinin, 1 μM IBMX in 50 mM HEPES, pH 7.4. Membranes and peptides were combined in 100 ml of assay buffer in 96 well filter-bottom plates (Millipore Corp., Bedford, Mass.). After 20 minutes incubation at 37° C., the assay was terminated by transfer of supernatant by filtration into a fresh 96 well plate using a Millipore vacuum manifold. Supernatant cAMP contents were quantitated by SPA imamunoassay. Peptide samples were run in the assay as triplicate points at 7 dilutions over a concentration range of 10−6M to 10−12M to generate response curves. The biological activity of a particular sample was expressed as an EC50 value, calculated as described above.
    • EXAMPLE 18 Determination of Blood Glucose Levels in db/db Mice
  • C57BLKS/J-m-db mice at least 3 months of age were utilized for the study. The mice were obtained from The Jackson Laboratory and allowed to acclimate for at least one week before use. Mice were housed in groups of ten at 22° C.±1° C. with a 12:12 light:dark cycle, with lights on at 6 a.m. All animals were deprived of food for 2 hours before taking baseline blood samples. Approximately 70 μl of blood was drawn from each mouse via eye puncture, after a light anesthesia with metophane. After collecting baseline blood samples, to measure plasma glucose concentrations, all animals receive subcutaneous injections of either vehicle (10.9% NaCl), exendin-4 or test compound (1 μg) in vehicle. Blood samples were drawn again, using the same procedure, after exactly one hour from the injections, and plasma glucose concentrations were measured. For each animal, the % change in plasma value, from baseline value, was calculated.
    • EXAMPLE 19 Dose Response Determination of Blood Glucose Levels in db/db Mice
  • C57BLKS/J-m-db/db mice, at least 3 months of age were utilized for the study. The mice were obtained from The Jackson Laboratory and allowed to acclimate for at least one week before use. Mice were housed in groups of ten at 22° C.±1° C. with a 12:12 light:dark cycle, with lights on at 6 a.m. All animals were deprived of food for 2 hours before taking baseline blood samples. Approximately 70 μl of blood was drawn from each mouse via eye puncture, after a light anesthesia with metophane. After collecting baseline blood samples, to measure plasma glucose concentrations, all animals receive subcutaneous injections of either vehicle, exendin-4 or test compound in concentrations indicated. Blood samples were drawn again, using the same procedure, after exactly one hour from the injections, and plasma glucose concentrations were measured. For each animal, the % change in plasma value, from baseline value, was calculated and a dose dependent relationship was evaluated using Graphpad Prizmm software.
    • EXAMPLE 20 Gastric Emptying
  • The following study was and may be carried out to examine the effects of exendin-4 and/or an exendin agonist compound on gastric emptying in rats. This experiment followed a modification of the method of Scarpignato, et al., Arch. Int. Pharmacodvn. Ther. 246:286-94, 1980. Male Harlan Sprague Dawley (HSD) rats were used. All animals were housed at 22.7±0.8 C in a 12:12 hour light:dark cycle (experiments being performed during the light cycle) and were fed and watered ad libitum (Diet LM-485, Teklad, Madison, Wis.). Exendin-4 was synthesized according to standard peptide synthesis methods. The preparation of exendin-4 is described in Example 2. The determination of gastric emptying by the method described below was performed after a fast of ˜20 hours to ensure that the stomach contained no chyme that would interfere with spectrophotometric absorbance measurements.
  • Conscious rats received by gavage, 1.5 ml of an acaloric gel containing 1.5% methyl cellulose (M-0262, Sigma Chemical Co, St Louis, Mo.) and 0.05% phenol red indicator. Twenty minutes after gavage, rats were anesthetized using 5% halothane, the stomach exposed and clamped at the pyloric and lower esophageal sphincters using artery forceps, removed and opened into an alkaline solution which was made up to a fixed volume. Stomach content was derived from the intensity of the phenol red in the alkaline solution, measured by absorbance at a wavelength of 560 nm. In separate experiments on 7 rats, the stomach and small intestine were both excised and opened into an alkaline solution. The quantity of phenol red that could be recovered from the upper gastrointestinal tract within 20 minutes of gavage was 89±4%; dye which appeared to bind irrecoverably to the gut luminal surface may have accounted for the balance. To account for a maximal dye recovery of less than 100%, percent of stomach contents remaining after 20 min were expressed as a fraction of the gastric contents recovered from control rats sacrificed immediately after gavage in the same experiment. Percent gastric contents remaining=(absorbance at 20 min)/(absorbance at 0 mm)×100.
  • One skilled in the art would readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The molecular complexes and the methods, procedures, treatments, molecules, specific compounds described herein are presently representative of preferred embodiments are exemplary and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention are defined by the scope of the claims.
  • It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention.
  • All patents and publications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.
  • The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations, which is not specifically disclosed herein. Thus, for example, in each instance herein any of the terms “comprising”, “consisting essentially of” and “consisting of” may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.
  • In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group. For example, if X is described as selected from the group consisting of bromine, chlorine, and iodine, claims for X being bromine and claims for X being bromine and chlorine are fully described.
  • The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein. Other embodiments are within the following claims.

Claims (18)

1. A pharmaceutical formulation which is a liquid dosage gorm suitable for multi-use administration comprising about 0.005% (w/v) to about 0.4% (w/v) of an exendin, an exendin analog or a combination thereof, a buffer, an iso-osmolality modifier, and (bout 0.005% to about 1.0% (w/v) of a preservative selected from the group consisiting of m-cresol, phenol, benzyl alcohol, methyl-, ethyl-, propyl and but-n-paraben and any combination thereof, wherein said formulation has a pH of between about 3.0 and about 7.0 and said exendin is not exendin-4.
2. The formulation of claim 1, said formulation having a pH of between about 4.0 and about 6.0.
3. The formulation of claim 1, wherein said exendin or exendin analog is present at a concentration of between about 0.005% (w/v) and about 0.05%
4. The formulation of claim 1, wherein said buffer is selected from the group consisting of an acetate buffer, a glutamate buffer, a citrate buffer, a phosphate buffer, and any combination thereof.
5. The formulation of claim 1, wherein, said buffer is at a concentration between about 0.02% (w/v) and about 0.5% (w/v).
6. The formulation of claim 1, wherin said iso-osmolality modifier is a carbohydrate, a polyhydric alcohol or a combination thereof, and said iso-osmolality modifier is at a concentration between about 1% (w/v) and 10% (w/v).
7. The formuation of claim 6, wherein said polyhydric alcohol is selected from the group consisting of sorbitol, mannitol, inositol, glycerol, xylitol, polyethylene glycols, and any combination tlereof.
8. The formulation of claim 1, wherein said iso-osmolality modifier is mannitol, sorbitolm, or a combination therof.
9. The formulation of claim 2, wherein said formulation is suitable for administration via injection to achieve a dose of from about 0.1 μg/kg to about 0.5 μ/kg of saId exendin or exendin analog.
10. A pharmaceutical formulation which is a liquid dosage form suitable for multi-use administration comprising an exendin, an exendin analog or a combination thereof, a buffer, an iso-osmolality modifier, and about 0.005% (w/v) to aboutI 1.0% (w/v) of a preservative selected from the group consisting of m-cresol, phenol, benzyl alcohol, methyl-, ethyl,-, propyl- and butyl-paraben and any combination thereof, wherein said formulation has a pH of betveen about 3.0 and about 6.0 and said exendin is not exendin-4.
11. The formulation of claim 10, wherein said formulation is suitable for a route of administration selected from the group consisiting of:
oral adinstation to achieve a dose of from about 500 μg/day to about 12,000 μg/day of said exendin or exenidin, analog In a single or divided dose;
pulmonary administration to achieve a dose from about 100 μg/day to about 12,000 μg/day of said exetdin or exendin analog in a single or divided dose;
sublingual administraton to achieve a dose from about 10 μg/day to about 8,000 μg/day of said exendin or exerndn analog in a single or divided dose;
nasal administration to achieve a dose from about 10 μg/day to about 12,000 μg/day of said exendln or eorendn analog if a single or divided dose; and
buccal admstration to achee a dose from about 100 μg/day to about 12,000 μg/day of said exendin or exendin anialog in a single or divided dose.
12. The formulation of claim 26, said formulation having a pH of between about 4:0 and about 6.0.
13. The formulation of claim 26, wherein said buffer is selected from the group consisting of an acetate buffer, a flutamate bvuffer, a citrate buffer, a phosphate buffer, and any combination thereof.
14. The formulation of claim 26, wherein said buffer is at a concentration between about 0.02% (w/v) and about 0.50 (w/v).
15. The formulation of claim 1, wherein the formulation comprises the exendin analog.
16. The formulation of claim 1, wherein the formulation comprises the comprises the amino acId sequence of SEQ ID NO. 41, 42, 43, 44, A5, 46, 47, or 48.
17. The formulation of claim 10, wherein the formulation comprises the exendin analog.
18. The formulation of claim 10, wherein the exendin or the exendin analog comprises the amino acid sequence of SEQ ID NO. 42, 4D, 44, 45, 46, 47, or 48.
US12/100,880 1999-01-14 2008-04-10 Exendin Analog Formulations Abandoned US20080249018A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US12/100,880 US20080249018A1 (en) 1999-01-14 2008-04-10 Exendin Analog Formulations
US12/389,509 US7906146B2 (en) 1999-01-14 2009-02-20 Lyophilized formulations of exendins and exendin agonist analogs
US13/045,334 US20110281798A1 (en) 1999-01-14 2011-03-10 Methods for Lowering Plasma Glucagon with Exendins and Exendin Agonist Analogs
US13/672,562 US20130165379A1 (en) 1999-01-14 2012-11-08 Formulations of Exendins and Exendin Agonist Analogs
US14/553,237 US20150080308A1 (en) 1999-01-14 2014-11-25 Formulations and Uses of Exendins and Exendin Agonist Analogs

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US11638099P 1999-01-14 1999-01-14
US13201799P 1999-04-30 1999-04-30
US17536500P 2000-01-10 2000-01-10
US09/889,331 US6872700B1 (en) 1999-01-14 2000-01-14 Methods for glucagon suppression
PCT/US2000/000942 WO2000041548A2 (en) 1999-01-14 2000-01-14 Methods for glucagon suppression
US11/083,730 US7153825B2 (en) 1999-01-14 2005-03-18 Methods for glucagon suppression using modified exendins
US11/272,488 US7399489B2 (en) 1999-01-14 2005-11-10 Exendin analog formulations
US12/100,880 US20080249018A1 (en) 1999-01-14 2008-04-10 Exendin Analog Formulations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/272,488 Continuation US7399489B2 (en) 1999-01-14 2005-11-10 Exendin analog formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/389,509 Continuation US7906146B2 (en) 1999-01-14 2009-02-20 Lyophilized formulations of exendins and exendin agonist analogs

Publications (1)

Publication Number Publication Date
US20080249018A1 true US20080249018A1 (en) 2008-10-09

Family

ID=46323143

Family Applications (6)

Application Number Title Priority Date Filing Date
US11/272,488 Expired - Lifetime US7399489B2 (en) 1999-01-14 2005-11-10 Exendin analog formulations
US12/100,880 Abandoned US20080249018A1 (en) 1999-01-14 2008-04-10 Exendin Analog Formulations
US12/389,509 Expired - Fee Related US7906146B2 (en) 1999-01-14 2009-02-20 Lyophilized formulations of exendins and exendin agonist analogs
US13/045,334 Abandoned US20110281798A1 (en) 1999-01-14 2011-03-10 Methods for Lowering Plasma Glucagon with Exendins and Exendin Agonist Analogs
US13/672,562 Abandoned US20130165379A1 (en) 1999-01-14 2012-11-08 Formulations of Exendins and Exendin Agonist Analogs
US14/553,237 Abandoned US20150080308A1 (en) 1999-01-14 2014-11-25 Formulations and Uses of Exendins and Exendin Agonist Analogs

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/272,488 Expired - Lifetime US7399489B2 (en) 1999-01-14 2005-11-10 Exendin analog formulations

Family Applications After (4)

Application Number Title Priority Date Filing Date
US12/389,509 Expired - Fee Related US7906146B2 (en) 1999-01-14 2009-02-20 Lyophilized formulations of exendins and exendin agonist analogs
US13/045,334 Abandoned US20110281798A1 (en) 1999-01-14 2011-03-10 Methods for Lowering Plasma Glucagon with Exendins and Exendin Agonist Analogs
US13/672,562 Abandoned US20130165379A1 (en) 1999-01-14 2012-11-08 Formulations of Exendins and Exendin Agonist Analogs
US14/553,237 Abandoned US20150080308A1 (en) 1999-01-14 2014-11-25 Formulations and Uses of Exendins and Exendin Agonist Analogs

Country Status (1)

Country Link
US (6) US7399489B2 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104487053A (en) * 2012-07-25 2015-04-01 韩美药品株式会社 A liquid formulation of long acting insulinotropic peptide conjugate
US8999932B2 (en) 2009-07-29 2015-04-07 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
US9670261B2 (en) 2012-12-21 2017-06-06 Sanofi Functionalized exendin-4 derivatives
US9694053B2 (en) 2013-12-13 2017-07-04 Sanofi Dual GLP-1/glucagon receptor agonists
US9751926B2 (en) 2013-12-13 2017-09-05 Sanofi Dual GLP-1/GIP receptor agonists
US9750788B2 (en) 2013-12-13 2017-09-05 Sanofi Non-acylated exendin-4 peptide analogues
US9758561B2 (en) 2014-04-07 2017-09-12 Sanofi Dual GLP-1/glucagon receptor agonists derived from exendin-4
US9771406B2 (en) 2014-04-07 2017-09-26 Sanofi Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4
US9775904B2 (en) 2014-04-07 2017-10-03 Sanofi Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
US9789165B2 (en) 2013-12-13 2017-10-17 Sanofi Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US9982029B2 (en) 2015-07-10 2018-05-29 Sanofi Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
US10441665B2 (en) 2012-07-25 2019-10-15 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
US10758592B2 (en) 2012-10-09 2020-09-01 Sanofi Exendin-4 derivatives as dual GLP1/glucagon agonists
US10806797B2 (en) 2015-06-05 2020-10-20 Sanofi Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399489B2 (en) * 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
MXPA06012260A (en) * 2004-04-23 2006-12-15 Conjuchem Biotechnologies Inc Method for the purification of albumin conjugates.
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US20060293913A1 (en) * 2005-06-10 2006-12-28 Pioneer Hi-Bred International, Inc. Method and system for licensing by location
WO2007053946A1 (en) * 2005-11-09 2007-05-18 Conjuchem Biotechnologies Inc. Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
CN101384623B (en) * 2005-12-22 2013-07-24 常山凯捷健生物药物研发（河北）有限公司 Process for the production of preformed conjugates of albumin and a therapeutic agent
CN101454342A (en) * 2006-05-26 2009-06-10 安米林药品公司 Composition and methods for treatment of congestive heart failure
DK2020990T3 (en) 2006-05-30 2010-12-13 Intarcia Therapeutics Inc An internal channel flow modulator for a two-part osmotic feeding system
ES2398126T3 (en) 2006-08-09 2013-03-13 Intarcia Therapeutics, Inc Osmotic release systems and piston units
NZ580447A (en) 2007-04-23 2011-06-30 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
CN101987868B (en) * 2009-07-30 2013-09-04 江苏豪森医药集团有限公司 Derivative or pharmaceutically acceptable salt of GLP-1 analogue and application of derivative or pharmaceutically-acceptable salt of a GLP-1 analogue
KR101321461B1 (en) * 2009-08-10 2013-10-29 아크레이 가부시키가이샤 Molecular probe for imaging of pancreatic islet and precursor thereof, and use of the molecular probe or the precursor
RU2547990C2 (en) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Fast achievement and/or completion of substantial stable drug delivery
CA2797133C (en) 2010-04-27 2019-08-06 Zealand Pharma A/S Peptide conjugates of glp-1 receptor agonists and gastrin and their use
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
TR201108946A2 (en) * 2011-09-12 2012-04-24 World Medicine İlaç Sanayi̇ Ve Ti̇caret Li̇mi̇ted Şi̇rketi̇ Freeze-dried ATP, vitamin B complex preparation and injection.
MX2014005351A (en) 2011-11-03 2014-05-28 Zealand Pharma As Glp-1 receptor agonist peptide gastrin conjugates.
BR112015001451B1 (en) 2012-07-23 2022-03-29 Zealand Pharma A/S Compound, nucleic acid construct, expression vector, host cell, pharmaceutical composition, use of a compound or its pharmaceutically acceptable salt or solvate
TWI608013B (en) 2012-09-17 2017-12-11 西蘭製藥公司 Glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
UA122767C2 (en) 2013-10-17 2021-01-06 Зіленд Фарма А/С Acylated glucagon analogues
CA2929107C (en) 2013-11-06 2023-09-26 Zealand Pharma A/S Glucagon-glp-1-gip triple agonist compounds
MX2016005556A (en) 2013-11-06 2016-07-15 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods.
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AU2015340586B2 (en) 2014-10-29 2020-04-30 Zealand Pharma A/S GIP agonist compounds and methods
CA2980978A1 (en) 2015-04-16 2016-10-20 Zealand Pharma A/S Acylated glucagon analogue
ES2968262T3 (en) 2015-06-03 2024-05-08 I2O Therapeutics Inc Implant placement systems
JP7011830B2 (en) 2015-10-14 2022-01-27 エックス－サーマ インコーポレイテッド Compositions and Methods for Reducing Ice Crystal Formation
TWI754643B (en) 2016-05-16 2022-02-11 美商因塔希亞治療公司 Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
RU2753193C2 (en) 2016-12-09 2021-08-12 Зилэнд Фарма А/С Acylated double agonists of glp-1/glp-2
KR20190104039A (en) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Methods Including Continuous Administration of GLP-1 Receptor Agonists and Co-administration of Drugs

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5264372A (en) * 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5686511A (en) * 1996-06-28 1997-11-11 The Valspar Corporation Esterifying epoxy resin with carboxyl polymer and quenching
US5839443A (en) * 1996-05-16 1998-11-24 The Trustees Of Columbia University In The City Of New York Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
US6051557A (en) * 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6376549B1 (en) * 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
US20050026834A1 (en) * 1999-01-14 2005-02-03 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6902744B1 (en) * 1999-01-14 2005-06-07 Amylin Pharmaceuticals, Inc. Exendin agonist formulations and methods of administration thereof
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US7399489B2 (en) * 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1134110A (en) 1993-09-07 1996-10-23 安米林药品公司 Method for regulating gastrointestinal motility
US5474691A (en) * 1994-07-26 1995-12-12 The Procter & Gamble Company Dryer-added fabric treatment article of manufacture containing antioxidant and sunscreen compounds for sun fade protection of fabrics
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
WO1997004647A1 (en) * 1995-07-27 1997-02-13 Thomas Jefferson University Methods of detecting duplication mutated fibrillin-1 gene and compositions and methods of using the same
CA2257119A1 (en) 1996-06-05 1997-12-11 Boehringer Mannheim Gmbh Exendin analogues, processes for their production and pharmaceutical preparations containing them
WO1998005351A1 (en) 1996-08-08 1998-02-12 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
PT1629849E (en) 1997-01-07 2013-07-09 Amylin Pharmaceuticals Llc Pharmaceutical compositions comprising exendins and agonists thereof
CA2299425A1 (en) 1997-08-08 1999-02-18 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US7157555B1 (en) * 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US5924264A (en) * 1997-09-19 1999-07-20 Vierra; Douglas L. Concrete footing and foundation wall system for accurate on-site fittings to manufactured buildings
EP1032587B2 (en) 1997-11-14 2013-03-13 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
ES2294822T3 (en) 1997-11-14 2008-04-01 Amylin Pharmaceuticals, Inc. NEW COMPOUNDS OF EXENDINE AGONISTS.
ATE366115T1 (en) 1998-02-13 2007-07-15 Amylin Pharmaceuticals Inc INOTROPIC AND DIURETIC EFFECTS OF EXENDIN AND GLP-1
DK1143989T3 (en) 1999-01-14 2007-04-16 Amylin Pharmaceuticals Inc Exendins for glucagon suppression
US6451974B1 (en) * 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
MY127032A (en) * 1999-12-28 2006-11-30 Hitachi Metals Ltd Work chamfering apparatus and work chamfering method
EP1661907B1 (en) * 2003-06-04 2012-02-15 Dalian Zhen-Ao Pharmaceutical Co., Ltd. Method of preparing cardio myopeptidin
WO2006045710A2 (en) * 2004-10-27 2006-05-04 Novo Nordisk A/S Insulin receptor binding peptides with non-insulin gene activation profiles and uses thereof
US7902744B2 (en) 2006-06-20 2011-03-08 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Heteroionic junction light emitting electrochemical cell

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5264372A (en) * 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5839443A (en) * 1996-05-16 1998-11-24 The Trustees Of Columbia University In The City Of New York Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
US5686511A (en) * 1996-06-28 1997-11-11 The Valspar Corporation Esterifying epoxy resin with carboxyl polymer and quenching
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6051557A (en) * 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
US6376549B1 (en) * 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
US20050026834A1 (en) * 1999-01-14 2005-02-03 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6902744B1 (en) * 1999-01-14 2005-06-07 Amylin Pharmaceuticals, Inc. Exendin agonist formulations and methods of administration thereof
US7399489B2 (en) * 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8999932B2 (en) 2009-07-29 2015-04-07 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
US9801950B2 (en) * 2012-07-25 2017-10-31 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
US20150238629A1 (en) * 2012-07-25 2015-08-27 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
CN104487053A (en) * 2012-07-25 2015-04-01 韩美药品株式会社 A liquid formulation of long acting insulinotropic peptide conjugate
US10441665B2 (en) 2012-07-25 2019-10-15 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
US10758592B2 (en) 2012-10-09 2020-09-01 Sanofi Exendin-4 derivatives as dual GLP1/glucagon agonists
US9670261B2 (en) 2012-12-21 2017-06-06 Sanofi Functionalized exendin-4 derivatives
US9745360B2 (en) 2012-12-21 2017-08-29 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/glucagon agonists
US10253079B2 (en) 2012-12-21 2019-04-09 Sanofi Functionalized Exendin-4 derivatives
US9694053B2 (en) 2013-12-13 2017-07-04 Sanofi Dual GLP-1/glucagon receptor agonists
US9789165B2 (en) 2013-12-13 2017-10-17 Sanofi Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists
US9750788B2 (en) 2013-12-13 2017-09-05 Sanofi Non-acylated exendin-4 peptide analogues
US9751926B2 (en) 2013-12-13 2017-09-05 Sanofi Dual GLP-1/GIP receptor agonists
US9775904B2 (en) 2014-04-07 2017-10-03 Sanofi Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
US9771406B2 (en) 2014-04-07 2017-09-26 Sanofi Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4
US9758561B2 (en) 2014-04-07 2017-09-12 Sanofi Dual GLP-1/glucagon receptor agonists derived from exendin-4
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US10806797B2 (en) 2015-06-05 2020-10-20 Sanofi Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate
US9982029B2 (en) 2015-07-10 2018-05-29 Sanofi Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists

Also Published As

Publication number Publication date
US20090215694A1 (en) 2009-08-27
US20060069029A1 (en) 2006-03-30
US20110281798A1 (en) 2011-11-17
US7906146B2 (en) 2011-03-15
US20150080308A1 (en) 2015-03-19
US7399489B2 (en) 2008-07-15
US20130165379A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
US7399489B2 (en) Exendin analog formulations
US6872700B1 (en) Methods for glucagon suppression
US7683030B2 (en) Methods of treating diabetes with albumin-conjugated exendin peptides
AU775063C (en) Modified exendins and exendin agonists
US20080119393A1 (en) Novel exendin agonist compounds
US20090029913A1 (en) Novel exendin agonist compounds
WO1999025728A1 (en) Novel exendin agonist compounds
EP1938830A1 (en) Novel exendin agonist compounds
AU2008200171A1 (en) Modified exendins and exendin agonists

Legal Events

Date Code Title Description
AS Assignment

Owner name: AMYLIN PHARMACEUTICALS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOLTERMAN, ORVILLE G.;YOUNG, ANDREW A.;L'ITALIEN, JAMES L.;REEL/FRAME:020785/0689;SIGNING DATES FROM 20060228 TO 20060418

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION